# Author Index For Volume 42


Aazib L (abst) ..... 228
Abaigar P (abst) ..... 209
Abat E (abst) ..... 200
Abbal M (abst) ..... 231
Abbott F *See* Savill J et al ..... 924
Abraham CR *See* Campistol JM et al ..... 915
Abraham MI, Burckhardt G, Kempson SA: Sodium-dependent phosphate transport in a rat kidney endosomal fraction ..... 1070
Abrahamson DR *See* Hudson BG et al ..... 179
Abramowicz D (abst) ..... 228
Abramowicz D *See* Pradier O et al ..... 1124
Abramson RG *See* London RD et al ..... 300
Accavitti MA (abst) ..... 797
Achard JM *See* Fournier A et al ..... 38:S-50
Ackermann D (abst) ..... 803
Adal Y (abst) ..... 1049, 1050
Adamson JW *See* Eschbach JW et al ..... 407
Adeva M (abst) ..... 203, 203
Adida C *See* Meulders Q et al ..... 327
Admosoerodjo J (abst) ..... 1284
Adrogué HJ: Glucose homeostasis and the kidney (Nephrology Forum) ..... 1266
Agar JWM (abst) ..... 1031
Aglibut S (abst) ..... 1050
Aguado J (abst) ..... 226
Aguado S (abst) ..... 207, 207, 207, 207, 208
Aguayo ML (abst) ..... 224
Aguilar D (abst) ..... 223, 224, 224
Aguiree R (abst) ..... 216
Ajzen H *See* Boim MA et al ..... 567
Akabane S *See* Imanishi M et al ..... 417
Akano N *See* Yoshioka K et al ..... 1253
Akita H *See* Yoshioka K et al ..... 1253
Al Muzairai I (abst) ..... 1032, 1047
Alamartine E (abst) ..... 231
Alarcon AS (abst) ..... 213
Alaupovic P *See* Attman P-O et al ..... 1381
Albarracin C (abst) ..... 217, 221
Alberola ML (abst) ..... 198
Alberracin C (abst) ..... 218
Albert C (abst) ..... 237, 238
Alcazar JM (abst) ..... 226
Alcorn D (abst) ..... 1049
Alcorn D *See* Zhuo J et al ..... 1372
Alderman F *See* Gitelman HJ et al ..... 957
Alkhayat R (abst) ..... 234
Allen AM *See* Zhuo J et al ..... 1372
Allen G (abst) ..... 1041
Allison MEM *See* Lindsay RM et al ..... 38:S-32
Almagro Sanchez de Puerta M (abst) ..... 206
Alonso A (abst) ..... 203, 203
Alonso J (abst) ..... 223
Alpers CE, Seifert RA, Hudkins KL, Johnson RJ, Bowen-Pope DF: Developmental patterns of PDGF B-chain, PDGF-receptor, and $\alpha$-actin expression in human glomerulogenesis ..... 390
Alpers CE *See* Floege J et al ..... 573
Alsina J (abst) ..... 203
Altman JJ (abst) ..... 229
Alvarez E (abst) ..... 226
Alvarez G (abst) ..... 201
Alvarez Grande J (abst) ..... 207
Alvarez J (abst) ..... 207
Alvarez-Arroyo MV (abst) ..... 204
Alvarez-Grande J (abst) ..... 207, 207, 207, 208, 208
Alvarez-Ude F (abst) ..... 214
Alvestrand A *See* Gutierrez A et al ..... 38:S-86
Amann K, Wiest G, Zimmer G, Gretz N, Ritz E, Mall G: Reduced capillary density in the myocardium of uremic rats—A stereological study ..... 1079
Amenabar JJ (abst) ..... 216, 217
Amoura Z (abst) ..... 233
Anaya F (abst) ..... 218, 218, 218, 218, 222, 222
Anderson CM *See* Tucker BJ et al ..... 1160
Anderson RJ, Breckon R: Cytokine regulation of adenylate cyclase activity in LLC-PK$_1$ cells ..... 559
Andres A (abst) ..... 212, 213, 226, 226, 226, 226, 227, 227, 227
Andreucci VE *See* Memoli B et al ..... 320
Andreucci VE *See* Sabbatini M et al ..... 875
Andujar M (abst) ..... 224, 224
Aneiros J (abst) ..... 223, 223, 224
Antignac C, Zhou J, Sanak M, Cochat P, Roussel B, Deschênes G, Gros F, Knebelmann B, Hors-Cayla M-C, Tryggvason K, Gubler M-C: Alport syndrome and diffuse leiomyomatosis: Deletions in the 5′ end of the COL4A5 collagen gene ..... 1178
Antonana MA (abst) ..... 217
Aparicio M (abst) ..... 230
Aparicio M *See* Lafage M-H et al ..... 1217
Aperia A *See* Meister B et al ..... 617
Appay M-D (abst) ..... 228, 228
Apperloo AJ (abst) ..... 1285
Ara JM (abst) ..... 214, 215
Archilla E (abst) ..... 210
Arduino MJ *See* Pegues DA et al ..... 1232
Argiles A (abst) ..... 1040, 1044, 1045, 1045, 1045
Arisz L (abst) ..... 793, 797, 1286, 1287
Armada E (abst) ..... 204, 208
Armstrong WMD *See* Macias WL et al ..... 308
Arnaiz P (abst) ..... 202
Arreba E (abst) ..... 214
Arribas I (abst) ..... 210
Arrizabalaga P (abst) ..... 199
Arrojo F (abst) ..... 203, 203
Artlett CM (abst) ..... 1036
Arvieux C (abst) ..... 229
Asencio C (abst) ..... 223
Asensio C (abst) ..... 201, 223, 224
Asensio Peinado C (abst) ..... 206
Assael BM (abst) ..... 800
Assambo-Kieli C (abst) ..... 228
Assensio C (abst) ..... 222
Assmann KJM (abst) ..... 793
Assmann KJM *See* Termaat R-M et al ..... 1363
Atkins RC (abst) ..... 1033, 1034, 1035, 1036, 1037, 1037, 1040, 1051

Attman P-O, Nyberg G, William-Olsson T, Knight-Gibson C, Alaupovic P: Dyslipoproteinemia in diabetic renal failure ..... 1381
Attoyan C (abst) ..... 230
Aubia J (abst) ..... 214
Aukema HM, Ogborn MR, Tomobe K, Takahashi H, Hibino T, Holub BJ: Effects of dietary restriction and oil type on the early progression of murine polycystic kidney disease ..... 837
Aupetit J (abst) ..... 229
Aventaggiato L *See* Montinaro V et al ..... 341
Awazu M, Yared A, Swift LL, Hoover RL, Ichikawa L: Dietary fatty acid modulates glomerular atrial natriuretic peptide receptor ..... 265
Ayala JA (abst) ..... 205
Aymard B (abst) ..... 238
Baamonde E (abst) ..... 198, 208
Bachmann S *See* Mundel P et al ..... 1017
Bachofen M (abst) ..... 808, 809
Bader M *See* Mundel P et al ..... 1017
Badr KF: 15-Lipoxygenase products as leukotriene antagonists: Therapeutic potential in glomerulonephritis .... 38:S-101
Baelde H (abst) ..... 1284
Baeza J (abst) ..... 202
Baggio B *See* Gambaro G et al ..... 285
Bagni B *See* Gallieni M et al ..... 1191
Bai IQ (abst) ..... 489
Bai KM (abst) ..... 493
Bai LQ (abst) ..... 489
Bailey RR (abst) ..... 1030, 1040, 1041, 1043, 1043
Baird J *See* Lindsay RM et al ..... 38:S-32
Bajo A (abst) ..... 214
Bajo MA (abst) ..... 204, 204, 205, 205, 205
Baker LRI *See* Roger SD et al ..... 975
Bakker MAH (abst) ..... 793
Bakker WW (abst) ..... 1283
Balestrieri C *See* Camussi G et al ..... 1309
Balfe JW *See* Geary DF et al ..... 102
Balfour DJK *See* Lang CC et al ..... 433
Baller JFW (abst) ..... 1283
Ballesta A (abst) ..... 221
Ballester F *See* Hudson BG et al ..... 179
Ballester M (abst) ..... 221
Bankir L *See* Hadj-Aïssa A et al ..... 1207
Barac-Nieto M *See* Brosius FC III et al ..... 1086
Barclay PG (abst) ..... 1046
Bariety J (abst) ..... 228, 228
Bar-Khayim Y *See* Brockhaus M et al ..... 663
Barratt L (abst) ..... 1041
Barratt TM *See* Fitzpatrick MM et al ..... 951
Barril G (abst) ..... 205, 211
Barry M *See* Paller MS et al ..... 1345
Basadonna G, Matas AJ, Najarian JS: Kidney transplantation in diabetic patients: The University of Minnesota experience ..... 38:S-193
Bason L (abst) ..... 1030, 1035, 1050
Bastl CP, Hayslett JP: The cellular action of aldosterone in target epithelia (Editorial Review) ..... 250
Baud L (abst) ..... 210
Baylis PH (abst) ..... 1031
Beasley D, Brenner BM: Role of nitric oxide in hemodialysis hypotension ..... 38:S-96
Beathard GA: Percutaneous transvenous angioplasty in the treatment of vascular access stenosis ..... 1390
Beaufils H *See* Terzi F et al ..... 354
Beck F-X, Giebisch G, Thurau K: Effect of K depletion on renal K and Rb excretion: Evidence for activation of K reabsorption ..... 272
Beck F-X, Sone M, Dörge A, Thurau K: Effect of loop diuretics on organic osmolytes and cell electrolytes in the renal outer medulla ..... 843
Becker G (abst) ..... 1046
Beck-Sague CM *See* Pegues DA et al ..... 1232
Bedani P *See* Gallieni M et al ..... 1191
Bedrossian J (abst) ..... 236
Behme TC *See* Lonnemann G et al ..... 61
Belch JJF *See* Taylor JE et al ..... 442
Bendayan M *See* Ghitescu L et al ..... 25
Benedet P (abst) ..... 233
Beneyto I (abst) ..... 220, 221, 221, 221
Benigni A *See* Rota S et al ..... 981
Benitez M (abst) ..... 201
Benitez Sanchez M (abst) ..... 206
Benmaadi A (abst) ..... 234
Bennett WM *See* Gardner KD Jr. et al ..... 1199
Bennis D (abst) ..... 229
Berden JHM (abst) ..... 793, 794, 798, 1283
Berden JHM *See* Termaat R-M et al ..... 1363
Bergström J *See* Gutierrez A et al ..... 38:S-86
Bergström J *See* Lindholm B et al ..... 38:S-165
Berkoben M *See* Slatopolsky E et al ..... 38:S-43
Bermejo M (abst) ..... 215, 224, 225, 225, 225, 225
Bernat A (abst) ..... 219, 219, 220
Bernis C (abst) ..... 205, 211
Bernstein J *See* Schwartz MM et al ..... 743
Berse B *See* Brown LF et al ..... 1457
Berthoux F (abst) ..... 231
Berthoux P (abst) ..... 231
Bertram JF (abst) ..... 1051
Bestard J (abst) ..... 213
Beukeboom M (abst) ..... 794
Bi ZQ (abst) ..... 488, 489, 489, 497, 498
Bian XX (abst) ..... 499
Biancone L *See* Camussi G et al ..... 1309
Bichet DG *See* Hadj-Aïssa A et al ..... 1207
Biechy MM (abst) ..... 201, 222
Bills T *See* Kakinuma Y et al ..... 46
Bindels RJM (abst) ..... 797
Binswanger U (abst) ..... 803, 804, 804, 804, 806, 808
Binswanger U *See* Schneditz D et al ..... 1425
Bismuth A *See* Charpentier BM et al ..... 38:S-176
Blagg CR *See* Held PJ et al ..... 38:S-16
Blanco A (abst) ..... 227
Bland LA *See* Pegues DA et al ..... 1232
Blantz RC *See* Tucker BJ et al ..... 1160
Blauw GJ (abst) ..... 1285
Blindauer KM *See* Leypoldt JK et al ..... 1412
Bloom RD *See* Brennan DC et al ..... 279
Blum G (abst) ..... 198, 216
Blum M *See* Weintraub M et al ..... 1247
Bo YH (abst) ..... 498
Boadle RA (abst) ..... 1052, 1052, 1053
Bobe P (abst) ..... 228
Bock A (abst) ..... 807
Bock H (abst) ..... 808
Bock HA (abst) ..... 809
Böcker G *See* Kooman JP et al ..... 718
Boer P (abst) ..... 1286
Boer P *See* de Roose R et al ..... 459
Boer WH (abst) ..... 1286
Boer WH *See* de Roose R et al ..... 459

Boes A (abst) ..... 798
Boeschoten EW (abst) ..... 1287
Bogman MJJT (abst) ..... 794
Bogusky RT *See* Kellerman PS et al ..... 896
Boim MA, Ajzen H, Ramos OL, Schor N: Glomerular hemodynamics and hormonal evaluation during starvation in rats ..... 567
Bolle J-F (abst) ..... 801
Bolton WK: The nature of clinical trials in nephrology (Editorial Review) ..... 1061
Bonal J (abst) ..... 200, 214
Bonet J (abst) ..... 200, 214
Bonvalet J-P *See* Kenouch S et al ..... 56
Bonzalo A (abst) ..... 225
Boomsma F (abst) ..... 793
Bordalba JR (abst) ..... 203
Border WA *See* Tomooka S et al ..... 1462
Borghi M *See* Zucchelli P et al ..... 452
Borras M (abst) ..... 200, 200, 214
Borrego F (abst) ..... 205, 205, 214, 215
Borsa-Lebas F (abst) ..... 234
Borsatti A *See* Gambaro G et al ..... 285
Bosch J (abst) ..... 214
Bosiger P (abst) ..... 803
Bosque E (abst) ..... 205, 205, 205
Botella J (abst) ..... 198, 204, 208
Bouillie M (abst) ..... 807
Bourquelot P (abst) ..... 233
Bouzernidj M *See* Fournier A et al ..... 38:S-50
Bowen-Pope DF *See* Alpers CE et al ..... 390
Bradbury M (abst) ..... 800
Brady HR, Denton MD, Jimenez W, Takata S, Palliser D, Brenner BM: Chemoattractants provoke monocyte adhesion to human mesangial cells and mesangial cell injury ..... 480
Brancaccio D *See* Gallieni M et al ..... 1191
Brandenburg HCR (abst) ..... 1285
Brasseur J (abst) ..... 228, 238
Bravo J (abst) ..... 223
Bravo Soto JA (abst) ..... 206
Breckon R *See* Anderson RJ et al ..... 559
Brennan DC, Jevnikar AM, Bloom RD, Brissette WH, Singer GG, Kelley VR: Cultured mesangial cells from autoimmune MRL-*lpr* mice have decreased secreted and surface M-CSF ..... 279
Brennan DC *See* Gallo CD et al ..... 851
Brenner BM *See* Beasley D et al ..... 38:S-96
Brenner BM *See* Brady HR et al ..... 480
Brenner BM *See* Gunning ME et al ..... 38:S-127
Brezis M: Forefronts in Nephrology: Summary of the Newer Aspects of Renal Cell Injury ..... 523
Briancon S (abst) ..... 238
Brier ME (abst) ..... 209
Brieva JA (abst) ..... 216
Briggs D *See* Sacks SH et al ..... 882
Briggs G (abst) ..... 1048
Briggs JP *See* Brosius FC III et al ..... 1086
Brillet G (abst) ..... 235
Briner VA (abst) ..... 799, 799
Bringolf M (abst) ..... 801
Brink HS (abst) ..... 793
Briscoe DM, Kim MS, Lillehei C, Eraklis AJ, Levey RH, Harmon WE: Outcome of renal transplantation in children less than two years of age ..... 657
Briso-Montiano JM (abst) ..... 199
Brissette WH *See* Brennan DC et al ..... 279
Brockhaus M, Bar-Khayim Y, Gurwicz S, Frensdorff A, Haran N: Plasma tumor necrosis factor soluble receptors in chronic renal failure ..... 663
Bromberg J *See* Varani J et al ..... 1169
Bronzieri C *See* Gallieni M et al ..... 1191
Brooks PM (abst) ..... 1040
Brosius FC III, Briggs JP, Marcus RG, Barac-Nieto M, Charron MJ: Insulin-responsive glucose transporter expression in renal microvessels and glomeruli ..... 1086
Brouwer E (abst) ..... 793, 1284
Brown A *See* Slatopolsky E et al ..... 38:S-43
Brown LF, Berse B, Tognazzi K, Manseau EJ, Van De Water L, Senger DR, Dvorak HF, Rosen S: Vascular permeability factor mRNA and protein are expression in human kidney ..... 1457
Brown MA (abst) ..... 1044
Brown Z, Strieter RM, Neild GH, Thompson RC, Kunkel SL, Westwick J: IL-1 receptor antagonist inhibits monocyte chemotactic peptide 1 generation by human mesangial cells ..... 95
Bruggeman LA *See* Horikoshi S et al ..... 764
Bruijn JA (abst) ..... 797, 1284, 1284
Bruijn JA *See* Yard BA et al ..... 383
Bruning TA (abst) ..... 1285
Brunner F (abst) ..... 807, 809
Brunner FP, Selwood N: Profile of patients on RRT in Europe and death rates due to major causes of death groups ..... 38:S-4
Brunner HG *See* Smeets HJM et al ..... 83
Brunner HR: ACE inhibitors in renal disease (Nephrology Forum) ..... 463
Brunskill NJ, Morrissey JJ, Klahr S: G-protein stimulation inhibits amiloride-sensitive Na/H exchange independently of cyclic AMP ..... 11
Bruton JL *See* Tuttle KR et al ..... 167
Buisson C (abst) ..... 232
Burckhardt G *See* Abraham MI et al ..... 1070
Burgos D (abst) ..... 202
Burke J (abst) ..... 1048
Burns SM *See* Pegues DA et al ..... 1232
Burnside JS *See* Gardner KD Jr. et al ..... 1199
Burrell LM (abst) ..... 1031
Burstein A *See* Weintraub M et al ..... 1247
Burtin M *See* Terzi F et al ..... 354
Bustamante J (abst) ..... 199, 199
Bustamante R (abst) ..... 199, 199
Bustamene J (abst) ..... 214
Bustos M (abst) ..... 223, 224
Butterly DW *See* Yohay DA et al ..... 448
Buttimore AL (abst) ..... 1041, 1046
Caballero E (abst) ..... 221
Caballero T (abst) ..... 223
Cabello M (abst) ..... 201, 202
Cabili S *See* Weintraub M et al ..... 1247
Cabrera Garrido A (abst) ..... 206
Cachera C *See* Kandoussi A et al ..... 424
Caglioti A *See* Conte G et al ..... 673
Cai Y (abst) ..... 492
Cain BD *See* Curran KA et al ..... 1093
Calahorra L (abst) ..... 226
Callard P (abst) ..... 229, 232
Calvar C (abst) ..... 201
Cameron JS (abst) ..... 1035, 1038
Cameron JS: The future of nephrology with special regard to advances in treatment ..... 38:S-203
Campbell C *See* Floege J et al ..... 573

Campiche M (abst) ..... 801
Campistol JM, Shirahama T, Abraham CR, Rodgers OG, Solé M, Cohen AS, Skinner M: Demonstration of plasma proteinase inhibitors in $\beta_2$-microglobulin amyloid deposits ..... 915
Campo C (abst) ..... 205, 212, 213, 226, 226, 227
Campos A (abst) ..... 198
Campos C (abst) ..... 205
Camps J (abst) ..... 201, 201
Camus C (abst) ..... 229
Camussi G, Biancone L, Iorio EL, Silvestro L, Da Col R, Capasso C, Rossano F, Servillo L, Balestrieri C, Tufano MA: Porins stimulate platelet activating factor biosynthesis by cultured human mesangial cells ..... 1309
Camussi G *See* Mariano F et al ..... 735
Canaud B (abst) ..... 1044, 1045, 1045
Candel M (abst) ..... 222, 222
Canessa M *See* Pontremoli R et al ..... 1355
Cantarell MC (abst) ..... 205, 206, 206
Canton CG (abst) ..... 211
Cao M (abst) ..... 203, 203
Capasso C *See* Camussi G et al ..... 1309
Capdevila L (abst) ..... 205, 206, 206
Capel P *See* Pradier O et al ..... 1124
Caracuel MD (abst) ..... 223, 223
Caralps A (abst) ..... 200, 214
Caramelo C (abst) ..... 198, 216
Carbonetto S *See* Cybulsky AV et al ..... 1099
Caridad A (abst) ..... 217, 217
Carmona A (abst) ..... 203
Carney SC (abst) ..... 1039
Carquin J (abst) ..... 235
Carrasco ML (abst) ..... 209
Carrera M (abst) ..... 203
Carretero OA *See* Torres V et al ..... 364
Carrio J (abst) ..... 208, 209
Casado S (abst) ..... 198
Cases A, Escolar G, Reverter JC, Ordinas A, Lopez-Pedret J, Revert L, Castillo R: Recombinant human erythropoietin treatment improves platelet function in uremic patients ..... 668
Casez JP (abst) ..... 805, 808
Casley D (abst) ..... 1030
Castelao AM (abst) ..... 203
Castellano G (abst) ..... 226
Castellanos G (abst) ..... 227
Castells J (abst) ..... 206
Castillo R *See* Cases A et al ..... 668
Castro MJ (abst) ..... 204
Cattell V *See* Jansen A et al ..... 1107
Cattran D *See* Pei Y et al ..... 960
Caudwell V *See* Vincent C et al ..... 1434
Cavalli PL *See* Mariano F et al ..... 735
Cavazzana AO *See* Gambaro G et al ..... 285
Cebrian MP (abst) ..... 227
Cenit M (abst) ..... 206
Cerezo S (abst) ..... 222, 223, 224
Cervero A (abst) ..... 220
Chadefaux B (abst) ..... 229
Chahin J (abst) ..... 212
Chai JP (abst) ..... 507
Chai SY *See* Song K et al ..... 639
Chambers S (abst) ..... 1030, 1035, 1050
Chan TM (abst) ..... 1035, 1038
Chanard J (abst) ..... 235, 235
Chanard J *See* Vincent C et al ..... 1434
Chang L (abst) ..... 1037
Chang LS *See* Lee YH et al ..... 292
Chang PC (abst) ..... 1285
Chao HD (abst) ..... 502
Chao HT (abst) ..... 499
Chapman JR (abst) ..... 1047
Charasse C (abst) ..... 229
Charlesworth JA (abst) ..... 1037
Charpentier BM, Hiesse C, Kriaa F, Rousseau P, Farahmand H, Bismuth A, Fries D: How to deal with the hyperimmunized potential recipients ..... 38:S-176
Charron MJ *See* Brosius FC III et al ..... 1086
Chartres AIRBP (abst) ..... 230
Chauveau P (abst) ..... 229
Chen A *See* Montinaro V et al ..... 341
Chen EH (abst) ..... 496
Chen HP (abst) ..... 490
Chen JL (abst) ..... 506
Chen JM (abst) ..... 502
Chen LO (abst) ..... 504
Chen MT *See* Lee YH et al ..... 292
Chen N (abst) ..... 229
Chen NM (abst) ..... 503
Chen SJ (abst) ..... 503
Chen SY (abst) ..... 497
Chen TS (abst) ..... 495
Chen XM (abst) ..... 489, 489, 505, 505, 509, 509
Chen X-W (abst) ..... 236
Chen Y *See* Wolf G et al ..... 647
Chen YP (abst) ..... 494, 495, 495, 509, 509
Chen YZ (abst) ..... 492
Chen ZY (abst) ..... 495
Cheng QL (abst) ..... 489, 509, 509
Cheng Y (abst) ..... 500
Chevalier RL, Thornhill BA, Gomez RA: EDRF modulates renal hemodynamics during unilateral ureteral obstruction in the rat ..... 400
Chisholm LJ (abst) ..... 1046
Chomant J (abst) ..... 231
Chou S-Y *See* Reiser IW et al ..... 867
Choy A-MJ *See* Lang CC et al ..... 433
Chrysostomou A (abst) ..... 1046, 1047
Chu Q (abst) ..... 494
Cibert J (abst) ..... 232
Ciceri DP *See* Wharton WW III et al ..... 174
Cigarran S (abst) ..... 209, 209
Cimadevilla R (abst) ..... 207
Cisterna R (abst) ..... 222
Claas F (abst) ..... 1284
Clark EC *See* Nath KA et al ..... 38:S-109
Clement J (abst) ..... 1285
Clore J, Schoolwerth A, Watlington CO: When is cortisol a mineralocorticoid? (Editorial Review) ..... 1297
Cochat P *See* Antignac C et al ..... 1178
Cochran M (abst) ..... 1040, 1041, 1050
Codoceo MR (abst) ..... 214
Coers W (abst) ..... 793
Coevoet B (abst) ..... 228, 238
Cofan F (abst) ..... 200, 214
Cohen AS *See* Campistol JM et al ..... 915
Cohen Tervaert JW (abst) ..... 1284
Colantonio G *See* Gallieni M et al ..... 1191
Colimon R *See* Kadereit S et al ..... 1012
Colina F (abst) ..... 226, 227
Coll R (abst) ..... 213
Collaborative Trial Committee Australian (abst) ..... 1046

Collins GM, Wicomb WN: New organ preservation solutions ..... 38:S-197
Collins JF (abst) ..... 1035
Collins RC *See* Tucker BJ et al ..... 1160
Colombi A (abst) ..... 803
Colton CK *See* Lonnemann G et al ..... 61
Combe C (abst) ..... 230
Combe C *See* Lafage M-H et al ..... 1217
Comper WD (abst) ..... 1049, 1050, 1050
Concepcion MT (abst) ..... 211, 212
Connors BA *See* Gardner KD Jr. et al ..... 1199
Constans J (abst) ..... 230
Conte G, Romano G, Sepe V, De Nicola L, Sabbatini M, Russo D, Memoli B, Ungaro B, Fuiano G, Cagli-oti A, Dal Canton A: Role of inhibition of atrial natri-uretic factor release in the down-regulation of salt excretion ..... 673
Conte G *See* Memoli B et al ..... 320
Conte G *See* Sabbatini M et al ..... 875
Cook HT *See* Jansen A et al ..... 1107
Coronel F (abst) ..... 214
Corral J (abst) ..... 216
Corrigan AB (abst) ..... 1044
Cortes V (abst) ..... 223
Corvazier M (abst) ..... 230
Coto E (abst) ..... 207, 207
Coude M (abst) ..... 229
Courel M (abst) ..... 200
Couser WG *See* Floege J et al ..... 573
Coutry N *See* Kenouch S et al ..... 56
Covarsi A (abst) ..... 198
Cowin GJ (abst) ..... 1030, 1049
Craven PA, Melhem MF, DeRubertis FR: Thrombox-ane in the pathogenesis of glomerular injury in diabetes ..... 937
Crespaldi G *See* Gambaro G et al ..... 285
Crews FT *See* Guzman NJ et al ..... 33
Cross M (abst) ..... 1030
Crowley P (abst) ..... 797
Cruz JM (abst) ..... 220, 220, 220, 220, 221, 221, 221
Cuesta V (abst) ..... 198
Cuevas X (abst) ..... 214
Cundy T (abst) ..... 1035
Cunningham C (abst) ..... 1032
Curran KA, Hebert MJ, Cain BD, Wingo CS: Evidence for the presence of a K-dependent acidifying adeno-sine triphosphatase in the rabbit renal medulla ..... 1093
Cybulsky AV, Carbonetto S, Huang Q, McTavish AJ, Cyr M-D: Adhesion of rat glomerular epithelial cells to extracellular matrices: Role of $\beta_1$ integrins ..... 1099
Cyr M-D *See* Cybulsky AV et al ..... 1099
Da Col R *See* Camussi G et al ..... 1309
Daane CR (abst) ..... 794
Daha MR (abst) ..... 797, 1284
Daha MR *See* Yard BA et al ..... 383
Daina E *See* Rota S et al ..... 981
Dal Canton A *See* Conte G et al ..... 673
Dal Canton A *See* Memoli B et al ..... 320
Dallman MF (abst) ..... 800
D'Almeida EA (abst) ..... 1039
Dame M *See* Varani J et al ..... 1169
Daniels I *See* Haynes AP et al ..... 690
Danpure CJ *See* Katz A et al ..... 1408
Dansereau D *See* Gougoux A et al ..... 586
Dapena F (abst) ..... 199, 199, 214
d'Apice A (abst) ..... 1036, 1047
d'Apice AJF (abst) ..... 1036, 1041
Darnell L (abst) ..... 199
Daugirdas JT *See* Schneditz D et al ..... 1450
Davies JE, Ng LL, Kofoed-Enevoldsen A, Li LK, Earle KA, Trevisan R, Viberti GC: Intracellular pH and $Na^+/H^+$ antiport activity of cultured skin fibro-blasts from diabetics ..... 1184
Dazza MC (abst) ..... 238
de Alvaro F (abst) ..... 199, 199, 204, 205, 205, 205, 214, 214
de Arriba G (abst) ..... 210, 211, 211, 211, 211
De Bock R (abst) ..... 1285
de Castro M (abst) ..... 205
de Fijter CWH, Verbrugh HA, Oe LP, Peters EDJ, van der Meulen J, Donker AJM, Verhoef J: Peritoneal defense in continuous ambulatory versus continuous cyclic peritoneal dialysis ..... 947
de Groote D (abst) ..... 230
De Heer E (abst) ..... 1284
de Jong PE (abst) ..... 795, 1285
de la Piedra C (abst) ..... 204
De la Sen ML (abst) ..... 224
de la Torre M (abst) ..... 198
de Moerloose P (abst) ..... 235, 807
De Nicola L *See* Conte G et al ..... 673
de Nobel E (abst) ..... 794
de Ona M (abst) ..... 207
De Pauw L (abst) ..... 228
De Pauw L *See* Pradier O et al ..... 1124
de Precigout V (abst) ..... 230
De Roo G (abst) ..... 1284
de Roose R, Boer P, Fransen R, Boer WH, Koomans HA: Use of a microwave oven in the flurometric mi-cro-inulin determination (Technical Note) ..... 459
de Saussure Ph (abst) ..... 803
de Vries PMJM (abst) ..... 796
de Wind A (abst) ..... 1287
de Zeeuw D (abst) ..... 795, 1285
Degiannis D *See* Donati D et al ..... 681
Del Pino Pino MaD (abst) ..... 206
Delahousse M (abst) ..... 230
Delmez J *See* Slatopolsky E et al ..... 38:S-43
Delons S (abst) ..... 234
Demelis J (abst) ..... 1032
Denton MD *See* Brady HR et al ..... 480
Derkx F (abst) ..... 1287
Derkx FHM (abst) ..... 793
DeRubertis FR *See* Craven PA et al ..... 937
Desassis JF (abst) ..... 1283
Descamps-Latscha B (abst) ..... 230
Deschênes G *See* Antignac C et al ..... 1178
Descoeudres C (abst) ..... 803, 805, 807, 808
DeSimone JA Jr. *See* Silver SM et al ..... 161
Desjardins M *See* Ghitescu L et al ..... 25
Diaz A (abst) ..... 211
Diaz Bailon JC (abst) ..... 205
Diaz Gonzalez R (abst) ..... 226, 226
Diez J (abst) ..... 210
Diez Marques ML (abst) ..... 210
Dijkman HBPM (abst) ..... 793
Dijkman HBPM *See* Termaat R-M et al ..... 1363
Dilena B (abst) ..... 1050
Dillon MJ *See* Fitzpatrick MM et al ..... 951
Dinarello CA: Interleukin-1 and tumor necrosis factor and their naturally occurring antagonists during hemodialysis ..... 38:S-68
Dinarello CA *See* Pereira BJG et al ..... 1419

Ding XY (abst) ..... 510
Disney APS (abst) ..... 1031
Divakar D (abst) ..... 1041
Dixon BS (abst) ..... 799
Doecke C (abst) ..... 1041
Dominguez ML (abst) ..... 211
Dominquez P (abst) ..... 218
Dommergues JP (abst) ..... 233
Donadelli R *See* Rota S et al ..... 981
Donati D, Degiannis D, Raskova J, Raska K Jr: Uremic serum effects on peripheral blood mononuclear cell and purified T lymphocyte responses ..... 681
Dong DC (abst) ..... 494, 498, 499
Dong XO (abst) ..... 502
Dong YZ (abst) ..... 497
Donker AJM (abst) ..... 796, 796
Donker AJM *See* de Fijter CWH et al ..... 947
Donker AJM *See* ter Wee PM et al ..... 38:S-114
Donovan KA *See* Torres V et al ..... 364
Dooper PhMM (abst) ..... 794
Dörge A *See* Beck F-X et al ..... 843
Dosquet P (abst) ..... 230, 238
Doucet A (abst) ..... 800
Douglas JG *See* Romero MF et al ..... 1130
Doutrelepont JM (abst) ..... 228
Dracon M *See* Kandoussi A et al ..... 424
Driguez E (abst) ..... 228
Droz D (abst) ..... 228
Drüeke TB *See* Lindner A et al ..... 1328
Du J (abst) ..... 501
Du SF (abst) ..... 497
Du XH (abst) ..... 503, 508
Duan JH (abst) ..... 498
Duan L (abst) ..... 504
Dubreuil P (abst) ..... 232
Dumler F *See* Varani J et al ..... 1169
Durand D (abst) ..... 231
Durmuller U (abst) ..... 799
Dvorak HF *See* Brown LF et al ..... 1457
Eadie P (abst) ..... 1041
Earle KA *See* Davies JE et al ..... 1184
Ebb RG *See* Jurkovitz CT et al ..... 595
Ecija JL (abst) ..... 202
Eckert RL *See* Romero MF et al ..... 1130
Edez-Reyes MJ (abst) ..... 205
Egrie JC *See* Eschbach JW et al ..... 407
Eiam-Ong S, Hilden SA, King AJ, Johns CA, Madias NE: Endothelin-1 stimulates the $Na^+/H^+$ $Na^+/HCO_3^-$ transporters in rabbit renal cortex ..... 18
El Esjer N *See* Fournier A et al ..... 38:S-50
El Yandouzi EH *See* Le Grimellec C et al ..... 825
Elias A (abst) ..... 238
Elving LD (abst) ..... 794
Emancipator SN *See* Gesualdo L et al ..... 106
Endre ZH (abst) ..... 1030, 1049
England BK *See* Jurkovitz CT et al ..... 595
Epstein FH *See* Heyman S et al ..... 41
Eraklis AJ *See* Briscoe DM et al ..... 657
Ericksen M *See* Wolf G et al ..... 647
Esbrit P (abst) ..... 199
Escalada P (abst) ..... 207, 207
Escano A (abst) ..... 202
Eschbach JW, Haley NR, Egrie JC, Adamson JW: A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects ..... 407
Escolar G *See* Cases A et al ..... 668
Esparza A *See* Montinaro V et al ..... 341
Esquerda A (abst) ..... 208
Etienne I (abst) ..... 234
Eugene M (abst) ..... 236
Evan AP *See* Gardner KD Jr. et al ..... 1199
Evans RA (abst) ..... 1044
Exner M (abst) ..... 1051
Faas MM (abst) ..... 1283
Fadda GZ *See* Kiersztejn M et al ..... 602
Fadden K *See* Montinaro V et al ..... 341
Fairley KF (abst) ..... 1032, 1042
Fakir M (abst) ..... 235
Falcon TC (abst) ..... 203
Falk M (abst) ..... 1036
Falk MC (abst) ..... 1032, 1047
Falk RJ *See* Iskandar SS et al ..... 1401
Fang IJ (abst) ..... 493
Fang YC (abst) ..... 499
Fanning G (abst) ..... 1032
Faraco P (abst) ..... 1052
Farahmand H *See* Charpentier BM et al ..... 38:S-176
Farias I (abst) ..... 227
Farman N *See* Kenouch S et al ..... 56
Favero MS *See* Pegues DA et al ..... 1232
Favre H (abst) ..... 800, 801
Fdez-Fdez J (abst) ..... 198, 204, 208
Fdez-Giron F (abst) ..... 204
Fdez-Mora F (abst) ..... 202, 212
Fehlman C *See* Krapf R et al ..... 727
Fehrenbach P *See* Zeier M et al ..... 1259
Feliu F (abst) ..... 201
Fellay G (abst) ..... 805, 805
Feng HF (abst) ..... 496, 500
Feng IM (abst) ..... 501
Feng JM (abst) ..... 490
Feng ML (abst) ..... 503
Feraille E (abst) ..... 800
Ferluga D *See* Zidar N et al ..... 1444
Fernanadez MJ (abst) ..... 204
Fernandez G (abst) ..... 226
Fernandez M (abst) ..... 215
Fernandez MJ (abst) ..... 205, 214, 215
Fernandez Rivera C (abst) ..... 203
Fernandez T (abst) ..... 226
Fernandez Vega F (abst) ..... 207
Fernandez Zatarain G (abst) ..... 227
Fernandez-Reyes MJ (abst) ..... 205
Fernandez-Rivera C (abst) ..... 203
Fernandez-Vega F (abst) ..... 208
Fernandez-Zatarain G (abst) ..... 226
Feron R (abst) ..... 237
Fessi H (abst) ..... 238
Feydy P (abst) ..... 228
Field MJ (abst) ..... 1035, 1049, 1050
Fillastre JP (abst) ..... 232, 234, 236
Fillastre J-P *See* Moulin B et al ..... 127
Finbloom DS *See* Montinaro V et al ..... 341
Fine RN: Stimulating growth in uremic children (Nephrology Forum) ..... 188
Fischer A *See* Mundel P et al ..... 1017
Fischer ER (abst) ..... 1041, 1046
Fisicaro N (abst) ..... 1036
Fitzpatrick MM, Shah V, Trompeter RS, Dillon MJ, Barratt TM: Interleukin-8 and polymorphoneutrophil leucocyte activation in hemolytic uremic syndrome of childhood ..... 951

Flavier JL (abst) ..... 1044, 1045, 1045
Fleming SJ (abst) ..... 1030
Fletcher J *See* Haynes AP et al ..... 690
Floege J, Johnson RJ, Gordon K, Yoshimura A, Campbell C, Iruela-Arispe L, Alpers CE, Couser WG: Altered glomerular extracellular matrix synthesis in experimental membranous nephropathy ..... 573
Floege J, Schäffer J, Koch KM, Shaldon S: Dialysis related amyloidosis: A disease of chronic retention and inflammation? ..... 38:S-78
Floege J *See* Lonnemann G et al ..... 61
Florquin S (abst) ..... 228
Florquin S *See* Gallo CD et al ..... 851
Fogo A, Hellings SE, Inagami T, Kon V: Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity ..... 770
Fogo A *See* Kakinuma Y et al ..... 46
Fontan MP (abst) ..... 203
Foraster A (abst) ..... 199
Forester A (abst) ..... 200
Fort J (abst) ..... 201, 201
Fortenbery EJ *See* Hasbargen JA et al ..... 1398
Fournier A, Morinière P, Hamida FB, El Esjer N, Shenovda M, Ghazali A, Bouzernidj M, Achard JM, Westeel PF: Use of alkaline calcium salts as phosphate binder in uremic patients ..... 38:S-50
Fournier A *See* Lafage M-H et al ..... 1217
Fournier G (abst) ..... 230
Fraile M (abst) ..... 206
Frampton G (abst) ..... 1035, 1038
Franco A (abst) ..... 208, 224
Francois A *See* Moulin B et al ..... 127
Fransen R (abst) ..... 1286
Fransen R *See* de Roose R et al ..... 459
Fraser IR (abst) ..... 1052, 1053
Fraysse M *See* Hadj-Aïssa A et al ..... 1207
Freese D *See* Katz A et al ..... 1408
Frenken LAM *See* Koene RAP et al ..... 38:S-142
Frensdorff A *See* Brockhaus M et al ..... 663
Freudiger H (abst) ..... 806
Frey BM (abst) ..... 800, 808
Frey FJ (abst) ..... 800, 808
Fried G *See* Meister B et al ..... 617
Friedlander G *See* Le Grimellec C et al ..... 825
Fries D *See* Charpentier BM et al ..... 38:S-176
Frimat L (abst) ..... 238
Fritz AL *See* Macias WL et al ..... 308
Fromentin L (abst) ..... 238
Fruchart JC *See* Kandoussi A et al ..... 424
Frutos MA (abst) ..... 201
Fu J (abst) ..... 502
Fuentespina E (abst) ..... 213
Fuiano G *See* Conte G et al ..... 673
Fujiwara Y *See* Isaka Y et al ..... 1006
Fukuda K *See* Horikoshi S et al ..... 764
Fukui T *See* Kohno M et al ..... 860
Funai M *See* Kagami S et al ..... 700
Fusaroli M *See* Zucchelli P et al ..... 452
Ga Canton C (abst) ..... 205
Gabriel JP (abst) ..... 805
Gaggi R *See* Zucchelli P et al ..... 452
Gagne E-R *See* Lindner A et al ..... 1328
Gago E (abst) ..... 207, 207, 207, 208
Galan A (abst) ..... 218, 218, 218, 218, 221, 222
Galindo P (abst) ..... 201, 223
Gallati H (abst) ..... 808
Gallego E (abst) ..... 212
Gallego N (abst) ..... 225
Gallery E (abst) ..... 1038
Gallery EDM (abst) ..... 1039
Gallet M (abst) ..... 232
Gallieni M, Brancaccio D, Padovese P, Rolla D, Bedani P, Colantonio G, Bronzieri C, Bagni B, Tarolo G: Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients ..... 1191
Gallo CD, Jevnikar AM, Brennan DC, Florquin S, Pacheco-Silva A, Kelley VR: Autoreactive kidney-infiltrating T-cell clones in murine lupus nephritis ..... 851
Gambaro G, Cavazzana AO, Luzi P, Piccoli A, Borsatti A, Crespaldi G, Marchi E, Venturini AP, Baggio B: Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats ..... 285
Gamez C (abst) ..... 215, 215, 215, 216, 216, 226
Gan H (abst) ..... 507
Gansevoort RT (abst) ..... 1285
Gantenbein H (abst) ..... 800
Gao J (abst) ..... 509
Garattini S *See* Rota S et al ..... 981
Garay R (abst) ..... 233
Garay R *See* Lindner A et al ..... 1328
Garces L (abst) ..... 219
Garcia C (abst) ..... 227
Garcia Canton C (abst) ..... 226, 226, 227
Garcia Cortes M (abst) ..... 223
Garcia de Vinuesa M (abst) ..... 218
Garcia del Moral R (abst) ..... 222, 223, 223, 223, 223, 224, 224
Garcia Erauzkin G (abst) ..... 217
Garcia Erauzquin G (abst) ..... 216
Garcia I (abst) ..... 227
Garcia J (abst) ..... 220, 220, 220
Garcia Perez R (abst) ..... 222
Garcia Vinuesa MS (abst) ..... 218, 218, 222
Garcia-Escribano C (abst) ..... 210, 210
Garcia-Martin F (abst) ..... 210, 211, 211, 211
Garcia-Nieto V (abst) ..... 212
Garcia-Ocana A (abst) ..... 199
Garcia-Otero G (abst) ..... 225
Garcia-Perez JJ (abst) ..... 212
Gardia-Martin F (abst) ..... 211
Gardner DG (abst) ..... 234
Gardner KD Jr., Burnside JS, Skipper BJ, Swan SK, Bennett WM, Connors BA, Evan AP: On the probability that kidneys are different in autosomal dominant polycystic disease ..... 1199
Garin J (abst) ..... 198
Garrigos E (abst) ..... 219, 220
Garron MP (abst) ..... 198
Gary J (abst) ..... 229
Garzoni D (abst) ..... 807
Gas JM (abst) ..... 208, 224
Gasco J (abst) ..... 213
Gaspari F *See* Rota S et al ..... 981
Gavras I: Bradykinin-mediated effects of ACE inhibition (Nephrology Forum) ..... 1020
Gay RE *See* van den Wall Bake AWL et al ..... 374
Gay S *See* van den Wall Bake AWL et al ..... 374
Gaylin DS *See* Wolfe RA et al ..... 991
Gea T (abst) ..... 204
Geary DF, Harvey EA, MacMillan JH, Goodman Y, Scott M, Balfe JW: The peritoneal equilibration test in children ..... 102
Geberth S *See* Zeier M et al ..... 1259

Geng L (abst) ..... 488, 488, 490
Gentil MA (abst) ..... 219
George CRP (abst) ..... 1044
Gesualdo L, Emancipator SN, Kesselheim C, Lamm ME: Glomerular hemodynamics and eicosanoid synthesis in a rat model of IGA nephropathy ..... 106
Geven W (abst) ..... 795
Ghannoun Z (abst) ..... 228
Ghazali A *See* Fournier A et al ..... 38:S-50
Ghitescu L, Desjardins M, Bendayan M: Immunocytochemical study of glomerular premeability to anionic, neutral and cationic albumins ..... 25
Gibbs DF *See* Varani J et al ..... 1169
Gie S (abst) ..... 229
Giebisch G *See* Beck F-X et al ..... 272
Gil L (abst) ..... 219
Gila J (abst) ..... 210
Gila JA (abst) ..... 210
Giliberti A *See* Sabbatini M et al ..... 875
Gillespie CG (abst) ..... 1048
Gillies AHB (abst) ..... 1039, 1042
Gimenez M (abst) ..... 219
Ginalski JM (abst) ..... 801
Giocoechae M (abst) ..... 218
Giocondi M-C *See* Le Grimellec C et al ..... 825
Giostra E (abst) ..... 803
Gitelman HJ, Alderman F, Perry SJ: Renal handling of silicon in normals and patients with renal insufficiency ..... 957
Gladziwa U *See* Kooman JP et al ..... 718
Glasgow EF (abst) ..... 1049, 1050
Glasscock RJ: Treatment of immunologically mediated glomerular disease ..... 38:S-121
Glez Parra E (abst) ..... 198
Glick AD *See* Hudson BG et al ..... 179
Gluck Z (abst) ..... 806
Gobernado JM (abst) ..... 225
Gokal R *See* Hutchison AJ et al ..... 38:S-153
Goldman M (abst) ..... 228
Goldman M *See* Pradier O et al ..... 1124
Golper TA (abst) ..... 209, 209
Gomez Campdera F (abst) ..... 218
Gomez E (abst) ..... 207, 207, 207, 207, 208, 208
Gomez F (abst) ..... 217, 221, 222
Gomez Morales M (abst) ..... 223, 224
Gomez R (abst) ..... 227
Gomez RA *See* Chevalier RL et al ..... 400
Gomez Ullate P (abst) ..... 216
Gomez-Morales M (abst) ..... 223
Gomez-Pardal A (abst) ..... 201
Gomez-Ullate P (abst) ..... 217
Gonzalez J (abst) ..... 212
Gonzalez Jaranay M (abst) ..... 223
Gonzalez JR (abst) ..... 198
Gonzalez L (abst) ..... 200
Gonzalez M (abst) ..... 198, 210, 210
Gonzalez Parra E (abst) ..... 204
Gonzalez R (abst) ..... 216
Gonzalez-Molina M (abst) ..... 201, 202
Gonzalez-Posada JM (abst) ..... 211, 212
Gonzalo A (abst) ..... 224, 225, 225
Goodman Y *See* Geary DF et al ..... 102
Gordon K *See* Floege J et al ..... 573
Gorostidi M (abst) ..... 207, 207, 207, 208, 208
Gorriz JL (abst) ..... 220, 220, 220, 220, 221, 221, 221
Goshima S *See* Yokoyama H et al ..... 755
Gotheil C (abst) ..... 229
Gougoux A, Zan N, Dansereau D, Vinay P: Metabolic effects of 4-pentenoate on isolated dog kidney tubules ..... 586
Goumaz C (abst) ..... 807
Gouyon J-B (abst) ..... 799
Grabowski P (abst) ..... 1032
Gradwohl SE *See* Wharton WW III et al ..... 174
Grasty MS *See* Roger SD et al ..... 975
Grau E (abst) ..... 217
Green Y (abst) ..... 1049
Greenspan B *See* Pegues DA et al ..... 1232
Greenwood C *See* Pei Y et al ..... 960
Gregson N (abst) ..... 1038
Gretz N *See* Amann K et al ..... 1079
Grigoras O (abst) ..... 799
Grino JM (abst) ..... 203
Grond J (abst) ..... 793, 795, 798, 1283, 1284
Gros F *See* Antignac C et al ..... 1178
Groussin A (abst) ..... 230
Grudenich R (abst) ..... 1048
Grunfeld J-P (abst) ..... 233
Gruss E (abst) ..... 205
Gu H (abst) ..... 497
Gu J (abst) ..... 505
Gu YM (abst) ..... 504
Gubler M-C *See* Antignac C et al ..... 1178
Gudat F (abst) ..... 799
Guerin C (abst) ..... 231
Guerrero A (abst) ..... 219
Guignard J-P (abst) ..... 799, 800, 802
Guivarch G (abst) ..... 229
Gunning ME, Brenner BM: Natriuretic peptides and the kidney: Current concepts ..... 38:S-127
Gunwar S *See* Hudson BG et al ..... 179
Gurwicz S *See* Brockhaus M et al ..... 663
Gutierrez A, Alvestrand A, Bergström J: Membrane selection and muscle protein catabolism ..... 38:S-86
Guzman NJ, Crews FT: Regulation of inositol transport by glucose and protein kinase C in mesangial cells ..... 33
Gyory AZ (abst) ..... 1039, 1040, 1043
Gyr K (abst) ..... 802, 806
Haas HG (abst) ..... 806
Hacini J (abst) ..... 231
Hack CE (abst) ..... 796
Hadj-Aïssa A, Bankir L, Fraysse M, Bichet DG, Laville M, Zech P, Pozet N: Influence of the level of hydration on the renal response to a protein meal ..... 1207
Haites NE (abst) ..... 1032, 1037
Hakim R *See* Held PJ et al ..... 38:S-16
Haley NR *See* Eschbach JW et al ..... 407
Hamel D (abst) ..... 237
Hamida FB *See* Fournier A et al ..... 38:S-50
Hammond TG, Majewski R: Analysis and isolation of renal tubular cells by flow cytometry (Technical Note) ..... 997
Han J (abst) ..... 505
Han KH (abst) ..... 506
Hancock W (abst) ..... 1046
Hancock WW (abst) ..... 1033, 1033
Hang QY (abst) ..... 488
Hannaert P *See* Lindner A et al ..... 1328
Hannedouche T (abst) ..... 229
Hao CL (abst) ..... 494
Hao CM (abst) ..... 508, 508
Haralson MA *See* Hudson BG et al ..... 179

Haran N *See* Brockhaus M et al ..... 663
Hardie I (abst) ..... 1048, 1048
Hardie IR (abst) ..... 1048
Hardy M *See* Nissim I et al ..... 775
Harmon WE *See* Briscoe DM et al ..... 657
Harris DCH (abst) ..... 1041, 1045, 1046, 1052, 1052, 1053
Harris PJ (abst) ..... 1048
Harris S (abst) ..... 1044
Hartley L (abst) ..... 1048, 1048
Harvey EA *See* Geary DF et al ..... 102
Hasbargen BJ *See* Hasbargen JA et al ..... 1398
Hasbargen JA, Hasbargen BJ, Fortenbery EJ: Effect of intraperitoneal neostigmine on peritoneal transport characteristics in CAPD ..... 1398
Hasslocher H (abst) ..... 802
Haverman JF (abst) ..... 1287
Hawley C (abst) ..... 1048
Hawley CM (abst) ..... 1048
Hay N (abst) ..... 1043
Hay NM (abst) ..... 1043
Haynes AP, Daniels I, Porter C, Fletcher J, Morgan AG: Abnormal cytoplasmic pH regulation during activation in uremic neutrophils ..... 690
Hayslett JP *See* Bastl CP et al ..... 250
Hazel SJ (abst) ..... 1048
He CJ (abst) ..... 231
He C-J *See* Meulders Q et al ..... 327
He GR (abst) ..... 499
He YX (abst) ..... 499
He YZ (abst) ..... 499
Hebert MJ *See* Curran KA et al ..... 1093
Heeg JE (abst) ..... 1285
Heidenheim RP *See* Lindsay RM et al ..... 38:S-32
Held PJ, Blagg CR, Liska DW, Port FK, Hakim R, Levin N: The dose of hemodialysis according to dialysis prescription in Europe and the United States ... 38:S-16
Held PJ *See* Port FK et al ..... 967
Held PJ *See* Wolfe RA et al ..... 991
Helderman JH *See* Hudson BG et al ..... 179
Hellings SE *See* Fogo A et al ..... 770
Hemmelder MH (abst) ..... 795
Henderson IS *See* Taylor JE et al ..... 442
Henderson LW, Jacobs C: Introduction ..... 38:S-1
Henderson TR *See* Wharton WW III et al ..... 174
Hennessy A (abst) ..... 1052
Henning P (abst) ..... 1044
Herbelin A (abst) ..... 230
Hermus ARMM (abst) ..... 1287
Hernandez C (abst) ..... 202
Hernandez D (abst) ..... 211, 212
Hernandez E (abst) ..... 212, 213
Hernando L (abst) ..... 216
Herrera J (abst) ..... 198
Herrero E (abst) ..... 215
Herve P (abst) ..... 237
Hess B (abst) ..... 803
Hesse CJ (abst) ..... 794
Hestin D (abst) ..... 238
Heule H (abst) ..... 802
Hevey K *See* Montinaro V et al ..... 341
Hewitson T (abst) ..... 1051, 1052
Hewitt IK (abst) ..... 1038
Heyman S, Spokes K, Rosen S, Epstein FH: Mechanism of glycine protection in hypoxic injury: Analogies with glycine receptor ..... 41
Hibino T *See* Aukema HM et al ..... 837
Hiesse C *See* Charpentier BM et al ..... 38:S-176
Hilbers C (abst) ..... 795
Hilden SA *See* Eiam-Ong S et al ..... 18
Hill GS *See* Schwartz MM et al ..... 743
Hoad K (abst) ..... 1045
Hodsman A *See* Lindsay RM et al ..... 38:S-32
Hoedemaeker PhJ (abst) ..... 1284
Hoitsma AJ (abst) ..... 794, 1286
Hökfelt T *See* Meister B et al ..... 617
Holdsworth SR (abst) ..... 1032, 1034
Holgert H *See* Meister B et al ..... 617
Holley K *See* Schwartz MM et al ..... 743
Holley KE *See* Torres V et al ..... 364
Holthöfer H *See* Reivinen J et al ..... 624
Holthöfer H *See* Suikkari A-M et al ..... 749
Holub BJ *See* Aukema HM et al ..... 837
Hong JM (abst) ..... 506
Hoogeveen E (abst) ..... 1287
Hoover RL *See* Awazu M et al ..... 265
Hopfer U *See* Romero MF et al ..... 1130
Horber FF (abst) ..... 803, 807, 808
Horikoshi S, Fukuda K, Ray PE, Sawada M, Bruggeman LA, Klotman PE: A PCR method for the quantitative assessment of mRNA for laminin A, B1, and B2 chains (Technical Note) ..... 764
Horio T *See* Kohno M et al ..... 860
Hörl WH *See* Ritz E et al ..... 38:S-37
Hors-Cayla M-C *See* Antignac C et al ..... 1178
Horvath JS (abst) ..... 1052
Hory B (abst) ..... 237
Hostetter MK *See* Nath KA et al ..... 38:S-109
Hostetter TH *See* Nath KA et al ..... 38:S-109
Hostikka SL *See* Smeets HJM et al ..... 83
Hou FF (abst) ..... 491, 500, 501
Hou XY (abst) ..... 495
House AK (abst) ..... 1038
Hu MC (abst) ..... 492
Hu WX (abst) ..... 510, 510
Hu YX (abst) ..... 499
Huang FX (abst) ..... 493
Huang GY (abst) ..... 500
Huang JK *See* Lee YH et al ..... 292
Huang JZ (abst) ..... 493
Huang Q *See* Cybulsky AV et al ..... 1099
Huang QY (abst) ..... 489, 489
Huang SM (abst) ..... 491
Huang WC *See* Lee YH et al ..... 292
Huang WH *See* Lowrie EG et al ..... 38:S-22
Huang XP (abst) ..... 506
Huang XZ (abst) ..... 492
Hudkins KL *See* Alpers CE et al ..... 390
Hudson BG, Kalluri R, Gunwar S, Weber M, Ballester F, Hudson JK, Noelken ME, Sarras M, Richardson WR, Saus J, Abrahamson DR, Glick AD, Haralson MA, Helderman JH, Stone WJ, Jacobson HR: The pathogenesis of Alport syndrome involves type IV collagen molecules containing $\alpha$3(IV) chain: Evidence from anti-GBM nephritis after renal transplantation ..... 179
Hudson JK *See* Hudson BG et al ..... 179
Huet F (abst) ..... 799
Huguet F (abst) ..... 211
Huitema MG (abst) ..... 1284
Huitema S (abst) ..... 793
Hulter HN *See* Krapf R et al ..... 727
Humbert G (abst) ..... 234
Humphreys MH (abst) ..... 234, 234, 234, 236

Huo M (abst) ..... 498
Hurlimann J (abst) ..... 801
Huser B (abst) ..... 809
Husi H (abst) ..... 802
Hutchinson P (abst) ..... 1037
Hutchison AJ, Gokal R: Improved solutions for peritoneal dialysis: Physiological calcium solutions, osmotic agents and buffers ..... 38:S-153
Huysmans FThM (abst) ..... 795
Huysmans FTM (abst) ..... 1286
Iaina A *See* Weintraub M et al ..... 1247
Ibels LS (abst) ..... 1040
Ichikawa I *See* Kakinuma Y et al ..... 46
Ichikawa L *See* Awazu M et al ..... 265
Idatte JM (abst) ..... 236
Ikeda K *See* Yokoyama H et al ..... 755
Ikeda M *See* Kohno M et al ..... 860
Ikram H (abst) ..... 1041
Imai H *See* Wakui H et al ..... 888
Imanishi M, Akabane S, Kawamura M, Matsushima Y, Kuramochi M, Omae T: Angiotensin II does not increase renal prostaglandin $E_2$ in response to pressure reduction ..... 417
Imbimbo BP (abst) ..... 1042
Inagami T *See* Fogo A et al ..... 770
Inagami T *See* Torres V et al ..... 364
Inai S *See* Yoshioka K et al ..... 1253
Inkster JA (abst) ..... 1041
Inoue T *See* Isaka Y et al ..... 1006
Iorio EL *See* Camussi G et al ..... 1309
Iruela-Arispe L *See* Floege J et al ..... 573
Isaka Y, Fujiwara Y, Yamamoto S, Ochi S, Shin SH, Inoue T, Tagawa K, Kamada T, Ueda N: Modified plasma clearance technique using nonradioactive iothalamate for measuring GFR (Technical Note) ..... 1006
Ishino T *See* Wakui H et al ..... 888
Iskandar SS, Falk RJ, Jennette JC: Clinical and pathologic features of fibrillary glomerulonephritis ..... 1401
Jabari NS (abst) ..... 214
Jackson B (abst) ..... 1030
Jackson S (abst) ..... 797
Jackson S *See* van den Wall Bake AWL et al ..... 374
Jacobberger JW *See* Romero MF et al ..... 1130
Jacobs C *See* Henderson LW et al ..... 38:S-1
Jacobs IG (abst) ..... 1044
Jacobson HR *See* Hudson BG et al ..... 179
Jaeger P *See* Krapf R et al ..... 727
Jaeger Ph. (abst) ..... 803
Jaeger Ph (abst) ..... 801, 805, 808
James WE (abst) ..... 1041
Jandeleit K (abst) ..... 1030
Jansen A, Lewis S, Cattell V, Cook HT: Arginase is a major pathway of L-arginine metabolism in nephritic glomeruli ..... 1107
Jansen EHJM (abst) ..... 1283
Jansen JLJ (abst) ..... 1287
Jansen JWCM (abst) ..... 797
Jansweijer MCE *See* Smeets HJM et al ..... 83
Jarillo MD (abst) ..... 210, 211, 211, 211, 211
Jarvis WR *See* Pegues DA et al ..... 1232
Jeannet M (abst) ..... 807
Jeekel J (abst) ..... 1285
Jennette JC *See* Iskandar SS et al ..... 1401
Jennische E *See* Matejka GL et al ..... 1113
Jevnikar AM *See* Brennan DC et al ..... 279
Jevnikar AM *See* Gallo CD et al ..... 851
Ji DX (abst) ..... 503
Ji YL (abst) ..... 501
Jia JK (abst) ..... 499
Jiang GW (abst) ..... 496
Jiang XY (abst) ..... 492
Jimenez AC (abst) ..... 205
Jimenez C (abst) ..... 205, 205
Jimenez M (abst) ..... 216
Jimenez W *See* Brady HR et al ..... 480
Jimeno A (abst) ..... 212
Jin H (abst) ..... 508
Jin YF (abst) ..... 510
Jofre R (abst) ..... 217, 218, 221
Johchi M *See* Kohno M et al ..... 860
Johns CA *See* Eiam-Ong S et al ..... 18
Johnson CM *See* Torres V et al ..... 364
Johnson RJ *See* Alpers CE et al ..... 390
Johnson RJ *See* Floege J et al ..... 573
Johnston CI (abst) ..... 1030
Joles JA (abst) ..... 1283, 1284
Jones BF (abst) ..... 1039
Jones MC (abst) ..... 1037, 1047
Joordens J (abst) ..... 795
Jordans JGM (abst) ..... 795
Joyeux V (abst) ..... 237, 238
Julian BA (abst) ..... 797
Julian BA *See* van den Wall Bake AWL et al ..... 374
Julkunen M *See* Suikkari A-M et al ..... 749
Junco E (abst) ..... 221
Jungbluth H (abst) ..... 806
Jungers P (abst) ..... 229
Jungers P *See* Lindner A et al ..... 1328
Jurkovitz CT, England BK, Ebb RG, Mitch WE: Influence of ammonia and pH on protein and amino acid metabolism in LLC-$PK_1$ cells ..... 595
Kachko A (abst) ..... 231
Kadereit S, Michelson S, Mougenot B, Thibault P, Verroust PJ, Mignon F, Colimon R, Ronco PM: Polymerase chain reaction detection of cytomegalovirus genome in renal biopsies (Technical Note) ..... 1012
Kagami S, Okada K, Funai M, Matui K, Oite T, Kawachi H, Shimizu F, Kuroda Y: A monoclonal antibody (1G10) recognizes a novel human mesangial antigen ..... 700
Kainer G (abst) ..... 1040
Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A: Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure ..... 46
Kalina S (abst) ..... 1041
Kallenberg CGM (abst) ..... 1284
Kalluri R *See* Hudson BG et al ..... 179
Kalowski S (abst) ..... 1044
Kamada T *See* Isaka Y et al ..... 1006
Kämäräinen M *See* Suikkari A-M et al ..... 749
Kamoun P (abst) ..... 229
Kaname S, Uchida S, Ogata E, Kurokawa K: Autocrine secretion of transforming growth factor-$\beta$ in cultured rat mesangial cells ..... 1319
Kanazawa M (abst) ..... 1030
Kandoussi A, Cachera C, Pagniez D, Dracon M, Fruchart JC, Tacquet A: Plasma level of lipoprotein Lp(a) is high in predialysis or hemodialysis, but not in CAPD patients ..... 424
Kanfer A (abst) ..... 231, 804
Karmali M (abst) ..... 1286

Kashtan CE, Kim Y: Distribution of the α1 and α2 chains of collagen IV and of collagens V and VI in Alport syndrome ..... 115
Kasiske BL *See* Keane WF et al ..... 38:S-134
Katz A, Freese D, Danpure CJ, Scheinman JI, Mauer SM: Success of kidney transplantation in oxalosis is unrelated to residual hepatic enzyme activity ..... 1408
Kaufman AM *See* Schneditz D et al ..... 1450
Kawachi H *See* Kagami S et al ..... 700
Kawamura M *See* Imanishi M et al ..... 417
Kawamura T *See* Kakinuma Y et al ..... 46
Kazatchkine M (abst) ..... 228
Kazatchkine MD (abst) ..... 228
Keane WF, St. Peter JV, Kasiske BL: Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory? ..... 38:S-134
Kelber J *See* Slatopolsky E et al ..... 38:S-43
Kellerman PS, Bogusky RT: Microfilament disruption occurs very early in ischemic proximal tubule cell injury ..... 896
Kelley VR *See* Brennan DC et al ..... 279
Kelley VR *See* Gallo CD et al ..... 851
Kemeny E (abst) ..... 799
Kemp GJ (abst) ..... 1031, 1038, 1049
Kempson SA *See* Abraham MI et al ..... 1070
Kenner T *See* Schneditz D et al ..... 1425
Kenouch S (abst) ..... 230
Kenouch S, Coutry N, Farman N, Bonvalet J-P: Multiple patterns of 11β-hydroxysteroid dehydrogenase catalytic activity along the mammalian nephron ..... 56
Kepenekian G (abst) ..... 232
Kerjaschki D (abst) ..... 1034, 1051
Kerr PG (abst) ..... 1034, 1040, 1044, 1045, 1045, 1045
Keshaviah P: Adequacy of CAPD: A quantitative approach ..... 38:S-160
Kesselheim C *See* Gesualdo L et al ..... 106
Kessler M (abst) ..... 238
Keusch G (abst) ..... 808
Kida H *See* Yokoyama H et al ..... 755
Kiersztejn M, Smogorzewski M, Thanakitcharu P, Fadda GZ, Massry SG: Decreased $O_2$ consumption by PMNL from humans and rats with CRF: Role of secondary hyperparathyroidism ..... 602
Killen PD *See* Varani J et al ..... 1169
Kim MS *See* Briscoe DM et al ..... 657
Kim Y *See* Kashtan CE et al ..... 115
Kincaid-Smith P (abst) ..... 1038, 1042, 1047, 1051, 1052
Kincaid-Smith PS (abst) ..... 1032, 1052, 1053
King AJ *See* Eiam-Ong S et al ..... 18
King AJ *See* Pereira BJG et al ..... 1419
Kinnaert P (abst) ..... 228
Kinnaert P *See* Pradier O et al ..... 1124
Kinnear BF (abst) ..... 1038
Kirk KA *See* van den Wall Bake AWL et al ..... 374
Kirwan PD (abst) ..... 1052
Kiss D (abst) ..... 802, 806
Klahr S *See* Brunskill NJ et al ..... 11
Klahr S *See* Reyes AA et al ..... 632
Kleinknecht C *See* Terzi F et al ..... 354
Kleinknecht D (abst) ..... 229, 232, 233
Klok PA (abst) ..... 1283, 1284
Kloke HJ (abst) ..... 795
Klotman PE *See* Horikoshi S et al ..... 764
Knebelmann B *See* Antignac C et al ..... 1178
Knight JF (abst) ..... 1032, 1036, 1047
Knight-Gibson C *See* Attman P-O et al ..... 1381
Knoflach A (abst) ..... 804
Kobayashi K *See* Yokoyama H et al ..... 755
Kobayashi R *See* Wakui H et al ..... 888
Kobayashi S, Venkatachalam M: Differential effects of calorie restriction on glomeruli and tubules of the remnant kidney ..... 710
Koch KM *See* Floege J et al ..... 38:S-78
Koch KM *See* Lonnemann G et al ..... 61
Koene RAP (abst) ..... 794, 795, 1286
Koene RAP, Frenken LAM: Role of rHuEPO for treatment of uremic anemia prior to end-stage renal disease ..... 38:S-142
Kofoed-Enevoldsen A *See* Davies JE et al ..... 1184
Kohno M, Horio T, Ikeda M, Yokokawa K, Fukui T, Yasunari K, Kurihara N, Takeda T, Johchi M: Angiotensin II stimulates endothelin-1 secretion in cultured rat mesangial cells ..... 860
Koide H *See* Mizokuchi M et al ..... 335
Koistinen R *See* Suikkari A-M et al ..... 749
Koitabashi Y *See* Yoshioka K et al ..... 1253
Kokolo J (abst) ..... 228
Kolta A (abst) ..... 237
Komatsuda A *See* Wakui H et al ..... 888
Kon V *See* Fogo A et al ..... 770
Koolen MI (abst) ..... 1287
Kooman JP, Gladziwa U, Böcker G, van Bortel LMAB, van Hooff JP, Leunissen KML: Role of the venous system in hemodynamics during ultrafiltration and bicarbonate dialysis ..... 718
Koomans HA (abst) ..... 1283, 1286
Koomans HA *See* de Roose R et al ..... 459
Koomen GCM (abst) ..... 793, 797, 798, 1286
Koopman MG (abst) ..... 793
Kooymans-Couthino M (abst) ..... 1284
Kooymans-Couthino M *See* Yard BA et al ..... 383
Kortebi S (abst) ..... 219
Koumantakis G (abst) ..... 1038
Kouw PM (abst) ..... 796
Kraenzlin ME (abst) ..... 806
Kraft N (abst) ..... 1036, 1037
Kramers C (abst) ..... 793
Krapf R (abst) ..... 804
Krapf R, Jaeger P, Hulter HN, Fehlman C, Takkinen R: Chronic respiratory alkalosis induces renal PTH-resistance, hyperphosphatemia and hypocalcemia in humans ..... 727
Krediet RT (abst) ..... 797, 798, 1287
Kreis H: Antilymphocyte globulins in kidney transplantation ..... 38:S-188
Krenning E (abst) ..... 1287
Kriaa F *See* Charpentier BM et al ..... 38:S-176
Kriz W *See* Mundel P et al ..... 1017
Kriz W *See* Nagata M et al ..... 136
Kriz W *See* Nagata M et al ..... 148
Kubota M *See* Mizokuchi M et al ..... 335
Kummer W *See* Mundel P et al ..... 1017
Kunkel SL *See* Brown Z et al ..... 95
Kuo V (abst) ..... 1038
Kupiec-Weglinski J (abst) ..... 1046
Kupiec-Weglinski JW (abst) ..... 1033
Kuramochi M *See* Imanishi M et al ..... 417
Kurihara N *See* Kohno M et al ..... 860
Kuroda Y *See* Kagami S et al ..... 700
Kurokawa K *See* Kaname S et al ..... 1319
Kveder R *See* Zidar N et al ..... 1444

Lafage M-H, Combe C, Fournier A, Aparicio M: Keto-diet, physiological calcium intake and native vitamin D improve renal osteodystrophy ..... 1217
Lam SS (abst) ..... 1042
Lambert M-C *See* Lameire NH et al ..... 426
Lameire NH, Vanholder R, Veyt D, Lambert M-C, Ringoir S: A longitudinal, five year survey of urea kinetic parameters in CAPD patients ..... 426
Lamm ME *See* Gesualdo L et al ..... 106
Lampe M (abst) ..... 803
Lampreabe I (abst) ..... 216, 217
Lan HY (abst) ..... 1034, 1051
Lan S-P *See* Schwartz MM et al ..... 743
Landmann J (abst) ..... 807, 808, 809, 809
Lang CC, Choy A-MJ, Balfour DJK, Struthers AD: Prazosin attentuates the natriuretic response to atrial natriuretic factor in man ..... 433
Laouari D *See* Terzi F et al ..... 354
Lardelli P (abst) ..... 222, 223
Lavaud S (abst) ..... 235
Lavaud S *See* Vincent C et al ..... 1434
Laville M *See* Hadj-Aïssa A et al ..... 1207
Le Grimellec C, Friedlander G, El Yandouzi EH, Zlatkine P, Giocondi M-C: Membrane fluidity and transport properties in epithelia (Editorial Review) ..... 825
Le Moyec L (abst) ..... 236
Le Pogamp P (abst) ..... 237, 238
Ledingham JGG (abst) ..... 1031, 1038, 1049
Lee ASN (abst) ..... 1050
Lee KY (abst) ..... 1044
Lee P (abst) ..... 1043, 1044, 1045
Lee WT (abst) ..... 1035
Lee YH, Huang WC, Chang LS, Chen MT, Huang JK: Uninephrectomy enhances urolithiasis in ethylene glycol treated rats ..... 292
Leemhuis MP (abst) ..... 795
LeFebvre JM *See* Lindsay RM et al ..... 38:S-32
Lehmann HG *See* Wharton WW III et al ..... 174
Leivo I *See* Suikkari A-M et al ..... 749
Lemire JM *See* Portman RJ et al ..... 1238
Lemmink HH *See* Smeets HJM et al ..... 83
Lemoine R (abst) ..... 801, 804
Lenzner B *See* Lonnemann G et al ..... 61
Lepogamp P (abst) ..... 229
Lerch R (abst) ..... 233
Lesavre P (abst) ..... 229, 233
Leski M (abst) ..... 233, 233, 235, 801, 804, 805, 806, 807
Leslie G (abst) ..... 1044
Leumann E (abst) ..... 802
Leunissen KML *See* Kooman JP et al ..... 718
Lever M (abst) ..... 1030, 1035, 1050
Levey AS *See* Pereira BJG et al ..... 1419
Levey RH *See* Briscoe DM et al ..... 657
Levin N *See* Held PJ et al ..... 38:S-16
Levin NW *See* Schneditz D et al ..... 1450
Levy M (abst) ..... 229
Lew NL *See* Lowrie EG et al ..... 38:S-22
Lewis DJ (abst) ..... 1043
Lewis EJ *See* Schwartz MM et al ..... 743
Lewis S *See* Jansen A et al ..... 1107
Lewis-Barned NJ (abst) ..... 1030, 1039
Leypoldt JK, Blindauer KM: Convection does not govern plasma to dialysate transport of protein ..... 1412
Li HO (abst) ..... 501, 503
Li HQ (abst) ..... 490
Li J (abst) ..... 506
Li JJ (abst) ..... 494, 501
Li JZ (abst) ..... 506
Li LK *See* Davies JE et al ..... 1184
Li LM (abst) ..... 502
Li LS (abst) .. 488, 488, 489, 489, 490, 490, 490, 495, 498, 498, 503, 504, 504, 505, 510, 510
Li LX (abst) ..... 505
Li M (abst) ..... 1039
Li MB (abst) ..... 499
Li MH (abst) ..... 494
Li SM (abst) ..... 503, 506
Li XM (abst) ..... 505
Li XP (abst) ..... 490, 503
Li XW (abst) ..... 488, 489, 489, 504
Li YJ (abst) ..... 493
Li ZQ (abst) ..... 496
Liang M (abst) ..... 500
Liano F (abst) ..... 215, 216, 216
Liao LI (abst) ..... 506
Liao LS (abst) ..... 495, 503
Libetta C *See* Memoli B et al ..... 320
Lillehei C *See* Briscoe DM et al ..... 657
Lin SY (abst) ..... 504, 508, 508, 508
Lin ZG (abst) ..... 493
Linas SL, Whittenburg D, Parsons PE, Repine JE: Mild renal ischemia activates primed neutrophils to cause acute renal failure ..... 610
Lindberg JS *See* Wharton WW III et al ..... 174
Lindholm B, Bergström J: Nutritional aspects of peritoneal dialysis ..... 38:S-165
Lindner A, Gagne E-R, Zingraff J, Jungers P, Drüeke TB, Hannaert P, Garay R: A circulating inhibitor of the RBC membrane calcium pump in chronic renal failure ..... 1328
Lindsay RM, Spanner E, Heidenheim RP, LeFebvre JM, Hodsman A, Baird J, Allison MEM: Which comes first, Kt/V or PCR—Chicken or egg? ..... 38:S-32
Ling YD (abst) ..... 500
Lipkowitz MS *See* London RD et al ..... 300
Liron M *See* Weintraub M et al ..... 1247
Liska DW *See* Held PJ et al ..... 38:S-16
Liu BC (abst) ..... 508
Liu DT (abst) ..... 1038
Liu MD (abst) ..... 507
Liu P (abst) ..... 500, 501
Liu SQ (abst) ..... 495
Liu SS (abst) ..... 507
Liu XR (abst) ..... 494, 510
Liu Y (abst) ..... 508
Liu YC (abst) ..... 491
Liu ZH (abst) ..... 488, 490
Livesey J (abst) ..... 1030
Loinaz C (abst) ..... 227
London RD, Lipkowitz MS, Abramson RG: Altered membrane ionic permeability in a rat model of chronic renal failure ..... 300
Lonergan MA (abst) ..... 1050
Lonnemann G, Behme TC, Lenzner B, Floege J, Schulze M, Colton CK, Koch KM, Shaldon S: Permeability of dialyzer membranes to TNFα-inducing substances derived from water bacteria ..... 61
Loose-Mitchell DS *See* Portman RJ et al ..... 1238
Lopez Caballero J (abst) ..... 223
Lopez Caballero JJ (abst) ..... 223
Lopez de Novales E (abst) ..... 201, 202
Lopez Gomez JM (abst) ..... 221

Lopez Larrea C (abst) ..... 207, 207
Lopez Longo J (abst) ..... 217
Lopez M (abst) ..... 232
Lopez-Gomez JM (abst) ..... 217, 218
Lopez-Larrea C (abst) ..... 207
Lopez-Pedret J *See* Cases A et al ..... 668
Lopez-Revuelta K (abst) ..... 204, 205, 205, 205
Lorenzo V (abst) ..... 211, 212
Lou DX (abst) ..... 499, 502, 502
Lou HM (abst) ..... 496
Lowrie EG, Lew NL, Huang WH: Race and diabetes as death risk predictors in hemodialysis patients ..... 38:S-22
Lozano L (abst) ..... 210, 211, 211
Lu JY (abst) ..... 501
Lu LJ (abst) ..... 504
Lu T (abst) ..... 501
Lu YX (abst) ..... 493, 493, 507
Lucas A (abst) ..... 200
Lucio J (abst) ..... 210
Lui YH (abst) ..... 507
Lun LT (abst) ..... 496
Luno J (abst) ..... 222
Lupus Nephritis Collaborative Study Group *See* Schwartz MM et al ..... 743
Luykx-de Bakker SA (abst) ..... 796
Luzar S *See* Zidar N et al ..... 1444
Luzi P *See* Gambaro G et al ..... 285
Lynn KL (abst) ..... 1040, 1041, 1043, 1043, 1046
Ma HH (abst) ..... 492
Ma L (abst) ..... 497
Ma LJ (abst) ..... 509
Ma PD (abst) ..... 496
Ma XY (abst) ..... 492
Ma YR (abst) ..... 504
Maack T *See* Price DA et al ..... 75
Machado M (abst) ..... 211
Machielsen T (abst) ..... 794
Macia A (abst) ..... 214
Macia MA (abst) ..... 199, 199
Macias WL, McAteer JA, Tanner GA, Fritz AL, Armstrong WMD: NaCl transport by Madin Darby canine kidney cyst epithelial cells ..... 308
Mackow RC *See* Pegues DA et al ..... 1232
MacMillan JH *See* Geary DF et al ..... 102
Macrae J (abst) ..... 1036
Mactier RA *See* Taylor JE et al ..... 442
Maddens E (abst) ..... 1048
Madias NE *See* Eiam-Ong S et al ..... 18
Maduell F (abst) ..... 217, 217
Maguire J (abst) ..... 1033, 1033
Mahiques E (abst) ..... 222, 222
Mahony JF (abst) ..... 1031
Majdalani G (abst) ..... 231
Majewski R *See* Hammond TG et al ..... 997
Maki S *See* Yoshioka K et al ..... 1253
Mal F (abst) ..... 229, 232
Mall G *See* Amann K et al ..... 1079
Mallafre JM (abst) ..... 208, 209
Malliaros J (abst) ..... 1034
Malluche HH, Monier-Faugere M-C: Risk of adynamic bone disease in dialyzed patients ..... 38:S-62
Mampaso F (abst) ..... 216
Man in 'tVeld A (abst) ..... 1287
Man NK (abst) ..... 230, 231, 237
Manchon J (abst) ..... 232
Mandet C (abst) ..... 228
Manivel JC *See* Paller MS et al ..... 1345
Manseau EJ *See* Brown LF et al ..... 1457
Mant TGK (abst) ..... 1042
Marcello M (abst) ..... 227
Marcen R (abst) ..... 215, 216, 226
Marchant A (abst) ..... 228
Marchant A *See* Pradier O et al ..... 1124
Marchi E *See* Gambaro G et al ..... 285
Marcus RG *See* Brosius FC III et al ..... 1086
Mariano F, Tetta C, Montrucchio G, Cavalli PL, Camussi G: Role of $\alpha$1-proteinase inhibitor in restraining peritoneal inflammation in CAPD patients ..... 735
Marigliano N (abst) ..... 198
Marin M (abst) ..... 205
Marin R (abst) ..... 207, 208
Marinoso LL (abst) ..... 214
Marshall BC *See* Tomooka S et al ..... 1462
Marti L (abst) ..... 221
Martin AA (abst) ..... 1048
Martin Ambrosio R (abst) ..... 210
Martin J (abst) ..... 220
Martin JE (abst) ..... 211
Martin L (abst) ..... 221
Martin MJ (abst) ..... 219, 219, 220
Martin RS (abst) ..... 803
Martin-Escobar E (abst) ..... 210, 211
Martinez A (abst) ..... 207, 207, 221, 221, 221
Martinez I (abst) ..... 216
Martinez ML (abst) ..... 218
Massart C (abst) ..... 238
Massry SG *See* Kiersztejn M et al ..... 602
Matas AJ *See* Basadonna G et al ..... 38:S-193
Matejka GL, Jennische E: IGF-I binding and IGF-I mRNA expression in the post-ischemic regenerating rat kidney ..... 1113
Mateos J (abst) ..... 219
Mateos ML (abst) ..... 226
Mathew T (abst) ..... 1047
Matsushima Y *See* Imanishi M et al ..... 417
Matthias S *See* Ritz E et al ..... 38:S-37
Mattlinger B (abst) ..... 229
Matui K *See* Kagami S et al ..... 700
Mauer SM *See* Katz A et al ..... 1408
Maurer O (abst) ..... 803
Mayer B *See* Mundel P et al ..... 1017
Mayeux D (abst) ..... 238
Mayor J (abst) ..... 211, 211, 211
Mazbar SA (abst) ..... 234
Mazuecos A (abst) ..... 212, 213
McAteer JA *See* Macias WL et al ..... 308
McAteer JA *See* Torres V et al ..... 364
McBiles M *See* Wharton WW III et al ..... 174
McCausland J (abst) ..... 1049
McCredie M (abst) ..... 1042
McDonald I (abst) ..... 1032
McIntyre HD (abst) ..... 1048, 1048
McIver M (abst) ..... 1042, 1043
McKay N (abst) ..... 1037
McKay NG (abst) ..... 1032
McKenzie A (abst) ..... 1036, 1041
McLaren M *See* Taylor JE et al ..... 442
McTavish AJ *See* Cybulsky AV et al ..... 1099
Medina Cano MT (abst) ..... 222
Medina F (abst) ..... 223
Medina J (abst) ..... 210
Medina MT (abst) ..... 223

Megyesi J *See* Storch S et al ..... 89
Mehls O (abst) ..... 802
Meier D (abst) ..... 803
Meister B, Fried G, Holgert H, Aperia A, Hökfelt T: Ontogeny of aromatic L-amino acid decarboxylase-containing tubule cells in rat kidney ..... 617
Melenhorst JJ *See* Smeets HJM et al ..... 83
Melhem MF *See* Craven PA et al ..... 937
Melin JP (abst) ..... 235
Melon S (abst) ..... 208
Melon S (abst) ..... 207
Memoli B, Libetta C, Rampino T, Dal Canton A, Conte G, Scala G, Ruocco MR, Andreucci VE: Hemodialysis related induction of interleukin-6 production by peripheral blood mononuclear cells ..... 320
Memoli B *See* Conte G et al ..... 673
Menachery A *See* Pontremoli R et al ..... 1355
Menault MC (abst) ..... 229
Mendelsohn FAO (abst) ..... 1048
Mendelsohn FAO *See* Song K et al ..... 639
Mendelsohn FAO *See* Zhuo J et al ..... 1372
Mendez ML (abst) ..... 212
Mendiluce A (abst) ..... 199, 199, 214
Meng ZH (abst) ..... 499
Menon SP (abst) ..... 1044
Mentre F (abst) ..... 237
Menzies B (abst) ..... 1048, 1048
Merkus JWS (abst) ..... 1286
Mery JPh (abst) ..... 230, 238
Mesa F (abst) ..... 223
Mestecky J (abst) ..... 797
Mestecky J *See* van den Wall Bake AWL et al ..... 374
Meulders Q, He C-J, Adida C, Peraldi M-N, Schleuning W-D, Sraer J-D, Rondeau E: Tumor necrosis factor $\alpha$ increases antifibrinolytic activity of cultured human mesangial cells ..... 327
Meyrier A (abst) ..... 232
Michel C (abst) ..... 237, 238
Michelson S *See* Kadereit S et al ..... 1012
Miescher PA (abst) ..... 801
Miettinen A *See* Reivinen J et al ..... 624
Mignon F (abst) ..... 237, 238
Mignon F *See* Kadereit S et al ..... 1012
Mignon F *See* Moulin B et al ..... 127
Miguel Alonso JL (abst) ..... 215
Miguel JL (abst) ..... 204, 214
Mihatsch M (abst) ..... 809
Mihatsch MJ (abst) ..... 799, 800, 802
Milcent T (abst) ..... 235
Milford E (abst) ..... 1033
Milis L (abst) ..... 1037
Mill G (abst) ..... 1052
Mill GK (abst) ..... 1052
Mion C (abst) ..... 1040, 1044, 1045, 1045
Mion CM (abst) ..... 1045
Miralles F (abst) ..... 217
Mirapeix E (abst) ..... 199
Mitch WE *See* Jurkovitz CT et al ..... 595
Mitsuishi Y, Terasaki PI: HLA matching effect on five-year graft survival and half-life in the cyclosporine era ..... 38:S-172
Miura AB *See* Wakui H et al ..... 888
Mizokuchi M, Kubota M, Tomino Y, Koide H: Possible mechanism of impaired calcium and vitamin D metabolism in nephrotic rats ..... 335
Moal MC (abst) ..... 236
Modesto A (abst) ..... 231
Moel DI, Sachs HK: Renal function 17 to 23 years after chelation therapy for childhood plumbism ..... 1226
Möhring K *See* Zeier M et al ..... 1259
Moisan A (abst) ..... 237
Molano J (abst) ..... 214
Moliz M (abst) ..... 216
Moll R (abst) ..... 219
Moncalian J (abst) ..... 203, 203
Monier-Faugere M-C *See* Malluche HH et al ..... 38:S-62
Monnens L (abst) ..... 795, 1286
Monnens LAH (abst) ..... 797
Monnens LAH *See* Smeets HJM et al ..... 83
Montagnac R (abst) ..... 235
Montandon A (abst) ..... 808
Monteil C (abst) ..... 232, 236
Montenegro J (abst) ..... 216
Montes A (abst) ..... 201, 222, 223, 223, 223, 224
Montes M (abst) ..... 224
Montes Puerta A (abst) ..... 206
Montinaro V, Hevey K, Aventaggiato L, Fadden K, Esparza A, Chen A, Finbloom DS, Rifai A: Extrarenal cytokines modulate the glomerular response to IgA immune complexes ..... 341
Montoyo C (abst) ..... 212, 213
Montrucchio G *See* Mariano F et al ..... 735
Montseny JJ (abst) ..... 232
Mora D (abst) ..... 202
Morad Z (abst) ..... 1044
Morales JM (abst) ..... 213, 226, 226, 226, 226, 227, 227, 227
Mora-Macia J (abst) ..... 202
Moreiras M (abst) ..... 200
Moreno E (abst) ..... 227
Moreno Otero R (abst) ..... 205
Morey A (abst) ..... 213
Morgan AG *See* Haynes AP et al ..... 690
Morgan TO (abst) ..... 1031
Morin JP (abst) ..... 232, 236
Morinière P *See* Fournier A et al ..... 38:S-50
Morris C (abst) ..... 1037
Morris H (abst) ..... 1040
Morrison PJ (abst) ..... 1042
Morrissey JJ *See* Brunskill NJ et al ..... 11
Moser F (abst) ..... 801
Moser M *See* Schneditz D et al ..... 1425
Mosquera JR (abst) ..... 213
Motellon J (abst) ..... 205
Mottet JJ (abst) ..... 805, 807
Mougenot B *See* Kadereit S et al ..... 1012
Mougenot B *See* Moulin B et al ..... 127
Moulin B (abst) ..... 232, 236
Moulin B, Ronco PM, Mougenot B, Francois A, Fillastre J-P, Mignon F: Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas ..... 127
Moya JL (abst) ..... 216
Moynot A (abst) ..... 232
Mpio I (abst) ..... 228
Mtnez-Zapico R (abst) ..... 204
Mulder MF (abst) ..... 796
Muldowney WP (abst) ..... 234
Mundel P, Bachmann S, Bader M, Fischer A, Kummer W, Mayer B, Kriz W: Expression of nitric oxide synthase in kidney macula densa cells ..... 1017
Muniz P (abst) ..... 222, 222
Munne J (abst) ..... 206
Munoz C (abst) ..... 224

Munoz Cepeda MA (abst) ..... 226
Munoz F (abst) ..... 217
Munoz J (abst) ..... 204
Munoz JL (abst) ..... 222
Munoz RI (abst) ..... 216
Murnane M (abst) ..... 1042
Murphy BF (abst) ..... 1032, 1036
My H (abst) ..... 232
Mylius AL (abst) ..... 1041
Nagata M, Kriz W: Glomerular damage after uninephrectomy in young rats. II. Mechanical stress on podocytes as a pathway to sclerosis ..... 148
Nagata M, Scharer K, Kriz W: Glomerular damage after uninephrectomy in young rats. I. Hypertrophy and distortion of capillary architecture ..... 136
Naish PF (abst) ..... 1034
Naito S *See* Sacks SH et al ..... 882
Naito T *See* Yokoyama H et al ..... 755
Najarian JS *See* Basadonna G et al ..... 38:S-193
Nakamoto Y *See* Wakui H et al ..... 888
Nankivell BJ (abst) ..... 1052, 1052, 1053
Nanra RS (abst) ..... 1039, 1041, 1042
Nanra SK (abst) ..... 1042
Naranjo J (abst) ..... 204
Narayan G *See* Pereira BJG et al ..... 1419
Naret C (abst) ..... 234
Nath KA, Salahudeen AK, Clark EC, Hostetter MK, Hostetter TH: Role of cellular metabolites in progressive renal injury ..... 38:S-109
Navarro N (abst) ..... 222, 223
Navas A (abst) ..... 223, 224
Nazareth C (abst) ..... 233
Neale TJ (abst) ..... 1034, 1051
Neild GH *See* Brown Z et al ..... 95
Nelas C (abst) ..... 237
Nelen MR *See* Smeets HJM et al ..... 83
Netzer K-O, Renders L, Zhou J, Pullig O, Tryggvason K, Weber M: Deletions of the COL4A5 gene in patients with Alport syndrome ..... 1336
Ng G (abst) ..... 1036
Ng LL *See* Davies JE et al ..... 1184
Ngolet A (abst) ..... 228
Nguyen AT (abst) ..... 230
N'Guyen P (abst) ..... 235
Nicholls K (abst) ..... 1042
Nicholls KM (abst) ..... 1052, 1053
Niembro E (abst) ..... 222
Niemczyk M (abst) ..... 801
Niemeyer J *See* Oberle GP et al ..... 69
Nieto J (abst) ..... 211, 211, 211
Nikolic-Paterson DJ (abst). 1033, 1034, 1035, 1036, 1037, 1051
Nissim I, Hardy M, Pleasure J, Nissim I, States B: A mechanism of glycine and alanine cytoprotective action: Stimulation of stress-induced HSP70 mRNA ..... 775
Nissim I *See* Nissim I et al ..... 775
Noble NA *See* Tomooka S et al ..... 1462
Noblins M (abst) ..... 233
Nochy D (abst) ..... 228, 230
Noel LH (abst) ..... 229, 233
Noelken ME *See* Hudson BG et al ..... 179
Nogues X (abst) ..... 199, 200
Nolph KD: What's new in peritoneal dialysis—An overview ..... 38:S-148
Nolph KD *See* Port FK et al ..... 967
Nomura S *See* Sacks SH et al ..... 882
Noris M *See* Rota S et al ..... 981
Novillo R (abst) ..... 198
Nyberg G *See* Attman P-O et al ..... 1381
Oberle GP, Niemeyer J, Thaiss F, Schoeppe W, Stahl RAK: Increased oxygen radical and eicosanoid formation in immune-mediated mesangial cell injury ..... 69
O'Brien BMcC (abst) ..... 1041
O'Bryan M (abst) ..... 1036
Ocharan J (abst) ..... 216
Ochi S *See* Isaka Y et al ..... 1006
Ochoa E (abst) ..... 217
O'Connell PJ (abst) ..... 1036
Ocon-Pujadas J (abst) ..... 202
Odum J (abst) ..... 1034
Oe LP *See* de Fijter CWH et al ..... 947
Oetliker O (abst) ..... 802
Oey H (abst) ..... 1287
Offer R (abst) ..... 1043
Ogahara S *See* Sacks SH et al ..... 882
Ogata E *See* Kaname S et al ..... 1319
Ogborn MR *See* Aukema HM et al ..... 837
Ogle GD (abst) ..... 1040
Ohayon E (abst) ..... 231
Oite T *See* Kagami S et al ..... 700
Ojha PP (abst) ..... 1034, 1051
Okada K *See* Kagami S et al ..... 700
Okada M *See* Yoshioka K et al ..... 1253
Okolicany J *See* Price DA et al ..... 75
Olah AJ (abst) ..... 806
Oliva JA (abst) ..... 208, 209
Olivares J (abst) ..... 208, 224
Oliver J (abst) ..... 203, 203
Olmos A (abst) ..... 201, 201
Olthof CG (abst) ..... 796
Omae T *See* Imanishi M et al ..... 417
Ona M. (abst) ..... 208
Onaindia JM (abst) ..... 212
Ootaka T (abst) ..... 1036
Ordi J (abst) ..... 208
Ordinas A *See* Cases A et al ..... 668
Orero E (abst) ..... 220, 220, 220, 221, 221, 221
Orofino L (abst) ..... 216, 225, 226
Orte L (abst) ..... 224, 225, 225, 225, 225, 225, 225
Ortega J (abst) ..... 199
Ortega R (abst) ..... 212
Ortiz A (abst) ..... 198, 216
Ortuno J (abst) ..... 215, 215, 215, 216, 216, 216, 224, 225, 225, 225, 225, 225, 225, 226
Ortuno T (abst) ..... 213, 227
Osorio JM (abst) ..... 201, 222
Osorio Moratalla JM (abst) ..... 206
Osterwalder M (abst) ..... 802
Osuna A (abst) ..... 201, 223
Oswald M *See* Schneditz D et al ..... 1425
Otero G (abst) ..... 225
Otero L. (abst) ..... 207
O'Valle F (abst) ..... 223, 223, 224
Paape ME (abst) ..... 1284
Paape ME *See* Yard BA et al ..... 383
Pacheco-Silva A *See* Gallo CD et al ..... 851
Packham DK (abst) ..... 1042
Padovese P *See* Gallieni M et al ..... 1191
Page B (abst) ..... 233, 233
Pagniez D *See* Kandoussi A et al ..... 424
Painter DM (abst) ..... 1052
Pallardo L (abst) ..... 221
Pallardo LM (abst) ..... 220, 220, 220, 220, 221

Paller MS, Manivel JC, Patten M, Barry M: Prostaglandins protect kidneys against ischemic and toxic injury by a cellular effect ... 1345
Palliser D *See* Brady HR et al ... 480
Palluel AM (abst) ... 230
Palmer JM (abst) ... 1031
Palomares L (abst) ... 200
Palomero B (abst) ... 210, 211
Pamplona M (abst) ... 226
Pan JS (abst) ... 505, 505
Pang JH (abst) ... 491
Pannatier J-G (abst) ... 805, 807
Pannekeet MM (abst) ... 1287
Paraiso V (abst) ... 211
Parent O (abst) ... 234
Parera M (abst) ... 198
Parra E (abst) ... 220
Parsons PE *See* Linas SL et al ... 610
Pascual J (abst) ... 215, 215, 215, 216, 216, 216, 225, 226
Pascual M (abst) ... 806
Pascual S (abst) ... 209
Pasma GP (abst) ... 1285
Pastor E (abst) ... 217
Patrick GM (abst) ... 1031
Patten M *See* Paller MS et al ... 1345
Pearse MJ (abst) ... 1036, 1041
Peces R (abst) ... 207, 207
Pechere Bertschi A (abst) ... 233
Pechere-Bertschi A (abst) ... 803
Peddie BA (abst) ... 1040
Pedraza A (abst) ... 222, 222
Pedro-Botet J (abst) ... 199, 200
Pedrotti A (abst) ... 800
Peer G *See* Weintraub M et al ... 1247
Pegues DA, Beck-Sague CM, Woollen SW, Greenspan B, Burns SM, Bland LA, Arduino MJ, Favero MS, Mackow RC, Jarvis WR: Anaphylactoid reactions associated with reuse of hollow-fiber hemodialyzers and ACE inhibitors ... 1232
Pei Y, Cattran D, Greenwood C: Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis ... 960
Pelaez E (abst) ... 209, 209
Pelegri A (abst) ... 199, 200
Penfold J (abst) ... 1044
Peng Y (abst) ... 493
Peral B (abst) ... 202
Peral V (abst) ... 198
Peraldi M-N *See* Meulders Q et al ... 327
Peramo B (abst) ... 204
Perdiguero M (abst) ... 198, 208, 224
Pereira BJG, Poutsiaka DD, King AJ, Strom JA, Narayan G, Levey AS, Dinarello CA: In vitro production of interleukin-1 receptor antagonist in chronic renal failure, CPAD and HD ... 1419
Pereira P (abst) ... 219
Perez A (abst) ... 219, 219, 220
Perez AJ (abst) ... 200
Perez de la Cruz A (abst) ... 201
Perez Garcia R (abst) ... 218, 218, 218, 218
Perez R (abst) ... 221, 222
Perna A *See* Rota S et al ... 981
Perol C (abst) ... 237
Perrin L (abst) ... 803
Perry GJ (abst) ... 1035, 1038, 1042
Perry SJ *See* Gitelman HJ et al ... 957
Perry-Keene DA (abst) ... 1048
Peters EDJ *See* de Fijter CWH et al ... 947
Petrie J (abst) ... 1048, 1048
Petrover M (abst) ... 236
Phippard AF (abst) ... 1052
Piccoli A *See* Gambaro G et al ... 285
Picozzi M (abst) ... 805
Pidgeon G (abst) ... 1043
Piera L (abst) ... 201, 201, 205, 206, 206, 208
Pieterman H (abst) ... 1287
Pillot J (abst) ... 232
Plaza JJ (abst) ... 216
Pleasure J *See* Nissim I et al ... 775
Pocewski H (abst) ... 1051
Poczewski H (abst) ... 1034
Pogglitsch H *See* Schneditz D et al ... 1425
Poignet JL (abst) ... 234
Polaschegg HD *See* Schneditz D et al ... 1450
Polihronis M (abst) ... 1036, 1041
Pollock B (abst) ... 1041
Pollock CA (abst) ... 1035, 1049
Pons M (abst) ... 803
Pontremoli R, Spalvins A, Menachery A, Torielli L, Canessa M: Red cell sodium-proton exchange is increased in Dahl salt-sensitive hypertensive rats ... 1355
Port FK, Held PJ, Nolph KD, Turenne MN, Wolfe RA: Risk of peritonitis and technique failure by CAPD connection technique: A national study ... 967
Port FK *See* Held PJ et al ... 38:S-16
Port FK *See* Wolfe RA et al ... 991
Porter C *See* Haynes AP et al ... 690
Portman RJ, Scott RC III, Rogers DD, Loose-Mitchell DS, Lemire JM, Weinberg RB: Decreased low-density lipoprotein receptor function and mRNA levels in lymphocytes from uremic patients ... 1238
Porush JG *See* Reiser IW et al ... 867
Potaux L (abst) ... 230
Potter JM (abst) ... 1038
Pou JM (abst) ... 208
Poutsiaka DD *See* Pereira BJG et al ... 1419
Poveda R (abst) ... 203
Power D (abst) ... 1036
Power DA (abst) ... 1032, 1032, 1037, 1047
Pozet N *See* Hadj-Aïssa A et al ... 1207
Pracht I (abst) ... 808
Pradier O (abst) ... 228
Pradier O, Marchant A, Abramowicz D, De Pauw L, Vereerstraeten P, Kinnaert P, Vanherweghem J-L, Capel P, Goldman M: Procoagulant effect of the OKT3 monoclonal antibody: Involvement of tumor necrosis factor ... 1124
Prados MC (abst) ... 208, 224
Praga M (abst) ... 212, 213, 213, 227
Pratt L (abst) ... 1049
Pratt MC (abst) ... 1030
Pratt MO (abst) ... 1039
Preisig R (abst) ... 808
Price DA, Okolicany J, Maack T: Renal receptors and effects of atrial natriuretic factor in compensatory renal hypertrophy ... 75
Price PM *See* Storch S et al ... 89
Probst W (abst) ... 806
Pruna A (abst) ... 236
Pu YF (abst) ... 504
Puig N (abst) ... 220
Pullig O *See* Netzer K-O et al ... 1336

Purkiss J (abst) ..... 1034
Pussell BA (abst) ..... 1037
Qi DK (abst) ..... 496
Qi MS (abst) ..... 491
Qi SL (abst) ..... 502
Qian JQ (abst) ..... 489, 494, 497, 497
Qiu C (abst) ..... 234, 234, 236
Qiu WD (abst) ..... 503
Qiu ZL (abst) ..... 496
Quarles LD *See* Yohay DA et al ..... 448
Quereda C (abst) ... 215, 216, 224, 225, 225, 225, 225, 225, 225
Quesada MJ (abst) ..... 223, 224
Quevedo E (abst) ..... 214
Quick J (abst) ..... 804, 804
Raasveld MHM (abst) ..... 796
Rabelink AJ (abst) ..... 1283
Radda GK (abst) ..... 1031, 1038, 1049
Raine AEG *See* Roger SD et al ..... 975
Rajagopalan B (abst) ..... 1031
Rambaldi A *See* Rota S et al ..... 981
Ramee MP (abst) ..... 229, 229
Ramirez de Arellano M (abst) ..... 201, 208
Ramirez M (abst) ..... 205, 206, 206
Ramm HC (abst) ..... 1033, 1036
Ramos OL *See* Boim MA et al ..... 567
Rampino T *See* Memoli B et al ..... 320
Rana M (abst) ..... 234
Rapado A (abst) ..... 204, 204
Raska K Jr *See* Donati D et al ..... 681
Raskova J *See* Donati D et al ..... 681
Rassin T *See* Weintraub M et al ..... 1247
Ray PE *See* Horikoshi S et al ..... 764
Read LC (abst) ..... 1048
Reber G (abst) ..... 235, 807
Reddingius RE (abst) ..... 797
Reeders ST: Molecular genetics of hereditary nephritis (Nephrology Forum) ..... 783
Rees A *See* Savill J et al ..... 924
Registry of Glomerulonephritis (REGN) Spanish (abst) ..... 219
Reichel H *See* Ritz E et al ..... 38:S-37
Reiser IW, Chou S-Y, Porush JG: Failure of atrial natriuretic peptide to induce natriuresis in aortocaval fistula dogs ..... 867
Reivinen J, Holthöfer H, Miettinen A: A cell-type specific ganglioside of glomerular podocytes in rat kidney: An O-acetylated GD3 ..... 624
Rembold-Schuster I (abst) ..... 802
Remuzzi G *See* Rota S et al ..... 981
Ren Q (abst) ..... 491, 507
Ren Y *See* Savill J et al ..... 924
Renders L *See* Netzer K-O et al ..... 1336
Rengel M (abst) ..... 221, 222
Renner EL (abst) ..... 808
Renoult E (abst) ..... 238
Repine JE *See* Linas SL et al ..... 610
Reutter FW (abst) ..... 800, 801
Revert L (abst) ..... 199
Revert L *See* Cases A et al ..... 668
Reverter JC *See* Cases A et al ..... 668
Reverter JL (abst) ..... 200
Revillard J-P *See* Vincent C et al ..... 1434
Reyero A (abst) ..... 198
Reyes AA, Klahr S: Renal function after release of ureteral obstruction: Role of endothelin and the renal artery endothelium ..... 632
Ribeiro AB: Abnormalities of systemic blood pressure in diabetes mellitus (Nephrology Forum) ..... 1470
Ricardo SD (abst) ..... 1051
Richardson WR *See* Hudson BG et al ..... 179
Rifai A *See* Montinaro V et al ..... 341
Rigby R (abst) ..... 1048, 1048, 1048
Rijksen G (abst) ..... 795
Rincon B (abst) ..... 205, 211
Ringel Y *See* Weintraub M et al ..... 1247
Ringoir S *See* Lameire NH et al ..... 426
Ringoir S *See* Vanholder R et al ..... 38:S-91
Ringoir SM *See* Vanholder RC et al ..... 540
Rinon C (abst) ..... 204, 204, 205, 205, 205
Riser B *See* Varani J et al ..... 1169
Ritz E, Matthias S, Seidel A, Reichel H, Szabo A, Hörl WH: Disturbed calcium metabolism in renal failure—Pathogenesis and therapeutic strategies ..... 38:S-37
Ritz E *See* Amann K et al ..... 1079
Ritz E *See* Zeier M et al ..... 1259
Rivalan J (abst) ..... 229
Rivera F (abst) ..... 198
Rivera M (abst) ..... 215, 224, 225, 225, 225, 225
Robina F (abst) ..... 199, 199
Robinson RR: ISN Membership Survey ..... 1295
Robinson RR: The Jerusalem Congress and its Scientific Program ..... 247
Robson R (abst) ..... 1030, 1035, 1041, 1050
Robson RA (abst) ..... 1040, 1043, 1043
Roca R (abst) ..... 201, 201
Rocha JL (abst) ..... 219
Rockman SP (abst) ..... 1036
Rodda C (abst) ..... 1042
Rodgers OG *See* Campistol JM et al ..... 915
Rodicio JL (abst) ..... 212, 213, 213, 226, 226, 226, 227, 227
Rodriguez A (abst) ..... 198, 211, 226
Rodriguez AP (abst) ..... 211, 212
Rodriguez C (abst) ..... 198
Rodriguez U (abst) ..... 211
Rodriguez Villarreal I (abst) ..... 202
Rodriguez-Algarra G (abst) ..... 219
Rodriguez-Mahou M (abst) ..... 217
Rodriguez-Pujol D (abst) ..... 210
Rodriguez-Pujol J (abst) ..... 210
Rodriguez-Pujol M (abst) ..... 210
Rodriguez-Puyol D (abst) ..... 210, 210, 210
Rodriguez-Puyol M (abst) ..... 210, 210
Roedecker T (abst) ..... 1035
Rogada A (abst) ..... 198
Roger SD, Grasty MS, Baker LRI, Raine AEG: Effects of oxygen breathing and erythropoietin on hypoxic vasodilation in uremic anemia ..... 975
Rogers DD *See* Portman RJ et al ..... 1238
Roldan E (abst) ..... 216
Rolla D *See* Gallieni M et al ..... 1191
Romano G *See* Conte G et al ..... 673
Romeo JR (abst) ..... 204
Romero JR (abst) ..... 204, 205, 205, 205
Romero MF, Douglas JG, Eckert RL, Hopfer U, Jacobberger JW: Development and characterization of rabbit proximal tubular epithelial cell lines ..... 1130
Romero R (abst) ..... 199, 200, 200, 200, 214
Ronco PM *See* Kadereit S et al ..... 1012
Ronco PM *See* Moulin B et al ..... 127
Rondeau E *See* Meulders Q et al ..... 327
Roob J *See* Schneditz D et al ..... 1425
Ropers H-H *See* Smeets HJM et al ..... 83

Ros F (abst) ..... 220, 221
Rose UM (abst) ..... 797
Rosello J (abst) ..... 205
Rosen S *See* Brown LF et al ..... 1457
Rosen S *See* Heyman S et al ..... 41
Rosenberg AR (abst) ..... 1040
Ross M (abst) ..... 1039, 1043
Rossano F *See* Camussi G et al ..... 1309
Rostaing L (abst) ..... 231
Rota S, Rambaldi A, Gaspari F, Noris M, Daina E, Benigni A, Perna A, Donadelli R, Remuzzi G, Garattini S: Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis ..... 981
Roth M (abst) ..... 807
Rouchon M (abst) ..... 228
Rouquette Ch (abst) ..... 237
Rousseau P *See* Charpentier BM et al ..... 38:S-176
Roussel B *See* Antignac C et al ..... 1178
Rousselot M (abst) ..... 800
Roy LP (abst) ..... 1032, 1036, 1047
Rubies-Prat J (abst) ..... 199, 200
Ruedin P (abst) ..... 233, 233, 235, 801, 804, 805, 806, 807
Ruilope LM (abst) ..... 213
Ruiz Avila I (abst) ..... 224
Ruiz P (abst) ..... 210
Ruocco MR *See* Memoli B et al ..... 320
Russ G (abst) ..... 1047
Russell DM (abst) ..... 1046
Russo D *See* Conte G et al ..... 673
Rutishauser W (abst) ..... 233
Rutledge WP *See* Skorecki KL et al ..... 1
Ryall R (abst) ..... 1044
Ryan GB (abst) ..... 1049, 1051
Ryffel B (abst) ..... 800, 802
Saada A (abst) ..... 237
Sabater J (abst) ..... 215, 224, 225, 225, 225, 225
Sabbatini M, Sansone G, Uccello F, Giliberti A, Conte G, Andreucci VE: Early glycosilation products induce glomerular hyperfiltration in normal rats ..... 875
Sabbatini M *See* Conte G et al ..... 673
Sachs HK *See* Moel DI et al ..... 1226
Sacks SH (abst) ..... 1042
Sacks SH, Nomura S, Warner C, Naito S, Ogahara S, Vaughan R, Briggs D: Analysis of complement C4 loci in Caucasoids and Japanese with idiopathic membranous nephropathy ..... 882
Saez GT (abst) ..... 222, 222
Safirstein R *See* Storch S et al ..... 89
Saggi S *See* Storch S et al ..... 89
Sahai A, Xu G, Sandler RS, Tannen RL: Hypoxia-mediated impaired differentiation by LLC-$PK_1$ cells: Evidence based on the protein kinase C profile ..... 1145
Saint-Hillier Y (abst) ..... 237
Salahudeen AK *See* Nath KA et al ..... 38:S-109
Salem HH (abst) ..... 1033, 1033
Salinas I (abst) ..... 200
Salto E (abst) ..... 226
Samad SA (abst) ..... 1044
Sanak M *See* Antignac C et al ..... 1178
Sanchez F (abst) ..... 210
Sanchez Izquierdo JA (abst) ..... 227
Sanchez J (abst) ..... 220, 220, 220, 220, 221, 221
Sanchez L (abst) ..... 207
Sanchez M (abst) ..... 210, 211, 211, 211, 211
Sanchez MT (abst) ..... 215
Sanchez O (abst) ..... 198
Sanchez P (abst) ..... 220, 220, 220, 220, 221, 221, 221
Sanchez R (abst) ..... 212, 213, 226, 227
Sanchez Tomero J (abst) ..... 211
Sanchez Tomero JA (abst) ..... 205
Sanchez-Ortega F (abst) ..... 211
Sanchis J (abst) ..... 219, 220
Sancho S (abst) ..... 226
Sandler RS *See* Sahai A et al ..... 1145
Sanmarti A (abst) ..... 200
San-Millan JL (abst) ..... 202
Sanna G *See* Zucchelli P et al ..... 452
Sansone G *See* Sabbatini M et al ..... 875
Santos JJ (abst) ..... 209
Sanz-Guajardo D (abst) ..... 198, 204, 208
Sanz-Moreno C (abst) ..... 198, 204, 208
Saracho R (abst) ..... 216
Sarraf C *See* Savill J et al ..... 924
Sarras M *See* Hudson BG et al ..... 179
Sasdelli M *See* Zucchelli P et al ..... 452
Saunders J (abst) ..... 1036
Saus J *See* Hudson BG et al ..... 179
Savige J (abst) ..... 1037
Savill J, Smith J, Sarraf C, Ren Y, Abbott F, Rees A: Glomerular mesangial cells and inflammatory macrophages ingest neutrophils undergoing apoptosis ..... 924
Savvas P (abst) ..... 1040
Sawada M *See* Horikoshi S et al ..... 764
Saxenhofer H (abst) ..... 803, 805, 807
Sayegh M (abst) ..... 1033
Scala G *See* Memoli B et al ..... 320
Schaad HJ (abst) ..... 808
Schaefer F (abst) ..... 802
Schäffer J *See* Floege J et al ..... 38:S-78
Schafroth M (abst) ..... 806
Schalekamp M (abst) ..... 1287
Schalekamp MADH (abst) ..... 793
Schambelan M (abst) ..... 234
Scharer K (abst) ..... 802
Scharer K *See* Nagata M et al ..... 136
Scheinman JI *See* Katz A et al ..... 1408
Schellekens PThA (abst) ..... 796
Schenk B (abst) ..... 804
Schifferli J (abst) ..... 233, 806
Schifferli JA (abst) ..... 803
Schillinger D (abst) ..... 235
Schillinger F (abst) ..... 235
Schipper P (abst) ..... 1287
Schleuning W-D *See* Meulders Q et al ..... 327
Schmidli M (abst) ..... 800, 801, 802
Schneditz D (abst) ..... 806
Schneditz D, Kaufman AM, Polaschegg HD, Levin NW, Daugirdas JT: Cardiopulmonary recirculation during hemodialysis (Technical Note) ..... 1450
Schneditz D, Roob J, Oswald M, Pogglitsch H, Moser M, Kenner T, Binswanger U: Nature and rate of vascular refilling during hemodialysis and ultrafiltration ..... 1425
Schoeppe W *See* Oberle GP et al ..... 69
Schoolwerth A *See* Clore J et al ..... 1297
Schor N *See* Boim MA et al ..... 567
Schrama E *See* Yard BA et al ..... 383
Schrier RW (abst) ..... 799, 799
Schrier RW *See* Skorecki KL et al ..... 1
Schroder CH (abst) ..... 797
Schröder CH *See* Smeets HJM et al ..... 83
Schrohenloher R (abst) ..... 797
Schuiling GA (abst) ..... 1283

Schulze M *See* Lonnemann G et al ..... 61
Schwab SJ *See* Yohay DA et al ..... 448
Schwartz MM, Lan S-P, Bernstein J, Hill GS, Holley K, Lewis EJ, Lupus Nephritis Collaborative Study Group: Role of pathology indices in the management of severe lupus glomerulonephritis ..... 743
Scicli G *See* Torres V et al ..... 364
Scott M *See* Geary DF et al ..... 102
Scott RC III *See* Portman RJ et al ..... 1238
Sechi LA (abst) ..... 234
Segarra A (abst) ..... 201, 201
Segasothy M (abst) ..... 1044
Segovia J (abst) ..... 198
Seidel A *See* Ritz E et al ..... 38:S-37
Seifert RA *See* Alpers CE et al ..... 390
Selgas R (abst) ..... 204, 204, 205, 205, 205, 214
Selwood N *See* Brunner FP et al ..... 38:S-4
Senger DR *See* Brown LF et al ..... 1457
Senti M (abst) ..... 199, 200
Sepe V *See* Conte G et al ..... 673
Seppälä M *See* Suikkari A-M et al ..... 749
Seron D (abst) ..... 203
Serrano P (abst) ..... 215, 215, 216, 226
Serrano S (abst) ..... 214
Servillo L *See* Camussi G et al ..... 1309
Shaariah W (abst) ..... 1044
Shah V *See* Fitzpatrick MM et al ..... 951
Shaldon S *See* Floege J et al ..... 38:S-78
Shaldon S *See* Lonnemann G et al ..... 61
Shand BI (abst) ..... 1030, 1041, 1046
Sharma K *See* Wolf G et al ..... 647
Shaw S, Weidmann P, Zimmermann A: Urodilatin, not nitroprusside, combined with dopamine reverses ischemic acute renal failure ..... 1153
Shenovda M *See* Fournier A et al ..... 38:S-50
Shi CY (abst) ..... 498, 501
Shi SZ (abst) ..... 489
Shimizu F *See* Kagami S et al ..... 700
Shin SH *See* Isaka Y et al ..... 1006
Shirahama T *See* Campistol JM et al ..... 915
Shumaker DK *See* Varani J et al ..... 1169
Siguenza F (abst) ..... 217, 217
Silver SM, DeSimone JA Jr., Smith DA, Sterns RH: Dialysis disequilibrium syndrome (DDS) in the rat: Role of the "reverse urea effect" ..... 161
Silvestro L *See* Camussi G et al ..... 1309
Simon F (abst) ..... 238
Simon P (abst) ..... 229, 229
Sinclair AJ (abst) ..... 1041
Singer GG *See* Brennan DC et al ..... 279
Singlas E (abst) ..... 234
Sivakumar P (abst) ..... 1042
Sizeland P (abst) ..... 1030, 1035, 1050
Skinner M *See* Campistol JM et al ..... 915
Skipper BJ *See* Gardner KD Jr. et al ..... 1199
Skorecki KL, Rutledge WP, Schrier RW: Acute cyclosporine nephrotoxicity—Prototype for a renal membrane signalling disorder (Editorial Review) ..... 1
Slatopolsky E, Berkoben M, Kelber J, Brown A, Delmez J: Effects of calcitriol and non-calcemic vitamin D analogs on secondary hyperparathyroidism ..... 38:S-43
Smeenk RJT *See* Termaat R-M et al ..... 1363
Smeets HJM, Melenhorst JJ, Lemmink HH, Schröder CH, Nelen MR, Zhou J, Hostikka SL, Tryggvason K, Ropers H-H, Jansweijer MCE, Monnens LAH, Brunner HG, van Oost BA: Different mutations in the COL4A5 collagen gene in two patients with different features of Alport syndrome ..... 83
Smit W (abst) ..... 1286
Smith AH (abst) ..... 1040
Smith DA *See* Silver SM et al ..... 161
Smith J *See* Savill J et al ..... 924
Smogorzewski M *See* Kiersztejn M et al ..... 602
Snyder TL *See* Wuthrich RP et al ..... 903
Sobel A (abst) ..... 234
Sobrado JA (abst) ..... 200
Sola R (abst) ..... 208
Soldevila J (abst) ..... 208
Solé M *See* Campistol JM et al ..... 915
Solis C (abst) ..... 214, 215
Sondeen JL *See* Wharton WW III et al ..... 174
Sone M *See* Beck F-X et al ..... 843
Song K, Zhuo J, Chai SY, Mendelsohn FAO: A new method to localize active renin in tissues by autoradiography: Application to dog kidney ..... 639
Soosaipillai MC (abst) ..... 1051
Sorio C (abst) ..... 225
Spalvins A *See* Pontremoli R et al ..... 1355
Spanner E *See* Lindsay RM et al ..... 38:S-32
Spiegel T (abst) ..... 801
Spokes K *See* Heyman S et al ..... 41
Sraer J-D *See* Meulders Q et al ..... 327
St. John A (abst) ..... 1045
St. Peter JV *See* Keane WF et al ..... 38:S-134
Stahl RAK *See* Oberle GP et al ..... 69
Stallone C *See* Zucchelli P et al ..... 452
Stanley CM (abst) ..... 1046
States B *See* Nissim I et al ..... 775
Steiger U (abst) ..... 808
Sterns RH *See* Silver SM et al ..... 161
Stewart JH (abst) ..... 1042
Stewart WK *See* Taylor JE et al ..... 442
Stewart-Richardson PA (abst) ..... 1030, 1049
Stoermann C (abst) ..... 233, 235, 806, 807
Stone WJ *See* Hudson BG et al ..... 179
Storch S, Saggi S, Megyesi J, Price PM, Safirstein R: Ureteral obstruction decreases renal prepro-epidermal growth factor and Tamm-Horsfall expression ..... 89
Stotler RE *See* Wharton WW III et al ..... 174
Strieter RM *See* Brown Z et al ..... 95
Strom JA *See* Pereira BJG et al ..... 1419
Strom TB: Molecular immunology and immunopharmacology of allograft rejection ..... 38:S-182
Struijk DG (abst) ..... 797, 798
Struthers AD *See* Lang CC et al ..... 433
Su G (abst) ..... 508
Suarez C (abst) ..... 202, 212
Suarez E (abst) ..... 212
Suikkari A-M, Leivo I, Kämäräinen M, Holthöfer H, Seppälä M, Julkunen M, Koistinen R: Expression of insulin-like growth factor binding protein-1 mRNA in human fetal kidney ..... 749
Sun XF (abst) ..... 491
Suranyi M (abst) ..... 1048
Suranyi MG (abst) ..... 1048
Sureda A (abst) ..... 216
Swan SK *See* Gardner KD Jr. et al ..... 1199
Swift LL *See* Awazu M et al ..... 265

Switalski LM *See* van den Wall Bake AWL et al ..... 374
Szabo A *See* Ritz E et al ..... 38:S-37
Sztajzel J (abst) ..... 233
Taburet AM (abst) ..... 234
Tacquet A *See* Kandoussi A et al ..... 424
Tagawa K *See* Isaka Y et al ..... 1006
Taira K (abst) ..... 1051
Takabatake T *See* Yokoyama H et al ..... 755
Takaeda M *See* Yokoyama H et al ..... 755
Takahashi H *See* Aukema HM et al ..... 837
Takasawa K *See* Yokoyama H et al ..... 755
Takata S *See* Brady HR et al ..... 480
Takeda T *See* Kohno M et al ..... 860
Takekoshi Y *See* Yoshioka K et al ..... 1253
Takemura T *See* Yoshioka K et al ..... 1253
Takkinen R *See* Krapf R et al ..... 727
Tang GZ (abst) ..... 510
Tang XH (abst) ..... 507
Tang Z (abst) ..... 489, 490
Tannen RL *See* Sahai A et al ..... 1145
Tanner GA *See* Macias WL et al ..... 308
Tarolo G *See* Gallieni M et al ..... 1191
Tay C (abst) ..... 1052, 1052
Tay M (abst) ..... 1049, 1050, 1050
Taylor CG *See* Varani J et al ..... 1169
Taylor DJ (abst) ..... 1031, 1038
Taylor JE, McLaren M, Mactier RA, Henderson IS, Stewart WK, Belch JJF: Effect of dialyzer geometry during hemodialysis with cuprophane membranes ..... 442
Teerlink T (abst) ..... 796
Teixido J (abst) ..... 200, 200, 214
Tejedor A (abst) ..... 218, 221, 221, 221, 222, 222
ten Berge RJM (abst) ..... 796
ter Wee PM, Donker AJM: Clinical strategies for arresting progression of renal disease ..... 38:S-114
Terasaki PI *See* Mitsuishi Y et al ..... 38:S-172
Termaat RM (abst) ..... 793
Termaat R-M, Assmann KJM, Dijkman HBPM, van Gompel F, Smeenk RJT, Berden JHM: Anti-DNA antibodies can bind to the glomerulus via two distinct mechanisms ..... 1363
Teruel JL (abst) ..... 215, 215, 215, 216, 216
Terzi F, Beaufils H, Laouari D, Burtin M, Kleinknecht C: Renal effect of anti-hypertensive drugs depends on sodium diet in the excision remnant kidney model ..... 354
Tetta C *See* Mariano F et al ..... 735
Thaiss F *See* Oberle GP et al ..... 69
Thanakitcharu P *See* Kiersztejn M et al ..... 602
Thatcher G (abst) ..... 1043
Thibault P *See* Kadereit S et al ..... 1012
Thibodeau SN *See* Torres V et al ..... 364
Thiel G (abst) ..... 807, 808, 809, 809
Thies RS *See* Tucker BJ et al ..... 1160
Thijs LG (abst) ..... 796
Thomas D (abst) ..... 1031
Thomas MAB (abst) ..... 1043, 1044, 1045
Thomas RJS (abst) ..... 1046
Thompson CH (abst) ..... 1031, 1038, 1049
Thompson RC *See* Brown Z et al ..... 95
Thomson NM (abst) ..... 1043
Thornhill BA *See* Chevalier RL et al ..... 400
Thorogood J (abst) ..... 1284
Thurau K *See* Beck F-X et al ..... 272
Thurau K *See* Beck F-X et al ..... 843
Tian J (abst) ..... 495
Tilney N (abst) ..... 1046
Timmermans V (abst) ..... 1037
Tipping PG (abst) ..... 1032, 1034
Todd RF III *See* Varani J et al ..... 1169
Tognazzi K *See* Brown LF et al ..... 1457
Toledo F (abst) ..... 211
Tomino Y *See* Mizokuchi M et al ..... 335
Tomobe K *See* Aukema HM et al ..... 837
Tomooka S, Border WA, Marshall BC, Noble NA: Glomerular matrix accumulation is linked to inhibition of the plasmin protease system ..... 1462
Tomosugi N *See* Yokoyama H et al ..... 755
Tong SC (abst) ..... 503
Toran D (abst) ..... 213
Torielli L *See* Pontremoli R et al ..... 1355
Torralbo M (abst) ..... 204
Torras A (abst) ..... 199
Torras J (abst) ..... 203
Torres A (abst) ..... 211, 212, 212
Torres G (abst) ..... 209
Torres V, Donovan KA, Scicli G, Holley KE, Thibodeau SN, Carretero OA, Inagami T, McAteer JA, Johnson CM: Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease ..... 364
Toupance O (abst) ..... 235, 235
Tovar JL (abst) ..... 206, 208
Traba ML (abst) ..... 204
Traver JA (abst) ..... 205, 211
Trevillian PR (abst) ..... 1039
Trevisan R *See* Davies JE et al ..... 1184
Trompeter RS *See* Fitzpatrick MM et al ..... 951
Tryggvason K *See* Antignac C et al ..... 1178
Tryggvason K *See* Netzer K-O et al ..... 1336
Tryggvason K *See* Smeets HJM et al ..... 83
Tsai P (abst) ..... 799, 799
Tsuchida A (abst) ..... 1033, 1033
Tu WZ (abst) ..... 495
Tucker BJ, Anderson CM, Thies RS, Collins RC, Blantz RC: Glomerular hemodynamic alterations during acute hyperinsulinemia in normal and diabetic rats ..... 1160
Tufano MA *See* Camussi G et al ..... 1309
Turenne MN *See* Port FK et al ..... 967
Tuttle KR, Bruton JL: Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes ..... 167
Uccello F *See* Sabbatini M et al ..... 875
Uchida S *See* Kaname S et al ..... 1319
Ueda H (abst) ..... 1046
Ueda N *See* Isaka Y et al ..... 1006
Ullrich R (abst) ..... 1034
Ungaro B *See* Conte G et al ..... 673
Urberuaga M (abst) ..... 216
Urra JM (abst) ..... 207
v Liebergen FJHM (abst) ..... 1287
Vaessen LMB (abst) ..... 794
Valderrabano F (abst) ..... 218, 218, 218, 218, 218, 221, 221, 222, 222
Valdes F (abst) ..... 203, 203
Valentin J-P (abst) ..... 234, 234, 234, 236
Valles M (abst) ..... 208
Valls V (abst) ..... 222, 222
van Acker BAC (abst) ..... 793, 798, 1286
van Bockel JH (abst) ..... 1284
van Bortel LMAB *See* Kooman JP et al ..... 718
van Boven WPL (abst) ..... 796

van Bruggen MCJ (abst) ..... 793
Van De Water L *See* Brown LF et al ..... 1457
van den Born J (abst) ..... 793, 1283
van den Bos GC (abst) ..... 796
van den Meiracker A (abst) ..... 1287
van den Wall Bake AWL (abst) ..... 797
van den Wall Bake AWL, Kirk KA, Gay RE, Switalski LM, Julian BA, Jackson S, Gay S, Mestecky J: Binding of serum immunoglobulins to collagens in IgA nephropathy and HIV infection ..... 374
van der Heul C (abst) ..... 796
van der Horst MLC (abst) ..... 793, 795, 1284
van der Meulen J *See* de Fijter CWH et al ..... 947
van der Woude FJ (abst) ..... 1284
van der Woude FJ *See* Yard BA et al ..... 383
van Diepen FNJ (abst) ..... 796
Van Es LA (abst) ..... 1284
van Es LA *See* Yard BA et al ..... 383
van Eyk HG (abst) ..... 796
van Gelder T (abst) ..... 794
van Gompel F *See* Termaat R-M et al ..... 1363
van Goor H (abst) ..... 793, 795, 1283, 1284
van Hamersvelt HW (abst) ..... 795
van Hinsbergh V (abst) ..... 1286
van Hooff JP *See* Kooman JP et al ..... 718
van Kraats AA (abst) ..... 796
van Lambalgen AA (abst) ..... 796
Van Leer EHG (abst) ..... 1284
van Lier HJ (abst) ..... 794
van Melle G (abst) ..... 807
van Oost BA *See* Smeets HJM et al ..... 83
van Os C (abst) ..... 795
van Os CH (abst) ..... 797
van Steenberge EPM (abst) ..... 1285
van Tol A (abst) ..... 1283, 1284
van Zwieten PA (abst) ..... 1285
Vanherweghem J-L *See* Pradier O et al ..... 1124
Vanholder R, Ringoir S: Polymorphonuclear cell function and infection in dialysis ..... 38:S-91
Vanholder R *See* Lameire NH et al ..... 426
Vanholder RC, Ringoir SM: Adequacy of dialysis: A critical analysis (Editorial Review) ..... 540
Varani J, Taylor CG, Riser B, Shumaker DK, Yeh K-Y, Dame M, Gibbs DF, Todd RF III, Dumler F, Bromberg J, Killen PD: Mesangial cell killing by leukocytes: Role of leukocyte oxidants and proteolytic enzymes ..... 1169
Vaughan R *See* Sacks SH et al ..... 882
Vazquez A (abst) ..... 209
Vazquez Martul M (abst) ..... 202
Vazquez S (abst) ..... 227
vd Kar N (abst) ..... 1286
Venkatachalam M *See* Kobayashi S et al ..... 710
Venturini AP *See* Gambaro G et al ..... 285
Verbrugh HA *See* de Fijter CWH et al ..... 947
Vereerstraeten P (abst) ..... 228
Vereerstraeten P *See* Pradier O et al ..... 1124
Verhoef J *See* de Fijter CWH et al ..... 947
Verhoeven AJ (abst) ..... 1034
Vermeij P (abst) ..... 1285
Verroust PJ *See* Kadereit S et al ..... 1012
Veyt D *See* Lameire NH et al ..... 426
Viard J-P (abst) ..... 233
Viberti GC *See* Davies JE et al ..... 1184
Vidal MT (abst) ..... 201
Vigil A (abst) ..... 214
Vila J (abst) ..... 205, 206, 206
Vila T (abst) ..... 225
Villafruela J (abst) ..... 225
Villafruela JJ (abst) ..... 215, 216, 224, 225
Villaro J (abst) ..... 219
Villiger L (abst) ..... 803
Vinay P *See* Gougoux A et al ..... 586
Vincent C, Chanard J, Caudwell V, Lavaud S, Wong T, Revillard J-P: Kinetics of $^{125}$I-$\beta_2$-microglobulin turnover in dialyzed patients ..... 1434
Vincent JP (abst) ..... 237
Vindimian M (abst) ..... 231
Vinuesa Garcia MS (abst) ..... 218
Viron B (abst) ..... 234, 237, 238
Vishwanath B (abst) ..... 800
Vizjak A *See* Zidar N et al ..... 1444
Vlcek J (abst) ..... 808
Vogels-Metink G (abst) ..... 795
Vogt B (abst) ..... 800
Volavšek M *See* Zidar N et al ..... 1444
Wada T *See* Yokoyama H et al ..... 755
Wade CE *See* Wharton WW III et al ..... 174
Wakui H, Komatsuda A, Ishino T, Imai H, Kobayashi R, Nakamoto Y, Miura AB: Localization of phosphoinositide-specific phospholipase C-$\alpha$ in porcine kidney ..... 888
Waldherr G (abst) ..... 802
Waldherr R *See* Zeier M et al ..... 1259
Walker AM (abst) ..... 1043
Walker R (abst) ..... 1047
Walker RJ (abst) ..... 1030, 1039
Walther U (abst) ..... 802
Wang BL (abst) ..... 493
Wang FJ (abst) ..... 501
Wang GY (abst) ..... 498, 498, 499, 501
Wang HB (abst) ..... 502
Wang HY (abst) ... 488, 488, 490, 490, 491, 505, 505, 506, 507, 509, 509, 509, 509, 1051
Wang HZ (abst) ..... 498
Wang JG (abst) ..... 492
Wang JH (abst) ..... 496
Wang LC (abst) ..... 491, 491
Wang PL (abst) ..... 509
Wang QW (abst) ..... 498
Wang SE (abst) ..... 498, 501
Wang SF (abst) ..... 494, 501
Wang SL (abst) ..... 508
Wang ST (abst) ..... 506
Wang XJ (abst) ..... 502
Wang XY (abst) ..... 500
Wang YH (abst) ..... 508, 508
Wang YO (abst) ..... 506
Wang YP (abst) ..... 492
Wang YQ (abst) ..... 492
Wang ZQ (abst) ..... 491, 504, 507
Warner C *See* Sacks SH et al ..... 882
Warr K (abst) ..... 1043
Warr KJ (abst) ..... 1044, 1045
Watlington CO *See* Clore J et al ..... 1297
Wauters JP (abst) ..... 801, 805, 807
Webb GI (abst) ..... 1031
Webb M (abst) ..... 1044
Weber BK (abst) ..... 1032, 1047
Weber M *See* Hudson BG et al ..... 179
Weber M *See* Netzer K-O et al ..... 1336
Weening JJ (abst) ..... 793, 1284

Wegmann W (abst) ..... 802
Weidmann P *See* Shaw S et al ..... 1153
Weimar W (abst) ..... 794, 1285
Weinberg RB *See* Portman RJ et al ..... 1238
Weintraub M, Burstein A, Rassin T, Liron M, Ringel Y, Cabili S, Blum M, Peer G, Iaina A: Severe defect in clearing postprandial chylomicron remnants in dialysis patients ..... 1247
Wells JE (abst) ..... 1041
Wen LP (abst) ..... 500
Westeel PF *See* Fournier A et al ..... 38:S-50
Westhuyzen J (abst) ..... 1030
Westwick J *See* Brown Z et al ..... 95
Wetzels JFM (abst) ..... 794, 795
Wharton WW III, Sondeen JL, McBiles M, Gradwohl SE, Wade CE, Ciceri DP, Lehmann HG, Stotler RE, Henderson TR, Whitaker WR, Lindberg JS: Measurement of glomerular filtration rate in ICU patients using $^{99m}$Tc-DTPA and inulin ..... 174
Whitaker WR *See* Wharton WW III et al ..... 174
Whittenburg D *See* Linas SL et al ..... 610
Whitworth JA (abst) ..... 1038, 1039
Wicomb WN *See* Collins GM et al ..... 38:S-197
Widmann J-J (abst) ..... 803
Wiedemann E (abst) ..... 236
Wiest G *See* Amann K et al ..... 1079
Willems J (abst) ..... 795
Willgoss DA (abst) ..... 1049
William-Olsson T *See* Attman P-O et al ..... 1381
Wingo CS *See* Curran KA et al ..... 1093
Witzum J (abst) ..... 1051
Wojta J (abst) ..... 1034
Wolf G, Sharma K, Chen Y, Ericksen M, Ziyadeh FN: High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-$\beta$ ..... 647
Wolfe RA, Gaylin DS, Port FK, Held PJ, Wood CL: Using USRDS generated mortality tables to compare local ESRD mortality rates to national rates ..... 991
Wolfe RA *See* Port FK et al ..... 967
Wolthuis A (abst) ..... 798
Wong T (abst) ..... 235, 235
Wong T *See* Vincent C et al ..... 1434
Wood CL *See* Wolfe RA et al ..... 991
Woollen SW *See* Pegues DA et al ..... 1232
Wu H (abst) ..... 503
Wu HS (abst) ..... 506
Wu JY (abst) ..... 496
Wu YJ (abst) ..... 501
Wuthrich RP, Snyder TL: Vascular cell adhesion molecule-1 (VCAM-1) expression in murine lupus nephritis ..... 903
Wynckel A (abst) ..... 235, 235
Xie XA (abst) ..... 492
Xing CY (abst) ..... 500
Xiong Y (abst) ..... 497
Xu G *See* Sahai A et al ..... 1145
Xu GZ (abst) ..... 491, 492, 494, 507, 510
Xu JL (abst) ..... 498
Xu OY (abst) ..... 492
Xu XK (abst) ..... 495
Yagi K *See* Yoshioka K et al ..... 1253
Yamamoto S *See* Isaka Y et al ..... 1006
Yan HI (abst) ..... 496
Yan HY (abst) ..... 494
Yanai M (abst) ..... 230
Yang B (abst) ..... 495
Yang CL (abst) ..... 503
Yang IP (abst) ..... 494
Yang JW (abst) ..... 504, 504
Yang JY (abst) ..... 493, 509
Yang LC (abst) ..... 499
Yang LP (abst) ..... 491
Yang M (abst) ..... 501
Yang NP (abst) ..... 510
Yang QQ (abst) ..... 499
Yang SH (abst) ..... 500
Yang WS (abst) ..... 506
Yao J (abst) ..... 494
Yao JH (abst) ..... 489
Yard BA (abst) ..... 1284
Yard BA, Daha MR, Kooymans-Couthino M, Bruijn JA, Paape ME, Schrama E, van Es LA, van der Woude FJ: IL-1$\alpha$ stimulated TNF$\alpha$ production by cultured human proximal tubular epithelial cells ..... 383
Yared A *See* Awazu M et al ..... 265
Yasunari K *See* Kohno M et al ..... 860
Ye PG (abst) ..... 493
Ye RG (abst) ..... 490, 501, 503
Yeh K-Y *See* Varani J et al ..... 1169
Yin DP (abst) ..... 503
Yin PD (abst) ..... 507
Yohay DA, Butterly DW, Schwab SJ, Quarles LD: Continuous arteriovenous hemodialysis: Effect of dialyzer geometry ..... 448
Yokokawa K *See* Kohno M et al ..... 860
Yokoyama H, Takabatake T, Takaeda M, Wada T, Naito T, Ikeda K, Goshima S, Takasawa K, Tomosugi N, Kobayashi K, Kida H: Up-regulated MHC-class II expression and $\gamma$-IFN and soluble IL-2R in lupus nephritis ..... 755
Yoshimura A *See* Floege J et al ..... 573
Yoshioka K, Takemura T, Akano N, Okada M, Yagi K, Maki S, Inai S, Akita H, Koitabashi Y, Takekoshi Y: IgA nephropathy in patients with congenital C9 deficiency ..... 1253
Yoshioka T *See* Kakinuma Y et al ..... 46
Yu LF (abst) ..... 497, 509, 509
Yu PY (abst) ..... 495
Yu TN (abst) ..... 492
Yu V (abst) ..... 1042
Yu Y (abst) ..... 503, 1033, 1035, 1037
Yu YF (abst) ..... 498, 499
Yu YS (abst) ..... 488, 489
Yuan FH (abst) ..... 495, 503
Yuill L (abst) ..... 1045
Yun JM (abst) ..... 489
Zachmann M (abst) ..... 802
Zan N *See* Gougoux A et al ..... 586
Zarama-Medina M (abst) ..... 1034
Zarrage S (abst) ..... 217
Zaruba J (abst) ..... 806, 808
Zaruba K (abst) ..... 806
Zech P *See* Hadj-Aïssa A et al ..... 1207
Zeier M, Fehrenbach P, Geberth S, Möhring K, Waldherr R, Ritz E: Renal histology in polycystic kidney disease with incipient and advanced renal failure ..... 1259
Zemel D (abst) ..... 798
Zender HO (abst) ..... 801
Zhai DP (abst) ..... 495, 499
Zhang B (abst) ..... 496
Zhang BK (abst) ..... 509
Zhang HY (abst) ..... 510

Zhang JH (abst) ..... 498
Zhang JX (abst) ..... 509
Zhang L (abst) ..... 499
Zhang LX (abst) ..... 501
Zhang P (abst) ..... 497
Zhang QY (abst) ..... 497, 497
Zhang RX (abst) ..... 500
Zhang SG (abst) ..... 507
Zhang X (abst) ..... 491, 500, 501
Zhang XJ (abst) ..... 496
Zhang Y (abst) ..... 506, 1036, 1047
Zhang YK (abst) ..... 490, 490, 491, 507
Zhang YX (abst) ..... 498
Zhang ZY (abst) ..... 502
Zhao J (abst) ..... 502, 502
Zhao MH (abst) ..... 490, 495
Zhao ZH (abst) ..... 507, 509, 509, 509, 1051
Zheng F (abst) ..... 495, 505
Zheng FL (abst) ..... 497
Zheng SF (abst) ..... 497
Zhou DK (abst) ..... 497
Zhou J *See* Antignac C et al ..... 1178
Zhou J *See* Netzer K-O et al ..... 1336
Zhou J *See* Smeets HJM et al ..... 83
Zhou JH (abst) ..... 492, 506
Zhou JY (abst) ..... 498
Zhou NM (abst) ..... 495
Zhou WZ (abst) ..... 506
Zhou XJ (abst) ..... 491, 507
Zhou YJ (abst) ..... 502
Zhou ZL (abst) ..... 492
Zhou ZZ (abst) ..... 494, 501
Zhu B (abst) ..... 499
Zhu CM (abst) ..... 498
Zhu HW (abst) ..... 500
Zhu JC (abst) ..... 507
Zhu N (abst) ..... 505, 505
Zhu P (abst) ..... 498, 498
Zhu SD (abst) ..... 499
Zhu SL (abst) ..... 491, 505, 509
Zhuo J (abst) ..... 1048
Zhuo J, Alcorn D, Allen AM, Mendelsohn FAO: High resolution localization of angiotensin II receptors in rat renal medulla ..... 1372
Zhuo J *See* Song K et al ..... 639
Zidar N, Ferluga D, Volavšek M, Vizjak A, Luzar S, Kveder R: Renal extraglomerular vascular immune deposits in IgA glomerulonephritis ..... 1444
Zimmer G *See* Amann K et al ..... 1079
Zimmermann A *See* Shaw S et al ..... 1153
Zingraff J (abst) ..... 230, 233, 237
Zingraff J *See* Lindner A et al ..... 1328
Ziyadeh FN *See* Wolf G et al ..... 647
Zlatkine P *See* Le Grimellec C et al ..... 825
Zou WZ (abst) ..... 495
Zuccalà A *See* Zucchelli P et al ..... 452
Zucchelli P, Zuccalà A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, Sanna G, Gaggi R: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency ..... 452
Zulfigar A (abst) ..... 1044
Zuo WZ (abst) ..... 488
Zurini M (abst) ..... 802
Zysset F (abst) ..... 801

# Subject Index For Volume 42


Acetate dialysis (abst) ..... 233, 806
Acetate-free bicarbonate dialysate (abst) ..... 237
Acetate-free biofiltration (abst) ..... 218, 230, 233, 501
Acid-base balance
  ion $H^+$ unit scale (abst) ..... 236
  pH changes, uremic neutrophils ..... 690
  relationship of EPO (abst) ..... 804
Acquired cystic renal disease (abst) ..... 198
Actin, PDGF in glomerulogenesis ..... 390
Acute arterial occlusion in ARF (abst) ..... 215
Acute pancreatitis, CAPD (abst) ..... 1287
Acute pyelonephritis (abst) ..... 1040, 1043
Acute renal failure
  acute arterial occlusion (abst) ..... 215
  insulin-like growth factor-I (abst) ..... 1048
  ischemic, urodilatin, dopamine ..... 1153
  mild renal ischemia ..... 610
  nephrotic syndrome (abst) ..... 495
  percutaneous biopsy (abst) ..... 495
  thrombocytopenia (abst) ..... 1044
Acyclovir, cytomegalovirus, allografts (abst) ..... 235
Adenosine triphosphatase in medulla ..... 1093
Adenylate cyclase activity, cytokines ..... 559
ADP, mitochondria-transport ATPases (abst) ..... 221
Adrenalectomy, lipocortin-1 mRNA (abst) ..... 800
Adriamycin
  blunted volume expansion natriuresis (abst) ..... 234
  glomerulosclerosis, captopril (abst) ..... 506
  nephropathy (abst) ..... 1283
  nephrotic syndrome, antioxidants (abst) ..... 507
Alanine cytoprotective action ..... 775
Albumin
  excretion, children (abst) ..... 1044
  excretion, glycosaminoglycans ..... 285
  GBM permeability ..... 25
Alcoholism, GN, post-infectious (abst) ..... 232
Aldosterone, target epithelia ..... 250
Alfacalcidol, hyperparathyroidism (abst) ..... 1035
Allografts
  acyclovir, cytomegalovirus (abst) ..... 235
  dysfunction, cytomegalovirus (abst) ..... 222
  dysfunction, Doppler (abst) ..... 221
  HLA sensitization (abst) ..... 220
  IL-2, TNF, neopterine, creatinine (abst) ..... 231
  rejection, immunopharmacology ..... 38:S-182
  rejection, T-cells (abst) ..... 1047
  renal artery stenosis, transplantation (abst) ..... 1286
  survival rates (abst) ..... 220
Alport syndrome
  COL4A5 deletion ..... 1336
  COL4A5 mutations ..... 83
  COL4A5 structure, diffuse leiomyomatosis ..... 1178
  collagen IV, GBM ..... 179
  collagen IV, V and VI ..... 115
Aluminum
  blood levels, hemoglobin (abst) ..... 502
  blood levels (abst) ..... 204
  bone disease, predialysis (abst) ..... 212
  bone disease, RF (abst) ..... 213
  renal osteodystrophy (abst) ..... 498
Aluminum toxicity
  calcium alginate, HD (abst) ..... 1045
  prurigo nodularis (abst) ..... 1044
Amiloride, lithium reabsorption (abst) ..... 1286
Ammonia, protein metabolism ..... 595
Amylase isoenzymes, renal clearance (abst) ..... 1286
Amyloidosis
  dialysis-related ..... 38:S-78
  dialysis-related, protease inhibitors ..... 915
  dialysis-related, systemic (abst) ..... 201
  HD membrane, $\alpha$-$_2$M (abst) ..... 1040
Analgesic nephropathy (abst) ..... 1044
Anaphylactoid reactions
  hemodialysis (abst) ..... 218
  reused dialyzers ..... 1232
Anemia
  hemodialysis, angiodysplasia (abst) ..... 228
  hemodialysis, rHuEPO (abst) ..... 501
  multiple myeloma, ESRD (abst) ..... 233
  pathogenesis in CRF (abst) ..... 796
  predialysis CRF, rHuEPO (abst) ..... 498
  transplantation, enalapril (abst) ..... 206
  transplantation, EPO-deficiency (abst) ..... 216
  uremia, EPO ..... 975
  uremia, EPO, hypoxic vasodilation ..... 975
  uremia, rHuEPO ..... 38:S-142
Angiodysplasia, HD, anemia (abst) ..... 228
Angiotensin, blood pressure, CRF ..... 46
Angiotensin converting enzyme (ACE) inhibition
  BP control (abst) ..... 220
  bradykinin, Nephrology Forum ..... 1020
  calcium antagonists, renal mass, BP (abst) ..... 211
  decrease in proteinuria (abst) ..... 1285
  EPO concentrations (abst) ..... 1030
  hypoxemia-induced insufficiency (abst) ..... 799
  metabolic effects (abst) ..... 1039
  microalbuminuria (abst) ..... 200
  nephrotic proteinuria (abst) ..... 213
  renal disease, Nephrology Forum ..... 463
Angiotensin II
  endothelin secretion, MC ..... 860
  receptors in rat medulla ..... 1372
  stenotic kidney ..... 417
Anisodamine, ARF (abst) ..... 495
Anti-DNA antibodies, glomerular binding ..... 1363
Anti-endothelial cell antibodies, SLE (abst) ..... 1038
Anti-GBM glomerulonephritis
  deoxyspergualin therapy (abst) ..... 1034
  glomerular fibrinolytic activity (abst) ..... 1034
  T-cells (abst) ..... 1032
Anti-hypertensive drugs, renal effect ..... 354
Anticardiolipin antibodies (abst) ..... 233
Antilymphocyte globulins, transplantation ..... 38:S-188
Antioxidants, adriamycin, nephrotic syndrome (abst) ..... 507

Antiphospholipid antibodies
glomerulopathy (abst) ... 225
HD, CRF (abst) ... 211
Aortocaval fistula, ANP, in dogs ... 867
Arginase, L-arginine metabolism, GN ... 1107
Arginine vasopressin, vascular smooth muscle cells (abst), 799
Aromatic L-amino acid decarboxylase ... 617
Arterial occlusion, acute in ARF (abst) ... 215
Astragalus Propinquns Schichk (abst) ... 505
Atenolol, diabetic nephropathy, GFR (abst) ... 794
ATP turnover (abst) ... 221
Atrial natriuretic factor
down-regulation of salt excretion ... 673
Prazosin, natriuresis ... 433
receptors, responses in hypertrophy ... 75
Atrial natriuretic peptide (ANP)
aortocaval fistula dogs ... 867
displacement by urodilatin (abst) ... 234
receptor, dietary fatty acid ... 265
renal action ... 38:S-127
severe hyponatremia (abst) ... 1031
Autoreactive kidney-infiltrating T-cell clones ... 851
Autosomal-dominant polycystic kidney disease (ADPKD)
acute cerebrovascular attacks (abst) ... 225
blood pressure, kidney volume (abst) ... 211
diagnosis with DNA probes (abst) ... 207
gene testing (abst) ... 491
genetic clinical study (abst) ... 202
genetic counseling (abst) ... 207
genetic diagnosis (abst) ... 210
probability kidneys are different in ... 1199
tubular renin ... 364
urinary excretion, microalbuminuria, NAG (abst) ... 211
Azathioprine
intolerance (abst) ... 205
transplantation (abst) ... 216

Bacterial contamination, dialyzer membrane ... 61
Bartter's syndrome (abst) ... 1287
$\beta_1$ integrins, glomerular epithelial cells ... 1099
$\beta_2$-microglobulin
elimination, HD (abst) ... 209
removal in hemodiafiltration (abst) ... 1045
turnover, dialysis ... 1434
Bezafibrate, lipoproteins, CRF, HD (abst) ... 199
Bicarbonate dialysis
acetate-free biofiltration (abst) ... 501
cardiac function and (abst) ... 233
pre-dialytic hypotension (abst) ... 230
vascular refilling (abst) ... 806
venous system hemodynamics ... 718
Bicarbonate diuresis (abst) ... 503
Biopsy
renal, detects CMV genome ... 1012
renal, diabetic nephropathy (abst) ... 229
renal percutaneous (abst) ... 494, 495
tubulointerstitial lesions (abst) ... 494
Blood pressure
ACE inhibitors (abst) ... 220
angiotensin, CRF ... 46
elevation, saline infusion (abst) ... 508
hemodialysis, CRF (abst) ... 215
systemic, DM, Nephrology Forum ... 1470
"white coat" hypertension (abst) ... 202
Blood transfusions, pretransplant (abst) ... 208
Bone disease
adynamic, dialysis ... 38:S-62
aluminum, advanced RF (abst) ... 213
aluminum (abst) ... 212, 498
aseptic necrosis (abst) ... 221
Bone marrow
hemopoietic progenitor, dialysis (abst) ... 502
rHuEPO, chronic insufficiency (abst) ... 206
Bone metabolism, renal insufficiency (abst) ... 499
Bone mineral density
dialysis (abst) ... 805
transplantation (abst) ... 211, 808, 1048
Bowman's capsule, leukocytes, anti-GBM disease (abst) ... 1051
Bradykinin-mediated effects of ACE inhibition, Nephrology Forum ... 1020

C4 null phenotype, mutations, gene deletions (abst) ... 1032
C4 RFLPs, membranous nephropathy ... 882
C9 deficiency and IgA nephropathy ... 1253
Calcineurin, cyclophilin-cyclosporine complex (abst) ... 802
Calcitriol
hyperparathyroidism, HD (abst) ... 1041
low-dose, dialysis ... 1191
non-calcemic vit D analogs ... 38:S-43
Calcium
intracellular, proximal tubules (abst) ... 797
ketodiet in osteodystrophy ... 1217
mass balance, calcium dialysate, HD (abst) ... 230
metabolism, nephrotic syndrome ... 335
metabolism, renal failure ... 38:S-37
renal lithiasis (abst) ... 204
Calcium alginate, aluminum toxicity, HD (abst) ... 1045
Calcium pump inhibitor, uremia ... 1328
Calcium renal stones (abst) ... 803
Calcium salts as phosphate binder, uremia ... 38:S-50
Calorie restriction and remnant kidney ... 710
Cancer, renal/pelvic (abst) ... 1042
CAPD
acute pancreatitis (abst) ... 1287
adequacy of ... 38:S-160
autoimmune hypothyroidism (abst) ... 198
complement system, children (abst) ... 797
fluid kinetics, hypo-osmotic solution (abst) ... 797
high molecular weight dialysate (abst) ... 503
IL-1 receptor antagonist, CRF ... 1419
intraperitoneal neostigmine ... 1398
lipoprotein level ... 424
older patients at home (abst) ... 503
peritoneal defenses, CCPD ... 947
peritoneal function (abst) ... 205
peritoneal inflammation ... 735
peritonitis, fungal (abst) ... 200
peritonitis, prostaglandins (abst) ... 798
peritonitis, rates/risks ... 967
staphylococcus aureus, rHuEPO (abst) ... 204
urea kinetic model of evaluation (abst) ... 205
Captopril
adriamycin, glomerulosclerosis (abst) ... 506
diabetic nephropathy, albuminuria (abst) ... 794
nifedipine, renal insufficiency ... 452
renal artery stenosis (abst) ... 206, 1287
Cardiac hypertrophy in uremic rats ... 1079
Cardiopulmonary recirculation modeling ... 1450

Carotid artery traction, natriuresis (abst) . . . . . 234
CD4 monoclonal antibody therapy (abst) . . . . . 1033
CD25 monoclonal antibody therapy (abst) . . . . . 1033, 1046
254Ag monoclonal antibody (abst) . . . . . 1036
Ceftizoxime, endotoxin influence (abst) . . . . . 507
Cell electrolytes, osmolytes in outer medulla . . . . . 843
Cell-type specific ganglioside of podocytes . . . . . 624
Cellular metabolites, renal injury . . . . . 38:S-109
Cerebrovascular attacks, ADPDK (abst) . . . . . 225
Children
  asymptomatic syndrome (abst) . . . . . 492
  complement system, CAPD (abst) . . . . . 797
  Dengue fever nephritis (abst) . . . . . 493
  glomerular disease (abst) . . . . . 492
  HBV glomerulonephritis (abst) . . . . . 493
  hemolytic uremic syndrome, IL-8 . . . . . 951
  lead poisoning, renal function . . . . . 1226
  lupus nephritis (abst) . . . . . 1043
  nephrotic syndrome (abst) . . . . . 492, 493, 1038
  orthostatic proteinuria (abst) . . . . . 493
  peritoneal equilibration test . . . . . 102
  rhGH, calcium (abst) . . . . . 1040
  TNF, glomerular disease (abst) . . . . . 492
  transplantation . . . . . 657, 1408
  transplantation (abst) . . . . . 802
  uremia, growth hormone, Nephrology Forum . . . . . 188
  urinary albumin excretion (abst) . . . . . 1044
Chinese herbal medicine (abst) . . . . . 498, 504, 505, 510
Chondrocalcinosis, Bartter's syndrome (abst) . . . . . 1287
Chromogranin, glomerular peripolar cells (abst) . . . . . 1049
Chronic lymphocytic leukemia, GN . . . . . 127
Chronic renal failure
  angiotensin effect on BP . . . . . 46
  anti-platelet antibodies (abst) . . . . . 497
  bacterial enzyme products (abst) . . . . . 497
  bone disease (abst) . . . . . 499
  calcium pump inhibitor . . . . . 1328
  children, Nephrology Forum . . . . . 188
  Chinese herbal medicine (abst) . . . . . 498, 504
  hyperhomocysteinemia (abst) . . . . . 229
  IL-1 receptor antagonist . . . . . 1419
  Liddle syndrome, nephrocalcinosis (abst) . . . . . 233
  membrane ionic permeability . . . . . 300
  $O_2$ consumption, PMNL . . . . . 602
  oxygen radicals, antioxidants (abst) . . . . . 496
  pathogenesis of anemia (abst) . . . . . 796
  predicting . . . . . 960
  prekallikrein-kallikrein system (abst) . . . . . 496
  PUFA, Oenothera Biennis L in CRF (abst) . . . . . 498
  rHuEPO, anemia, predialysis (abst) . . . . . 498
  serum hyaluronic acid (abst) . . . . . 496
  soluble TNF receptors . . . . . 663
  T-lymphocyte transformation, IL-2 (abst) . . . . . 497
  zinc, immunological functions (abst) . . . . . 499
Chylomicron remnants in dialysis . . . . . 1247
Cimetidine, creatinine, GFR (abst) . . . . . 793
COL4A5 and Alport syndrome . . . . . 83, 115, 1178, 1336
Collagen types, Alport syndrome . . . . . 115, 179
Complement system
  activation, OKT3, T-cells (abst) . . . . . 796
  CAPD, children (abst) . . . . . 797
Continuous arteriovenous hemodiafiltration (CAVHD)
  dialyzer geometry . . . . . 448
  role of convection (abst) . . . . . 209
  tobramycin clearance (abst) . . . . . 209
Contrast medium, medullary sponge kidney (abst) . . . . . 801
Converting enzyme inhibition, proteinuria (abst) . . . . . 795
Cordyceps sinensis, ARF (abst) . . . . . 495
Cortisol as a mineralocorticoid . . . . . 1297
CR1 mRNA expression (abst) . . . . . 228
Creatinine clearance (abst) . . . . . 1043
Creatinine kinetics of evaluating CAPD (abst) . . . . . 205
Crescentic glomerulonephritis (abst) . . . . . 489
Crescentic nephritis (abst) . . . . . 510
Cryoglobulinemia, hepatitis virus C (abst) . . . . . 803
Cuprophane membranes, dialyzer geometry . . . . . 442
Cyclic AMP
  G-protein stimulation, Na/H exchange . . . . . 11
  ionic permeability, CRF . . . . . 300
Cyclic peritoneal dialysis, CAPD . . . . . 947
Cyclophilin-cyclosporine complex (abst) . . . . . 802
Cyclophosphamide trials, idiopathic MGN (abst) . . . . . 1032
Cyclosporin A
  diltiazem, transplantation (abst) . . . . . 1047
  luteinizing hormone secretion (abst) . . . . . 802
  proteinuria, adriamycin nephropathy (abst) . . . . . 1283
Cyclosporine
  chronic liver disease (abst) . . . . . 226
  corticoid-resistant nephrotic syndrome (abst) . . . . . 802
  distal urinary acidification (abst) . . . . . 225
  gingival hyperplasia (abst) . . . . . 223
  glomerular thrombosis (abst) . . . . . 1052
  graft survival, HLA typing . . . . . 38:S-172
  HLA sensitization, allografts (abst) . . . . . 220
  liver transplantation, ARF (abst) . . . . . 227
  nephrotoxicity . . . . . 1
  nephrotoxicity, P-170 glycoprotein (abst) . . . . . 223
  proximal tubules (abst) . . . . . 221
  toxicity, endothelin antagonism . . . . . 770
  toxicity (abst) . . . . . 236
  transplantation (abst) . . . . . 205, 216, 226
Cyprofloxacin, acute pyelonephritis (abst) . . . . . 1040
Cyst epithelial cells, NaCl transport . . . . . 308
Cystic renal disease, acquired (abst) . . . . . 198
Cystitis, corinebacterium D2 group (abst) . . . . . 226
Cytokines
  adenylate cyclase activity . . . . . 559
  glomerular cell production (abst) . . . . . 1037
  IgA nephropathy . . . . . 341
Cytomegalovirus
  allografts, acyclovir (abst) . . . . . 235
  DNA, IgA nephropathy, hematuria (abst) . . . . . 488
  genome, renal biopsy detection . . . . . 1012
  infection, allograft dysfunction (abst) . . . . . 222
  transplantation (abst) . . . . . 207, 216

DDAVP, hemodynamics, renin secretion (abst) . . . . . 793
ddI as HIV treatment (abst) . . . . . 234
DEAE-dextran, glomerular selectivity (abst) . . . . . 1049
Dengue fever nephritis, children (abst) . . . . . 493
Deoxyspergualin, anti-GBM GN (abst) . . . . . 1034
Dextran sulfate (abst) . . . . . 1049
Diabetes
  dialysis, bone histomorphometry (abst) . . . . . 214
  transplantation . . . . . 38:S-193
Diabetes, non-insulin dependent
  glomerular volume (abst) . . . . . 1053
  glycemic control, nephropathy . . . . . 167
Diabetes insipidus
  hydronephrosis, UT traumatic rupture (abst) . . . . . 801

Diabetes mellitus
systemic BP, Nephrology Forum ..... 1470
Diabetic nephropathy
captopril, atenolol, GFR (abst) ..... 794
Chinese herbal medicine (abst) ..... 504
dyslipoproteinemia ..... 1381
enalapril, diet, microalbuminuria (abst) ..... 208
fibroblast Na/H antiport activity ..... 1184
glycemic control, NIDDM ..... 167
hyperinsulinemia, glomerular hemodynamics ..... 1160
prevention with glycosaminoglycans ..... 285
renal arteriosclerosis (abst) ..... 1052
renal biopsy (abst) ..... 229
thromboxane ..... 937
Dialysis
adequacy of, critical analysis ..... 540
adynamic bone disease ..... 38:S-62
amyloidosis and ..... 38:S-78
blood serotonin levels (abst) ..... 1045
bone mineral density (abst) ..... 805
clearing chylomicron remnants ..... 1247
dry weight measurement (abst) ..... 796
EPO, cytotoxic antibodies (abst) ..... 218
hepatitis C virus (abst) ..... 204
lipids, nutritional status (abst) ..... 200
polymorphonuclear cells, infection ..... 38:S-91
protease inhibitors, amyloidosis ..... 915
systemic amyloidosis (abst) ..... 201
Dialysis disequilibrium syndrome (DDS) ..... 161
Dialyzer geometry
CAVHD ..... 448
hemodialysis ..... 442
Dialyzer membranes
permeability to pyrogens ..... 61
reused, anaphylactoid reactions ..... 1232
Dietary fatty acid, ANP receptor ..... 265
Dietary protein
restriction, murine PKD ..... 837
vasopressin, hydration ..... 1207
Dietary salt
endothelin vasoconstrictive effect (abst) ..... 508
hypertension (abst) ..... 1038
Digital intra-venous arteriography substraction (abst) ..... 214
Diltiazem, transplantation, cyclosporin A (abst) ..... 1047
Dipyridamole trials, idiopathic MGN (abst) ..... 1032
Diuretic effect in outer medulla ..... 843
Dobutamine, renal metabolism, endotoxemia (abst) ..... 796
Donor organs
HLA typing (abst) ..... 224, 809
MLC-testing (abst) ..... 807
procurement (abst) ..... 227
Dopamine, urodilatin, ischemic ARF ..... 1153
Dopexamine, renal metabolism, endotoxemia (abst) ..... 796
Doppler
allograft dysfunction evaluation (abst) ..... 221
renal artery stenosis, transplantation (abst) ..... 201
Dry weight measurement, post-dialysis (abst) ..... 796
Dyslipoproteinemia, diabetic renal failure ..... 1381

Eicosanoids
glomerular hemodynamics, IgA nephropathy ..... 106
superoxides, cell injury ..... 69
Electrolytes, cell
osmolytes, outer medulla ..... 843
Enalapril
anemia, transplantation (abst) ..... 206
microalbuminuria, diet, IDDM (abst) ..... 208
End-stage renal disease
EPO, anemia, multiple myeloma (abst) ..... 233
HD, IgE associated (abst) ..... 230
hemodialysis, RBC (abst) ..... 496
prognosis with spinal cord injury (abst) ..... 1031
treatment (abst) ..... 802, 1043
tumor necrosis factor-$\alpha$ (abst) ..... 497
USRDS mortality tables ..... 991
Endoglin, differentiation marker, macrophages (abst) ... 1036
Endothelial cells, allo specific antibodies (abst) ..... 1284
Endothelial-derived relaxing factor, obstruction ..... 400
Endothelin
antagonism, cyclosporine toxicity ..... 770
blood volume (abst) ..... 508
glomerular mesangial cells (abst) ..... 509
renal artery obstruction ..... 632
vasoconstriction, dietary salt (abst) ..... 508
Endothelin-1
Na/H, Na/$HCO_3$ ..... 18
secretion, angiotensin II, MC ..... 860
Endothelium, renal artery obstruction ..... 632
Endotoxemia, interstitial nephropathy (abst) ..... 494
Endotoxin
low-dose, preeclampsia (abst) ..... 1283
metabolic of ceftizoxime (abst) ..... 507
Epidermal growth factor, MC production (abst) ..... 1036
Epithelial cells
adhesion, $\beta_1$ integrins ..... 1099
aldosterone action ..... 250
culture, cell lines (abst) ..... 236
membrane fluidity, transport ..... 825
Erythrocytosis post-transplant (abst) ..... 219
Erythropoietin
ACE inhibitors (abst) ..... 1030
anemia, ESRD, multiple myeloma (abst) ..... 233
anemia, transplantation (abst) ..... 216
arterial pressure (abst) ..... 215
cardiac effects (abst) ..... 1041
cell culture production (abst) ..... 510
glomerular hemostasis (abst) ..... 804
HD, CD34+ cells (abst) ..... 216
HD, hemoglobin, hematocrit (abst) ..... 237
hippuric acid (abst) ..... 804
hypobaric exposure (abst) ..... 804
$O_2$, hypoxic vasodilation ..... 975
relation to acidosis (abst) ..... 804
subcutaneous dosage (abst) ..... 805
uremia ..... 407
uremia (abst) ..... 1031
Essential fatty acids, graft survival (abst) ..... 1041
Essential hypertension
association with obesity (abst) ..... 208
insulin resistance (abst) ..... 225
metabolic tolerance to medical treatment (abst) ..... 225
Excretory urogram, medullary sponge kidneys (abst) ..... 801
Expert systems diagnose glomerular disease (abst) ..... 1031
Extraglomerular vascular immune deposits, IgA GN ..... 1444

Fatty acids
deficiency, graft survival (abst) ..... 1041
dietary, ANP receptor ..... 265
Felodipine
during dopamine blockade (abst) ..... 795

proximal tubule effect (abst) ..... 1031
Fenoterol, hyperkalemia treatment (abst) ..... 198
Fibrillary glomerulonephritis ..... 1401
Fibroblast Na/H antiport activity ..... 1184
Fibronectin
mRNA splice variants (abst) ..... 1037
synthesis, TGF-$\beta_1$, human MC (abst) ..... 1032
Flow cytometry, renal tubular cells ..... 997
Focal segmental glomerulosclerosis (abst) ..... 489, 799
Fungal peritonitis in CAPD (abst) ..... 200

G-protein stimulation, cyclic AMP ..... 11
Ganoderma capense (abst) ..... 504
Gastrointestinal bleeding, periodic HD (abst) ..... 201
Gentamicin toxicity (abst) ..... 232, 495
Gingival hyperplasia and cyclosporine (abst) ..... 223
Globotriaosylceramide, TNF, IL-1 (abst) ..... 1286
Glomerular basement membrane
anionic charge concentration (abst) ..... 1050
defect in Alport ..... 179
permeability ..... 25
Glomerular cell types in rat kidney (abst) ..... 1051
Glomerular disease
children (abst) ..... 492
diagnosis, applied machine learning (abst) ..... 1031
glucocorticoids ..... 981
immunologically mediated ..... 38:S-123
Glomerular fibrinolytic activity, anti-GBM GN (abst) ... 1034
Glomerular filtration rate
creatinine, cimetidine (abst) ..... 793
glycosilation products ..... 875
measurement, $^{99m}$Tc-DTPA, inulin ..... 174
modified plasma clearance ..... 1006
renal plasma flow (abst) ..... 218
Glomerular hemodynamics
hyperinsulinemia ..... 1160
starvation ..... 567
Glomerular hypertrophy, post-uninephrectomy ..... 136
Glomerular peripolar cells (abst) ..... 1049
Glomerular thrombosis, cyclosporine (abst) ..... 1052
Glomerulogenesis, actin and PDGF ..... 390
Glomerulonephritis
CLL, related lymphomas ..... 127
complicated with hemoptysis (abst) ..... 491
crescentic (abst) ..... 489
fibrillary ..... 1401
glomerular anionic sites (abst) ..... 491
IgA, eicosanoid synthesis ..... 106
IgA, mesangial proliferative (abst) ..... 223
IgA deficiency, mesangial (abst) ..... 219
incidence, Spain (abst) ..... 219
L-arginine metabolism, arginase ..... 1107
leukotriene antagonists ..... 38:S-101
MA histological analysis (abst) ..... 199
membrane attack complex (abst) ..... 507
mesangial, IL-1 (abst) ..... 507
mesangial, IL-6 (abst) ..... 800
plasmin protease system ..... 1462
post-infectious, alcoholism (abst) ..... 232
proliferative lupus, cyclophosphamide (abst) ..... 208
T-cells, lymphokines, anti-GBM GN (abst) ..... 1032
Glomerulopathy
antiphospholipid antibodies (abst) ..... 225
thromboxane, diabetes ..... 937
Glomerulosclerosis
adriamycin, captopril (abst) ..... 506
focal segmental (abst) ..... 489
IL-1 (abst) ..... 1051
Glomerulus
anti-DNA antibody binding ..... 1363
rat kidney (abst) ..... 1051
Glucocorticoids
glomerular disease ..... 981
renal effect ..... 1297
Glucose
homeostasis, Nephrology Forum ..... 1266
MC proliferation, TGF-$\beta$ ..... 647
transport, insulin-responsive ..... 1086
Glycine metabolism, proximal tubular (abst) ..... 1049
Glycine protective action ..... 41, 775
Glycosaminoglycans prevent nephropathy ..... 285
Glycosilation products, glomerular hyperfiltration ..... 875
Grafts
determining function (abst) ..... 203
embolization of with alcohol (abst) ..... 202
rejection, natural killer cells (abst) ..... 224
rejection, steroid/OKT3 therapy (abst) ..... 223
survival, cyclosporine, HLA typing ..... 38:S-172
survival, essential fatty acids (abst) ..... 1041
Growth hormone
calcium regulation, children (abst) ..... 1040
Growth hormone, uremic children, Nephrology Forum .. 188
Guanidines, assay in plasma, urine (abst) ..... 807

H-K-ATPase in renal medulla ..... 1093
5-hydroxytryptamine receptors, noradrenaline (abst) .... 1285
11$\beta$-hydroxysteroid dehydrogenase, mammalian
nephron ..... 56
Hantavirus nephropathy (abst) ..... 1285
Hematuria, asymptomatic, children (abst) ..... 492
Hemodiafiltration (abst) ..... 1044, 1045
Hemodialysis
AgHBs, dialysis ultrafiltrate (abst) ..... 232
amyloidosis, $\alpha$-$_2$m (abst) ..... 1040
anaphylactoid reactions (abst) ..... 218
angiodysplasia, anemia (abst) ..... 228
antioxidant capacity, uremic erythrocytes (abst) ..... 222
antiphospholipid antibodies, CRF (abst) ..... 211
$\beta_2$-microglobulin elimination (abst) ..... 209
$\beta_2$-microglobulin turnover ..... 1434
blood rheology (abst) ..... 1046
bone marrow hemopoietic progenitor (abst) ..... 502
calcitriol, hyperparathyroidism ..... 1191
calcium alginate, aluminum hydroxide (abst) ..... 1045
calcium balance, calcium dialysate (abst) ..... 230
cardiopulmonary recirculation modeling ..... 1450
circadian BP rhythm, CRF (abst) ..... 215
compared with hemodiafiltration (abst) ..... 1044
control of hyperphosphatemia (abst) ..... 807
deformability of RBC (abst) ..... 501
dialysates, ventricular function (abst) ..... 233
dialyzer geometry ..... 442, 448
echocardiographic studies (abst) ..... 216
elevated serum aluminum (abst) ..... 502
endotoxic antibody (abst) ..... 501
Europe and U.S. ..... 38:S-16
gastrointestinal bleeding (abst) ..... 201
hemodynamics, hemorrheology (abst) ..... 500
hemodynamics, venous system ..... 718
hepatitis B vaccination (abst) ..... 212

hepatitis C virus (abst) ..... 205, 207, 208, 209, 218
high-efficiency (abst) ..... 500
high-flux dialysis, polysulfone membrane (abst) ..... 500
hollow-fiber, hemostasis (abst) ..... 235
hollow-fiber, hemostatic disturbances (abst) ..... 807
HTLV-1 antibodies (abst) ..... 238
hypercalcemia (abst) ..... 806
hypotension, nitric oxide role ..... 38:S-96
IL-1, TNF ..... 38:S-68
IL-1 receptor antagonist, CRF ..... 1419
IL-2 generation (abst) ..... 199
IL-6 production ..... 320
Legionella outbreak (abst) ..... 219
lipoprotein level ..... 424
lipoproteins, CRF, bezafibrate (abst) ..... 199
lipoproteins, CRF (abst) ..... 200
low dialysate flow rate (abst) ..... 500
low molecular weight heparin (abst) ..... 217, 235
measuring mass transfer (abst) ..... 805
nutritional assessment (abst) ..... 201
parathyroid hormone, erythropoiesis (abst) ..... 502
post-catheterism vein stenosis (abst) ..... 235
prevention of hepatitis B (abst) ..... 501
race, diabetes and death risk ..... 38:S-22
RBC, ESRD (abst) ..... 496
rHuEPO, anemia (abst) ..... 501
rHuEPO, heme metabolism (abst) ..... 215
rHuEPO, hemorrheological parameters (abst) ..... 214
single-needle, citrate anticoagulation (abst) ..... 807
technetium-labeled heparin (abst) ..... 231
urea distribution volume (abst) ..... 217
urea kinetic model (abst) ..... 500
vascular access (abst) ..... 214, 232, 233
vascular refilling during ..... 1425
Hemodynamic dysfunction in DM, Nephrology Forum .. 1470
Hemolytic uremic syndrome
IL-1, TNF (abst) ..... 1286
IL-8, neutrophils, children ..... 951
Henoch-Schonlein purpura (abst) ..... 490
Heparin
glomerular proteinuria (abst) ..... 1050
low molecular weight, HD (abst) ..... 217, 235
technetium-labeled, HD (abst) ..... 231
Hepatitis B
chronic, glomerular disease (abst) ..... 229
vaccination, HD (abst) ..... 212
Hepatitis B virus
glomerulonephritis, children (abst) ..... 493
pathogenesis (abst) ..... 490
Hepatitis C virus
antibody, home HD (abst) ..... 207
cryoglobulinemia type II (abst) ..... 803
dialysis (abst) ..... 204
hemodialysis (abst) ..... 205, 208, 209, 218
transplantation (abst) ..... 226, 227
Herbal medicine (abst) ..... 498, 504, 505, 510
Heymann's nephritis (abst) ..... 1034, 1051
Hippuric acid, EPO response (abst) ..... 804
HIV infection
ddI treatment (abst) ..... 234
hemodialysis (abst) ..... 238
Ig binding to IgAN collagens ..... 374
renal disease (abst) ..... 230
HLA typing
allocating kidneys and (abst) ..... 1285
donor kidneys (abst) ..... 809
graft survival, cyclosporine ..... 38:S-172
lymphocytes, cadaver donors (abst) ..... 224
sensitization, potential recipients ..... 38:S-176
Hollow-fiber membranes
hemostatic disturbances (abst) ..... 235, 807
reused, anaphylactoid reactions ..... 1232
HSP70 mRNA transcription, regulation of ..... 775
Hyaluronic acid, serum, CRF (abst) ..... 496
Hypercalcemia
chronic hemodialysis (abst) ..... 806
transplantation (abst) ..... 1048
Hypercalciuria
idiopathic, renal lithiasis (abst) ..... 202
insulin resistance, hypertension (abst) ..... 225
prostaglandins (abst) ..... 212
Hypercapnia, chronic (abst) ..... 503
Hypercholesterolemia (abst) ..... 506
Hyperhomocysteinemia in CRF (abst) ..... 229
Hyperinsulinemia, glomerular hemodynamics ..... 1160
Hyperkalemia, fenoterol treatment (abst) ..... 198
Hyperlipidemia
glomerular injury (abst) ..... 506
nephrotic syndrome ..... 38:S-134
Hyperparathyroidism
calcitriol, dialysis ..... 1191
calcitriol, hemodialysis (abst) ..... 1041
calcitriol, non-calcemic vit D analogs ..... 38:S-43
hemodialysis, alfacalcidrol (abst) ..... 1035
hemodialysis, tumoral calcinosis (abst) ..... 806
low calcium dialysate (abst) ..... 1041
MRI, subtraction gammagraphy (abst) ..... 221
$O_2$, CRF, PMNL ..... 602
secondary uremic (abst) ..... 208
transplantation (abst) ..... 211, 806, 808, 1048
treatment, renal function (abst) ..... 204
Hyperphosphatemia
calcium acetate as phosphate binder (abst) ..... 807
chronic respiratory alkalosis ..... 727
Hypertension
ACTH, sodium chloride (abst) ..... 1039
dietary NaCl (abst) ..... 1038
exercise, pH recovery (abst) ..... 1038
insulin resistance, hypercalciuria (abst) ..... 225
insulin resistance, vascular risk factors (abst) ..... 224
monitoring "white coat" (abst) ..... 202
Na/H exchange ..... 1355
pregnancy, altered excretion rates (abst) ..... 1039
pregnancy, proteinuria (abst) ..... 1038
Hypertransaminasemia, hepatitis C virus, HD (abst) ..... 208
Hypobaric exposure, EPO response (abst) ..... 804
Hypocalcemia, chronic respiratory alkalosis ..... 727
Hypocalciuria in kidney injury (abst) ..... 216
Hypomagnesemia, Bartter's syndrome (abst) ..... 1287
Hyponatremia, ANP (abst) ..... 1031
Hypophosphatemia, post-transplant (abst) ..... 803
Hypothyroidism, autoimmune in CAPD (abst) ..... 198
Hypoxia
glycine protection mechanism ..... 41
protein kinase C, cell differentiation ..... 1145

ICAM-1 expression, effect on phagocytes (abst) ..... 1037
Idiopathic membranous glomerulonephritis
cyclophosphamide, warfarin, dipyridamole (abst) ..... 1032
predicting CRF ..... 960

Idiopathic membranous nephropathy
C4 RFLPs ... 882
early stage (abst) ... 488
IgA deficiency, mesangial GN (abst) ... 219
IgA glomerulonephritis
urinary platelet factor 4 (abst) ... 1051
vascular immune deposits ... 1444
IgA nephritis (abst) ... 238
IgA nephropathy
C9 deficient patients ... 1253
clinical classification (abst) ... 488
cytomegalovirus DNA, hematuria (abst) ... 488
extracellular matrix in glomeruli (abst) ... 489
extrarenal cytokines ... 341
glomerular hemodynamics, eicosanoids ... 106
HLA-DR genotyping (abst) ... 489
Ig binding, HIV infection ... 374
IL-2 receptor (abst) ... 198
immunogenetic studies (abst) ... 1036
lymphocyte function in tonsils (abst) ... 489
mesangial deposit idiotypes (abst) ... 797
mesangial proliferative GN (abst) ... 223
neutrophil cytoplasmic antigen antibodies (abst) ... 490
patterns of serum IgA (abst) ... 489
role of complement (abst) ... 506
IgE, with ESRD (abst) ... 230
IgM nephropathy, nephrotic syndrome (abst) ... 488
Immunoadsorption (abst) ... 222
Immunoglobulins, IgAN, HIV ... 374
Immunosuppression
comparison study (abst) ... 1046
herbal medicine study (abst) ... 504
pituitary-testicular function (abst) ... 207
transplantation (abst) ... 203
Impotence, erectile, treatment (abst) ... 226
Injury
glomerular, diabetes ... 937
glomerular, hyperlipidemia (abst) ... 506
hypocalciuria, early stages (abst) ... 216
hypoxic ... 41
ischemic, prostaglandin protection ... 1345
ischemic, proximal tubule cell ... 896
mesangial cell, monocyte adhesion ... 480
mesangial cell, superoxides, $TXB_2$ ... 69
post-ischemic regeneration, IGF-1 ... 113
renal, cellular metabolites ... 38:S-109
renal cell ... 523
renal hypoxia, free radicals, Na (abst) ... 1030
tissue in lupus nephritis ... 755
Inositol transport, mesangial cells ... 33
Insulin-like growth factor-1
binding protein ... 749
regenerating kidney ... 1113
Insulin-responsive glucose transporter ... 1086
Interleukin-1
glomerular sclerosis (abst) ... 1051
induces verocytotoxin receptor (abst) ... 1286
intrarenal (abst) ... 800
mesangial cells, autocrine/paracrine (abst) ... 509
mesangial cells, matrix synthesis (abst) ... 509
mesangial cells (abst) ... 509
mesangial proliferative GN (abst) ... 507
production, herbal medicine (abst) ... 510
TNF, hemodialysis ... 38:S-68
Interleukin-1 receptor antagonist
CRF, dialysis ... 1419
MCP-1 generation, MC ... 95
Interleukin-2
CRF, T-lymphocytes (abst) ... 497
generation during HD (abst) ... 199
production in renal disease (abst) ... 199
Interleukin-2 receptor
anti-CD25 monoclonal antibodies (abst) ... 794
idiopathic IgA nephropathy (abst) ... 198
Interleukin-6
hemodialysis-related production ... 320
mesangial cells (abst) ... 509
mesangial glomerulonephritis (abst) ... 800
TNF-$\alpha$ production, OKT3 (abst) ... 207
Interleukin-8, neutrophil activation, HUS ... 951
International Society of Nephrology, membership survey ... 1295
Interstitial nephropathy, endotoxemia (abst) ... 494
Intracavernosal vasoactive drugs (abst) ... 226
Inulin
determination with microwave oven ... 459
measuring GFR ... 174
Ionic permeability, CRF ... 300
Iron
blood levels (abst) ... 204
depletion, reactive oxygen species (abst) ... 1052
Ischemia
acute renal failure ... 610
lowered osmoprotectants (abst) ... 1050
nitroprusside ... 1153
PAF antagonists (abst) ... 203
prostaglandin protection ... 1345
proximal tubule cell injury ... 896
renal injury, prostaglandins ... 1345
urodilatin, dopamine, ARF ... 1153

K-dependent acidifying ATPase, medulla ... 1093
Ketodiet and Ca in osteodystrophy ... 1217
Kt/V
hemodiafiltration, urea rebound (abst) ... 1045
protein catabolic rate ... 38:S-32

L-arginine metabolism in GN ... 1107
15-Lipoxygenase products, leukotrienes, GN ... 38:S-101
Laminin mRNA quantitation by PCR ... 764
Lead nephropathy, children ... 1226
Legionella (abst) ... 219
Leiomyomatosis, Alport syndrome ... 1178
Leukemia, chronic lymphocytic, GN ... 127
Leukocytes, killing mesangial cells ... 1169
Liddle syndrome (abst) ... 233
Lipid peroxidation, Heymann's nephritis (abst) ... 1051
Lipids
nutritional status, dialysis (abst) ... 200, 214
serum changes, uremia (abst) ... 496
Lipoproteins
decreased receptor function, uremia ... 1238
HD, CRF, bezafibrate (abst) ... 199
hemodialysis, CRF (abst) ... 200
level in CAPD, HD ... 424
Lithium reabsorption (abst) ... 1286
Liver disease, cyclosporine induced (abst) ... 226
Liver function, post-renal transplantation (abst) ... 808
Liver growth factor, mesangial cells (abst) ... 210

Liver transplantation, cyclosporine, ARF (abst) ..... 227
Lomefloxacin, acute pyelonephritis (abst) ..... 1043
Loop diuretic effect in outer medulla ..... 843
Losartan, $AT_1$ angiotensin II receptors (abst) ..... 1048
Lupus glomerulonephritis
  pathology indices ..... 743
  proliferative, cyclophosphamide (abst) ..... 208
Lupus nephritis
  anti-CD26 autoantibodies (abst) ..... 1284
  anti-endothelial cell antibodies (abst) ..... 1035
  children, adolescents (abst) ..... 1043
  cuyoxin pulse therapy (abst) ..... 490
  GBM, anti-heparan sulfate, histones (abst) ..... 793
  histological transformation (abst) ..... 490
  kidney-infiltrating T-cell clones ..... 851
  pregnancy (abst) ..... 1042
  reversibility in dialysis (abst) ..... 501
  tissue injury ..... 755
  treatment, prognosis (abst) ..... 489
  tubular interstitial lesions (abst) ..... 490
  type IV prognosis (abst) ..... 489
  vascular cell adhesion molecule-1 ..... 903
Lupus nephropathy, cytoplasmic antibodies (abst) ..... 217
Luteinizing hormone, cyclosporine (abst) ..... 802
Lycium Barbarum Polysaccharide (abst) ..... 505
Lymphocytotoxic monoclonal autoantibodies (abst) ..... 1032
Lymphokine production, T-cells, anti-GBM GN (abst) ..... 1032
Lymphoma, CLL, glomerulonephritis ..... 127
Lysosomal iron
  proximal tubular, remnant kidney (abst) ..... 1053
  reactive oxygen species, puromycin nephrosis (abst) ..... 1052

Macrophage-colony stimulating factor, MC surface ..... 279
Magnesium concentration, erythrocytes (abst) ..... 795
Math model, cardiopulmonary recirculation ..... 1450
Medulla
  angiotensin II receptors ..... 1372
  loop diuretic effect ..... 843
Medullary sponge kidneys, contrast medium (abst) ..... 801
Membrane fluidity, epithelial cells ..... 825
Membrane selection, muscle protein catabolism ..... 38:S-86
Membranous glomerulonephritis, herbal medicine (abst) ..... 504
Membranous nephropathy
  altered matrix ..... 573
  antigen, immune deposits (abst) ..... 488
  idiopathic (abst) ..... 488
  prospective study (abst) ..... 1043
  renin angiotensin, ANP (abst) ..... 508
Mesangial antigen, monoclonal antibodies ..... 700
Mesangial cells
  angiotensin, endothelin secretion ..... 860
  antigen analysis, flow cytometry (abst) ..... 509
  autocrine secretion of TGF-$\beta$ ..... 1319
  endothelin effect (abst) ..... 509
  heparin, extracellular matrix (abst) ..... 798
  IL-1, TGF-$\beta$, matrix synthesis (abst) ..... 509
  IL-1 (abst) ..... 509
  IL-1 autocrine, paracrine (abst) ..... 509
  IL-6 (abst) ..... 509
  injury, monocyte adhesion ..... 480
  injury, superoxide and $TXB_2$ ..... 69
  inositol transport ..... 33
  killing by leukocytes ..... 1169
  liver growth factor (abst) ..... 210
  platelet activating factor ..... 1309
  platelet interaction (abst) ..... 210
  proliferation, TGF-$\beta$, glucose ..... 647
  secreted M-CSF ..... 279
  take up apoptotic neutrophils ..... 924
  TNF actions on (abst) ..... 210
  TNF-$\alpha$-induced PAI-1 release ..... 327
Methylprednisolone and glomerular diseases ..... 981
Microalbuminuria, ACE inhibition (abst) ..... 200
Microfilament disruption, ischemic proximal tubule injury ..... 896
Microscopic polyarteritis (abst) ..... 1039
Mineralocorticoids ..... 1297
Modified plasma clearance, measuring GFR ..... 1006
Monoclonal antibodies
  254Ag, complement C5b-9 deposits (abst) ..... 1036
  histological analysis of GN (abst) ..... 199
  HLA-B5 antigens (abst) ..... 1047
  lymphocytotoxic autoantibody encoded (abst) ..... 1032
  OKT3 procoagulant effect ..... 1124
  recognizing novel mesangial antigen ..... 700
  therapy, nephrotoxic nephritis (abst) ..... 1033
Monoclonal gammapathy, post-transplant (abst) ..... 231
Monocyte adhesion, mesangial cell injury ..... 480
Monocyte chemotactic peptide-1, IL-1ra, MC ..... 95
Multiple myeloma, EPO, anemia, ESRD (abst) ..... 233
Muscle protein catabolism, membrane selection ..... 38:S-86
Myeloperoxidase, renal perfusion (abst) ..... 1284
Myocardial capillary density, uremia ..... 1079

Na/H exchange
  antiport activity, diabetic nephropathy ..... 1184
  G-protein stimulation, cyclic AMP ..... 11
  hypertension ..... 1355
  transporters, ET-1 ..... 18
Na-K-ATPase, ouabain sensitivity, CCD (abst) ..... 800
NACl transport, MDCK cyst epithelial cells ..... 308
Natriuresis
  ANP, aortocaval fistula dogs ..... 867
  bilateral carotid artery traction (abst) ..... 234
  blunted volume expansion, adriamycin (abst) ..... 234
Neostigmine, intraperitoneal, CAPD ..... 1398
Nephrectomy
  graft embolization as alternative (abst) ..... 202
  tubuloglomerular feedback (abst) ..... 1049
Nephritis
  crescentic, cell transfer (abst) ..... 510
  hereditary, Nephrology Forum ..... 783
  monoclonal antibody therapy (abst) ..... 1033
Nephroblastoma (abst) ..... 228
Nephrocalcinosis (abst) ..... 233, 1042
Nephrology
  advances in treatment ..... 38:S-203
  clinical trials ..... 1061
Nephropathy
  analgesic, diagnosis of (abst) ..... 1044
  analgesic and reflux (abst) ..... 1041
  cyclosporine, lymphoid irradiation (abst) ..... 506
  immune complex, Paragonimiasis Westermani (abst) ..... 507
  interstitial, prostaglandin (abst) ..... 510
  thin membrane (abst) ..... 490
Nephrosis, ovarian hyperstimulation (abst) ..... 800
Nephrotic syndrome
  acute renal failure (abst) ..... 495
  adriamycin-induced, antioxidants, (abst) ..... 507

apolipoproteins (abst) ... 1284
Black African, histological (abst) ... 228
children (abst) ... 492
corticoid-resistant, cyclosporine (abst) ... 802
edema, children (abst) ... 493
glucocorticoid response (abst) ... 491
hyperlipidemia ... 38:S-134
idiopathic, leukocyte subsets (abst) ... 224
IgM nephropathy (abst) ... 488
lipoproteins, adriamycin (abst) ... 1283
lymphocyte response, children (abst) ... 1038
primary, fibrinolytic activity (abst) ... 491
protein metabolism, herbal medicine (abst) ... 505
sodium retention, glomerular changes (abst) ... 507
sodium retention, renal dopamine (abst) ... 491
tubular syndrome (abst) ... 212
Vitamin D, calcium metabolism ... 335
Nephrotoxicity
cyclosporine ... 1
cyclosporine, P-170 glycoprotein ... 223
monoclonal antibody therapy (abst) ... 1033
Netilmicin, acute pyelonephritis (abst) ... 1040
Neutral endopeptidase inhibition, oral SCH34826 (abst) ... 1030
Neutrophils
lysosomal enzymes (abst) ... 1037
uremic, pH changes ... 690
Nifedipine, renal insufficiency ... 452
Nitric oxide
hemodialysis, hypotension ... 38:S-96
synthase of macula densa ... 1017
Nitroprusside, ischemic ARF ... 1153
Nonamyloidotic fibrillary glomerulopathy (abst) ... 801
Nutcracker phenomenon, children (abst) ... 493
Nutritional status
calorie restriction, remnant kidney ... 710
dialysis (abst) ... 200
glomerular hemodynamics, starvation ... 567
hemodialysis (abst) ... 201
lipids, dialysis (abst) ... 214
muscle protein catabolism ... 38:S-86
peritoneal dialysis ... 38:S-165

1,25 $(OH)_2$-$D_3$
calcium reabsorption, renal lithiasis (abst) ... 204
uremic hyperparathyroidism (abst) ... 208
1,25 Vit D
calcium-phosphorous homeostasis, CRF (abst) ... 211
Obesity and essential hypertension (abst) ... 208
Oenothera Biennis L in CRF (abst) ... 498
OKT3 monoclonal antibody
dosage by body weight (abst) ... 808
induces TNF-$\alpha$, IL-6 production (abst) ... 207
procoagulant effect ... 1124
Ontogeny of AADC in rat kidney ... 617
Organ preservation solutions ... 38:S-197
Orthostatic proteinuria
nutcracker phenomenon (abst) ... 493
Osmolytes, cell electrolytes in outer medulla ... 843
Osmoprotectants
human kidney, Na, urea levels (abst) ... 1030
lowered by ischemia (abst) ... 1050
urinary excretion (abst) ... 1035
Osteodystrophy, renal
$^{99m}$Tc-MDP bone scan (abst) ... 498
aluminum (abst) ... 498
ketodiet, calcium, Vit D ... 1217
pathological analysis (abst) ... 499
PTH, 1,25$(OH)_2D_3$ (abst) ... 499
Ovarian hyperstimulation syndrome, nephrosis (abst) ... 800
Oxalosis, transplantation, children ... 1408
Oxygen consumption, hyperparathyroidism ... 602
Oxygen radicals
increased, eicosanoids, injury ... 69
injury, renal hypoxia, Na (abst) ... 1030

4-pentenoate, renal effects ... 586
Pancreatitis, CAPD (abst) ... 1287
Panel reactive cytotoxic antibodies, EPO (abst) ... 218
Paragonimiasis Westermani, nephropathy (abst) ... 507
Parathyroid hormone
hemodialysis, erythropoiesis (abst) ... 502
stimulation, phosphate loading (abst) ... 1050
suppression on dialysis (abst) ... 1045
Parathyroidectomy, graft dysfunction (abst) ... 1048
Pelvic cancer (abst) ... 1042
Peptides
intestinal, Na uptake (abst) ... 1050
plasma, uninephrectomy (abst) ... 236
Percutaneous transluminal angioplasty
renal artery stenosis (abst) ... 217
Percutaneous transvenous angioplasty
vascular access stenosis ... 1390
Perindoprilat, hypoxemia (abst) ... 799
Peritoneal catheters, Moncrief's technique (abst) ... 205
Peritoneal dialysis
adequacy (abst) ... 214
bone marrow hemopoiesis (abst) ... 502
catheter obstruction (abst) ... 503
intermittent whole-day, CRF (abst) ... 503
nutritional aspects ... 38:S-165
overview ... 38:S-148
peritonitis (abst) ... 503, 1046
solutions, 1% amino acid (abst) ... 803
solutions, improved ... 38:S-153
Peritoneal equilibration test in children ... 102
Peritoneal inflammation, CAPD ... 735
Peritonitis
bacterial, PD (abst) ... 503
CCPD, CAPD ... 947
fungal, CAPD (abst) ... 200
intestinal failure, PD (abst) ... 1046
prostaglandins, CAPD (abst) ... 798
rates/risks, CAPD ... 967
Phosphate
loading, parathyroid stimulation (abst) ... 1050
transport, kidney endosomes ... 1070
Phospholipase C-$\alpha$ from porcine kidney ... 888
Pituitary-testicular function (abst) ... 207
Plasmapheresis, acute vascular rejection (abst) ... 222
Plasmin protease system in GN ... 1462
Plasminogen activator inhibitor-1, TNF-$\alpha$, MC ... 327
Platelet activating factor
antagonist, warm ischemia time (abst) ... 203
porins stimulate PAF, MC ... 1309
Platelet-derived growth factor, glomerulogenesis ... 390
Platelet factor 4, IgA GN (abst) ... 1051
Platelets
function, EPO, uremia ... 668
mesangial cell interaction (abst) ... 210
Plumbism after chelation, childhood ... 1226

Podocytes
cell-type specific ganglioside ..... 624
focal segmental glomerulosclerosis (abst) ..... 799
structure, post-uninephrectomy ..... 148
Polyacrylonitrile membrane (abst) ..... 238
Polyamide membrane (abst) ..... 806
Polyarteritis, microscopic (abst) ..... 1039
Polycystic disease
dietary protein restriction ..... 837
renal histology ..... 1259
Polymorphonuclear leukocytes
CRF, $O_2$ consumption ..... 602
dialysis ..... 38:S-91
Polyunsaturated fatty acids, CRF (abst) ..... 498
Potassium reabsorption, rubidium ..... 272
Prazosin, ANF response ..... 433
Pre-term babies, nephrocalcinosis (abst) ..... 1042
Prednisone, transplantation (abst) ..... 216
Preeclampsia
glomerular changes (abst) ..... 1052
low-dose endotoxin (abst) ..... 1283
Pregnancy
hypertension, excretion rates (abst) ..... 1039
lupus nephritis (abst) ..... 1042
proteinuria, hypertension (abst) ..... 1038
proteinuria, renal function (abst) ..... 795
Prekallikrein-kallikrein system, CRF (abst) ..... 496
Primary hyperoxaluria type 1 ..... 1408
Primary vasculitis, renal involvement (abst) ..... 490
Procoagulant effect of OKT3 ..... 1124
Prostaglandin $E_2$
angiotensin II, stenotic kidney ..... 417
excretion, hypercalciuria (abst) ..... 212
Prostaglandins
interstitial nephropathy (abst) ..... 510
peritonitis, CAPD (abst) ..... 798
renal cytoprotection ..... 1345
Protease inhibitors, dialysis amyloidosis ..... 915
Protein, cytoskeletal, integrins, ECM (abst) ..... 793
Protein catabolism
membrane selection ..... 38:S-86
rate and Kt/V ..... 38:S-32
Protein kinase C, hypoxia ..... 1145
Protein meal and vasopressin ..... 1207
Protein metabolism
effect of ammonia ..... 595
effects of ketoacids (abst) ..... 497
Protein transport, transperitoneal ..... 1412
Proteinuria
analgesic and reflux nephropathy (abst) ..... 1041
CEI, mesangial expansion (abst) ..... 795
cyclosporin A, adriamycin nephropathy (abst) ..... 1283
decrease during ACE inhibition (abst) ..... 1285
glomerular, heparin sulfate (abst) ..... 1050
pregnancy, hypertension (abst) ..... 1038
pregnancy, renal function (abst) ..... 795
Proximal tubular epithelial cells ..... 383, 1130
Proximal tubule
cyclosporine (abst) ..... 221
felodipine effect (abst) ..... 1031
glycine metabolism (abst) ..... 1049
Prurigo nodularis, aluminum toxicity (abst) ..... 1044
Puromycin, nephrosis (abst) ..... 800, 1052
Pyelitis, encrusted, corinebacterium D2 group, transplantation (abst) ..... 226
Pyelonephritis, acute (abst) ..... 1040, 1043

Reactive oxygen species (abst) ..... 1052
Recombinant human erythropoietin
anemia, predialysis CRF (abst) ..... 498
bone marrow, chronic insufficiency (abst) ..... 206
CAPD, staphylococcus aureus (abst) ..... 204
dosage, hemodialysis (abst) ..... 805, 1046
uremia, platelet function ..... 668
uremia, primary hemostasia (abst) ..... 220
uremic anemia ..... 38:S-142
Red blood cell membrane, calcium pump, CRF ..... 1328
Reflux nephropathy (abst) ..... 493
Regenerating kidney and IGF-1 ..... 1113
Renal angiomyolipoma, tuberous sclerosis (abst) ..... 801
Renal artery stenosis
captopril, renal scintigraphy (abst) ..... 1287
captopril renography (abst) ..... 206
percutaneous transluminal angioplasty (abst) ..... 217
transplantation, Doppler (abst) ..... 201
transplantation (abst) ..... 1286
Renal cancer (abst) ..... 1042
Renal cortex, ET-1, Na/H, $Na/HCO_3$ ..... 18
Renal disease
acquired cystic (abst) ..... 198
arresting ..... 38:S-114
epidemiology, Spain (abst) ..... 213
HIV infection (abst) ..... 230
ischemia, ARF ..... 610
renal reserve pattern (abst) ..... 1042
sex hormone level (abst) ..... 492
Renal expression of GLUT4 ..... 1086
Renal failure
calcium metabolism ..... 38:S-37
calcium-related changes (abst) ..... 1040
captopril, nifedipine ..... 452
experimental, bacterial enzymes (abst) ..... 497
renal histology in PKD ..... 1259
Renal function
childhood lead poisoning ..... 1226
de-electrolyte water clearance (abst) ..... 494
endothelium, endothelin in obstruction ..... 632
handling of silicon ..... 957
oxidation patterns (abst) ..... 210
pregnancy (abst) ..... 795
Renal growth factor, post-uninephrectomy (abst) ..... 199
Renal hypertrophy
ANF receptors ..... 75
compensatory (abst) ..... 1035
Renal lithiasis
1,25$(OH)_2$ $D_3$, calcium reabsorption (abst) ..... 204
idiopathic hypercalciuria, metabolism (abst) ..... 202
Renal prepro-EGF, obstruction ..... 89
Renal replacement therapy, death rates ..... 38:S-4
Renin
autoradiographic localization ..... 639
tubular in ADPKD ..... 364
vasopressin agonist DDAVP, hemodynamics (abst) ..... 793
Renin angiotensin system, nephropathy, ANP (abst) ..... 508
Renotropin (abst) ..... 510
Respiratory alkalosis, mineral metabolism ..... 727
Reverse urea effect in DDS ..... 161
Rheum officinal(e) (abst) ..... 504, 505, 510
Rheumatoid arthritis, renal function (abst) ..... 1040
Rhubarb, therapeutic effect (abst) ..... 498

Rubidium, potassium reabsorption ..... 272
Rufloxacin, impaired renal function (abst) ..... 1042

Salt excretion down-regulation by ANF ..... 673
Schönlein-Henoch glomerulonephritis ..... 341
Serotonin, dialytic therapy (abst) ..... 1045
Sex hormone level in renal disease (abst) ..... 492
Shenshuai No 1. (abst) ..... 498
Signalling disorders, transmembrane, cyclosporine ..... 1
Silicon, renal handling of ..... 957
Single-needle hemodialysis, citrate (abst) ..... 807
Skeletal muscle metabolism, uremia (abst) ..... 1031, 1049
Sodium
  dietary, anti-hypertensives, renal effect ..... 354
  retention, nephrotic syndrome, glomerular changes (abst) ..... 507
Sodium chloride, ACTH hypertension (abst) ..... 1039
Sodium-dependent phosphate transport ..... 1070
Spinal cord injury, prognosis with ESRD (abst) ..... 1031
Staphylococcus aureus, CAPD, rHuEPO (abst) ..... 204
Superoxide dismutase, renal failure (abst) ..... 222
Sympathetic nervous system, ANF, natriuresis ..... 433
Systemic lupus erythematosus
  C8, C9, membrane attack complex (abst) ..... 1037
  drug therapy study (abst) ..... 801
  GN pathogenesis ..... 1363
  intraglomerular thrombi (abst) ..... 233
  membrane antigens (abst) ..... 1038

$^{99m}$Tc-DTPA, measuring GFR ..... 174
T-cells
  allograft rejection (abst) ..... 1047
  clones, lupus nephritis ..... 851
  lymphokine production, anti-GBM GN (abst) ..... 1032
  uremic serum ..... 681
Tamm-Horsfall expression
  chronic active hepatitis (abst) ..... 494
  ureteral obstruction ..... 89
Testicular-pituitary function (abst) ..... 207
Thin membrane nephropathy (abst) ..... 490
Thrombocytopenia, ARF, hemodiafiltration (abst) ..... 1044
Thrombomodulin glomerular activity (abst) ..... 231
Thrombotic microangiopathy (abst) ..... 229
Thromboxane, glomerulopathy, diabetes ..... 937
Thyroid function, age, CRF, dialysis (abst) ..... 237
Transforming growth factor-$\beta$
  fibronectin synthesis (abst) ..... 1032
  mesangial cells ..... 1319
  mesangial cells, glucose ..... 647
  mesangial proliferative GN (abst) ..... 507
  production, rat MC (abst) ..... 1033
Transmembrane signalling disorders ..... 1
Transperitoneal protein transport ..... 1412
Transplantation
  antilymphocyte globulins ..... 38:S-188
  azathioprine, cyclosporine, prednisone (abst) ..... 216
  blood transfusions, prior (abst) ..... 208
  bone mineral density (abst) ..... 211, 1048
  bone necrosis, aseptic (abst) ..... 221
  bone redistribution (abst) ..... 808
  children ..... 657
  children, growth potential (abst) ..... 802
  cross match techniques (abst) ..... 237
  cyclosporin A, diltiazem (abst) ..... 1047
  cyclosporine, azathioprine (abst) ..... 205
  cyclosporine (abst) ..... 226
  cytomegalovirus (abst) ..... 207, 216
  diabetic patients ..... 38:S-193
  enalapril, anemia (abst) ..... 206
  erectile impotence treatment (abst) ..... 226
  erythrocytosis (abst) ..... 219
  erythropoietin-deficient anemia (abst) ..... 216
  glomerular hyperfiltration (abst) ..... 809
  hepatitis B prevention (abst) ..... 501
  hepatitis C virus (abst) ..... 226, 227
  HLA-sensitization ..... 38:S-176
  HLA typing, allocating kidneys (abst) ..... 1285
  hyperparathyroidism (abst) ..... 211, 806, 808, 1048
  immunocytology, urinary sediments (abst) ..... 794
  immunosuppression, pituitary, testes (abst) ..... 207
  immunosuppression (abst) ..... 203, 1046
  liver function after (abst) ..... 808
  MLC-testing (abst) ..... 807
  monoclonal gammapathy after (abst) ..... 231
  OKT3 therapy (abst) ..... 223, 228
  parathyroidectomy (abst) ..... 1048
  patient profiles, death rates ..... 38:S-4
  PH 1 children ..... 1408
  prognosis after failed dialysis (abst) ..... 803
  pyelitis, cystitis (abst) ..... 226
  renal artery stenosis (abst) ..... 201, 1286
  triple drug protocol (abst) ..... 220
Trypterigium wilfodii (abst) ..... 504, 505
Tuberous sclerosis, renal angiomyolipoma (abst) ..... 801
Tubular cells
  Chinese herbal medicine (abst) ..... 505
  flow cytometry ..... 997
Tubuloglomerular feedback, post-nephrectomy (abst) ... 1049
Tubulointerstitial lesions in renal biopsy (abst) ..... 494
Tumor necrosis factor
  IL-1, hemodialysis ..... 38:S-68
  induces verocytotoxin receptor (abst) ..... 1286
  inhibition, herbal medicine (abst) ..... 510
  mesangial cells (abst) ..... 210
  OKT3 procoagulant effect ..... 1124
Tumor necrosis factor-$\alpha$
  ESRD (abst) ..... 497
  PAI-1 release, mesangial cells ..... 327
  production, IL-6, OKT3 (abst) ..... 207
  proximal tubular epithelial cell production ..... 383
Tumor necrosis factor receptor
  soluble in CRF ..... 663
Tumoral calcinosis (abst) ..... 806

Ultrafiltration
  vascular refilling during ..... 1425
  venous system hemodynamics ..... 718
Uninephrectomy
  glomerular hypertrophy ..... 136
  plasma concentration of peptides (abst) ..... 236
  podocyte structure changes ..... 148
  renal growth factor (abst) ..... 199
  urolithiasis ..... 292
U.S. Renal Data System, ESRD mortality tables ..... 991
Urea kinetic modeling
  CAPD (abst) ..... 205
  hemodialysis ..... 1450
  hemodialysis (abst) ..... 500
Uremia
  anemia, EPO ..... 38:S-142, 975
  calcium pump inhibitor ..... 1328

calcium salts as phosphate binder ..... 38:S-50
EPO, platelet function ..... 668
erythrocyte membrane transport (abst) ..... 496
erythropoietin response ..... 407
LDL receptor function, mRNA levels ..... 1238
myocardial capillary density ..... 1079
plasma MDA, erythrocyte MDA, SOD (abst) ..... 495
serum and T-cells ..... 681
serum lipids (abst) ..... 496
skeletal muscle metabolism (abst) ..... 1031, 1049
soluble TNF receptor ..... 663
Ureteral obstruction
endothelin, endothelium ..... 632
renal prepro-EGF, gene expression ..... 89
unilateral and EDRF ..... 400
Urinary sediments, transplant rejection (abst) ..... 794
Urinary tract, traumatic rupture (abst) ..... 801
Urodilatin
displacing labeled ANP (abst) ..... 234
dopamine, ischemic ARF ..... 1153
Urolithiasis, uninephrectomy ..... 292

Vascular access stenosis, PTVA ..... 1390
Vascular cell adhesion molecule-1
gene expression (abst) ..... 1035
lupus nephritis ..... 903
Vascular permeability factor, human kidney ..... 1457
Vascular refilling, HD, ultrafiltration ..... 1425
Vascular smooth muscle cells (abst) ..... 799
Vasopressin
agonist, hemodynamics, renin (abst) ..... 793
protein meal ..... 1207
Ventricular function
differing HD dialysates (abst) ..... 233
vitamin D-3 (abst) ..... 198
Verocytotoxin receptor, induced (abst) ..... 1286
Vitamin D
metabolism, nephrotic syndrome ..... 335
ventricular function (abst) ..... 198
Vitamin E and herbal medicine (abst) ..... 505

Warfarin trials, idiopathic MGN (abst) ..... 1032
Wegener's granulomatosis (abst) ..... 213
"White coat" hypertension (abst) ..... 202
Wilms' tumor (abst) ..... 228